Generation and characterization of bioactive peptides from flaxseed ( Linum usitatissimum L.) proteins by Marambe, P. W. M. Lesanthi Harsha Kumari
0 
 
 
 
GENERATION AND CHARACTERIZATION OF BIOACTIVE PEPTIDES FROM 
FLAXSEED (Linum usitatissimum L.) PROTEINS 
 
 
 
 
 
A Thesis Submitted 
to the College of Graduate Studies and Research 
in Partial Fulfillment of the Requirements 
for the Degree of Doctor of Philosophy 
in the Department of Food and Bioproduct Sciences 
University of Saskatchewan 
Saskatoon, Saskatchewan, Canada 
 
 
 
 
By 
Pathiraja Weerasingha Mudiynseralahamilage Lesanthi Harsha Kumari Marambe 
2011 
 
 
 
 
 
 
© Copyright Harsha Marambe, March 2011. All rights reserved.
 
 
i 
 
PERMISSION TO USE 
 
In presenting this thesis in partial fulfillment of the requirement of a postgraduate 
degree from the University of Saskatchewan, I agree that the libraries of the university 
may take it freely available for inspection. I further agree that the permission for 
copying of this thesis in any manner, in whole or in part, for scholarly purpose may be 
granted by the professor who supervised my thesis work or in their absence, by the 
Head of the Department or the Dean of the College in which, my thesis work was done. 
It is understood that any copying or publication or use of this thesis or parts thereof for 
financial gain shall not be allowed without my written permission. It is also understood 
that due recognition shall be given to me and to the University of Saskatchewan in any 
scholarly use, which may be made of any material in my thesis.  
 
Request for permission to copy or to make other use of material in this thesis in whole 
or part should be addressed to: 
 
Head of the Department of Food and Bioproduct Sciences, 
University of Saskatchewan, 
51 Campus Drive 
Saskatoon, SK 
Canada, S7N 5A8 
 
 
 
 
 
 
 
 
 
 
ii 
 
ABSTRACT 
The potential of flaxseed (Linum usitatissimum L.) protein to release bioactive peptides 
upon enzymatic hydrolysis was evaluated. Flaxseed protein released angiotensin I-
converting enzyme inhibitory (ACEI) peptides during in vitro simulated gastrointestinal 
(GI) digestion in a static (no removal of digested products) and a dynamic model 
(removal of <1 kDa molecules in the intestinal phase). The ACEI activity of the gastric 
plus intestinal digest (absorbed fraction-IC50: 0.04 mg N/mL; retained fraction-IC50: 
0.05 mg N/mL; degree of hydrolysis, DH: 46.78 %) of the dynamic model was 
significantly higher (P<0.05) than that of the static model (IC50: 0.39 mg N/mL; DH: 
43.95 %). Polypeptides of 48, 41, 29 and 20 kDa could be releasing these ACEI 
peptides. Six peptides in the highest ACEI fraction (0.5-1 kDa) of the absorbable gastric 
plus intestinal digest were identified via de novo sequencing. Only digests of the static 
model exhibited hydroxyl radical (OH•) scavenging activity (IC50: 0.40 mg N/mL), 
suggesting the inappropriateness of such models in this type of research. Presence of 
mucilage and oil interfered with the in vitro digestibility of flaxseed protein, which 
could limit the release of ACEI peptides during GI digestion. The protein digestibility 
of milled whole flaxseed (12.61 %) was significantly improved (P<0.05) with the 
removal of mucilage (51.00 %) and oil together with mucilage (66.79 %). The 
digestibility of isolated flaxseed protein was 68.00 %. 
 
Flaxseed protein, hydrolyzed (DH: 11.94-70.62 %) with Flavourzyme® in a central 
composite rotatable design, possessed bioactivities with identified optimum 
enzyme/substrate and time of hydrolysis combinations, including ACEI activity (71.59-
88.29 %, 83.7 LAPU/g protein, 19.9 h), scavenging of OH• (12.48-22.08 %, 30.2 
LAPU/ g protein, 1.5 h) and superoxide radical (O2•-) (26.33-39.41 %, 4.9 LAPU/ g 
protein, 16.3 h) and inhibiting linoleic acid oxidation (0.71-94.33 %, 1.6 LAPU/ g 
protein, 12.6 h). The degradation pattern of polypeptides during enzymatic hydrolysis 
indicated that 48 and 13 kDa molecules could be releasing these bioactive peptides. De 
novo sequencing identified two ACEI and five OH scavenging peptides in the 
hydrolysate fractions (0.5-1.05 kDa) with the highest bioactivities. The findings suggest 
the importance of flaxseed protein as a source of cardioprotective bioactive peptides. 
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1. INTRODUCTION 
 
Flaxseed (Linum usitatissimum L.) has received attention among consumers and health 
care professionals alike due to reported health benefits associated with its consumption. 
Some of these health benefits include reduction of atherogenic risk, anticancer, 
antiviral, bactericidal, anti-inflammatory and laxative effects (Collins et al., 2003). 
 
Flaxseed is rich in oil, protein, soluble fibre (mucilage/gum) and lignans. The major 
product obtained from flaxseed is oil, which is rich in the omega 3 (-3) fatty acid, -
linolenic acid (ALA). Currently, ground or whole flaxseed and defatted meal are 
marketed for food applications as a convenient source of dietary fibre, lignans, and 
soluble fibre. Whole flaxseed has 23 % protein (dry matter basis) on average (Flax 
Council of Canada, 2010). The defatted meal which is the byproduct from oil extraction 
contains 35-40 % protein (Sammour, 1999). However, the proteins of flaxseed meal 
have not yet been widely exploited for their value in human nutrition.  
 
Whole flaxseed, its meal as well as flaxseed constituents have demonstrated protection 
against cardiovascular disease (CVD) (Jenkins et al., 1999). Several studies have been 
conducted to identify the constituents in flaxseed, which contributed to heart health 
related benefits. Most of these studies focused on and relating to the ω-3 fatty acid, 
ALA in flaxseed oil, lignan and mucilage (Bloedon & Szapary, 2004; Prasad, 2005). 
However, findings of these studies are variable and inconsistent and the specific 
components of flaxseed, which contribute to these health benefits, has not been 
completely elucidated. Recent studies (Hallund et al., 2006; Sano et al., 2003) have 
challenged the hypothesis that ALA and lignans are the components responsible for the 
health benefits of flaxseed. This has raised interest in identifying the exact component.  
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in flaxseed leading to health benefits (Jenkins et al., 1999; Sano et al., 2003). The 
exerted antiatherogenic effect by defatted flaxseed meal but not by isolated lignans 
suggests that a non-lipid and non-lignan component in flaxseed meal could be the 
contributory factor for protection against CVD (Jenkins et al., 1999; Sano et al., 2003). 
Within the context of dietary health beneficial components of flaxseed, it is necessary to 
investigate the contribution of the protein fraction, especially the bioactivities of the 
digested protein products.  
 
Bioactive peptides are the specific protein derived fragments that have positive impact 
on body health (Kitts & Weiller, 2003). These peptides are inactive within the sequence 
of parent proteins but become active when released during gastrointestinal (GI) 
digestion or food processing. Upon release they exert various physiological functions 
based on the inherent amino acid composition and sequence. It is well accepted that 30-
50 % of dietary nitrogen is absorbed into the body as small peptides, which can also 
exert different bioactivities (Roberts et al., 1999). At present, several enzymatically 
hydrolyzed food proteins have been studied for their ability to release bioactive peptides 
with cardioprotective activities. Some of these activities include angiotensin I-
converting enzyme inhibitory (ACEI) activity (antihypertensive), antioxidant, bile acid 
binding, and antithrombotic activities.  
 
There are several published studies reporting the presence of bioactivities in 
enzymatically hydrolyzed flaxseed protein. Some examples are in vitro ACEI, renin 
inhibitory (Udenigwe et al., 2009) and antioxidative activity (Udenigwe et al., 2009) of 
flaxseed protein hydrolyzed with ficin, pancreatin, papain, pepsin and Thermolysin. Wu 
et al. (2004) reported in a patent that proteolytic digestion of defatted flaxseed meal 
generates a hydrolysate with ACEI activity. Also Omoni and Aluko (2006) reported in 
vitro calmodulin binding activity and calmodulin dependent neuronal nitric oxide 
synthase inhibitory activity of an Alcalase-hydrolysate of flaxseed protein. However, 
there is no published information available on the ability of flaxseed protein to generate 
cardioprotective bioactive peptides during GI digestion.  
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Flaxseed is consumed as whole flaxseeds, ground (milled) flaxseeds or defatted 
flaxseed meal. In whole flaxseed, the protein is present with other seed components 
such as mucilage and oil, whereas in the meal the oil is expressed out. Hence, the form 
in which flaxseed is consumed might affect the bioactivity of flaxseed protein derived 
peptides. Further, the use of food grade microbial enzymes that can extensively 
hydrolyze proteins may generate beneficial bioactive peptides. This information has the 
potential to add more value to flaxseed meal, which has not been commercially 
exploited as a protein source. 
 
In this study, three hypotheses were tested in relation to the generation of health 
beneficial bioactivities by flaxseed proteins. These hypotheses and objectives were as 
follows. 
 
Hypothesis 1: Seed proteins of flaxseed release bioactive peptides upon GI digestion 
that are resistant to further hydrolysis by digestive enzymes and have ACEI and 
antioxidant activities. 
Objectives:  
 To determine whether flaxseed protein releases peptides with ACEI and 
antioxidant [hydroxyl radical (OH•) scavenging] activities during the simulated 
GI digestion in vitro. 
 To identify the molecular mass and amino acid sequence of the peptides in the 
fractions with the highest levels of these bioactivities and released from in vitro 
digestion of flaxseed protein. 
 
Hypothesis 2: Digestibility of flaxseed proteins during simulated GI digestion is 
reduced by the presence of other constituents in the seed matrix, i.e. reduce the release 
of bioactive peptides.  
Objectives: 
 To investigate the digestibility of different forms of flaxseed protein sources 
(milled whole flaxseed, milled and demucilaged flaxseed, milled, demucilaged 
and defatted flaxseed and isolated protein). 
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 To determine the impact of presence of other seed components (mucilage and 
oil) on the digestibility and degradation of flaxseed proteins under simulated GI 
digestion. 
 
Hypothesis 3: Exogenous hydrolysis of flaxseed proteins with commercial fungal 
proteases can generate bioactive peptides with multiple cardioprotective activities. 
Objectives:  
 To determine whether peptides released during hydrolysis of flaxseed proteins 
by Flavourzyme® have bioactivities such as ACEI, anti-oxidative, anti-
thrombotic activities and bile acid binding ability and to identify their precursor 
proteins. 
 To identify the optimum reaction conditions that produce peptides with 
maximum activities for each of the bioactivities screened. 
 To identify molecular masses and amino acid sequences of peptides with 
bioactivities. 
 
Studies were designed, conducted and results were analyzed to test these hypotheses.
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2. LITERATURE REVIEW 
 
2.1 Flax as a crop 
Flax (Linum usitatissimum) is a blue flowered annual oilseed crop, which belongs to the 
family, Linaceae. The flax plant is native to Western Asia and the Mediterranean 
(Coskuner & Karababa, 2007) and grown as a crop in many cool climate regions of the 
world except the tropics and the arctic (Madhusudhan, 2009). In Canada, flax is grown 
mainly in the cool northern climate of the Western prairies. During ancient times flax 
plant was primarily used to obtain flax fibre. Around 6000 BC flax was used in Eastern 
Turkey to make cloth known as linen (Judd, 1995). These linen cloths were used to 
wrap the mummies in the early Egyptian tombs and flax spinning and weaving had been 
household industries in antiquity (Oplinger et al., 1989). However, with the invention of 
cotton, fibre flax production declined and the major use of flax was switched from fibre 
to oil extracted from the seeds. Traditionally, the flax oil was used in the manufacture of 
paints, varnishes and linoleum, due to its drying and hardening properties upon 
exposure to air and sun light (Coskuner & Karababa, 2007). In addition consumption of 
seeds of flax in various forms as a food ingredient and for its medicinal properties dates 
from 5000 BC since the start of its cultivation (Oomah & Mazza, 1998). 
 
Today, Canada is the world leader in the production and exports of flax (Flax Council 
of Canada, 2010) contributing about 50 % of the world flax production and representing 
about 80 % of the global flax trade (Agriculture and Agri-Food Canada, 2010). 
Canadian flax is exported mainly to Europe, the United States, Japan, and South Korea 
(Flax Council of Canada, 2010). The major areas in Canada that cultivate flax include 
Alberta, Manitoba, New Brunswick, Nova Scotia, Prince Edward Island and 
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Saskatchewan (Canadian Grain Commission, 2010). Saskatchewan leads Canadian 
commercial flax cultivation by contributing 70 % of the total production and 
representing 25 % of world production (Government of Saskatchewan, 2010). 
 
2 .2 Flaxseed; Structure and composition 
The seeds of flax are known as flaxseeds (also known as linseed) and are small, flat, 
oval shaped and pointed at one end. The seed has a smooth glossy surface and its colour 
ranges from medium, reddish brown to a light yellow. The seed dimension is 
approximately 3.0-6.4 mm in length, 1.8-3.4 mm in width and 0.5-1.6 mm in thickness 
(Freeman, 1995). Oily flaxseed is larger in size than fibre flaxseed (Green & Marshall, 
1981). The seed contains a seed coat (testa, true hull or spermoderm), an embryo or the 
germ, a thin endosperm and two large, flattened cotyledons. The cotyledons form the 
bulk of the seed (57 %) while the seed coat and the endosperm account for 38 % and the 
embryo comprises 5 % of the total seed weight (Wanasundara & Shahidi, 1998). The 
seed coat of flax has five distinct layers. The epidermal layer or the mucilage layer and 
the testa, which consists of pigmented cells that give the flaxseeds its color, are the two 
important layers of the seed coat. 
 
Flaxseed is rich in oil, protein and dietary fibre. The seed has 30-40 % oil, 20-25 % 
protein, 20-28 % dietary fibre, 4-8 % moisture, and 3-4 % ash (Bhatty, 1997; Carter, 
1993; Cunnane et al., 1993; Oomah & Mazza, 1998). Cotyledons are the major storage 
site for flaxseed oil (contain 75 % of the seed oil). The seed coat and the endosperm 
contain 22 % of the seed oil while the embryo contains only 3 % of the oil 
(Wanasundara & Shahidi, 1998). Flaxseed is naturally low in saturated lipids and nearly 
73 % of its constituent fatty acids are polyunsaturated. It has a lesser amount of linoleic 
acid, an ω-6 fatty acid. Flaxseed oil is the richest known source of α linolenic acid 
(ALA), which is an ω-3 fatty acid, (52 % of total fatty acids). The ω-3/ω-6 ratio of 
flaxseed oil is 1:0.3. It has superior ω-3 fatty acid content when compared with the fatty 
acid profile of algal, corn, fish or soybean oils (Madhusudhan, 2009). Flaxseed is also a 
rich source of protein, which has amino acid contents similar to that of soybean 
(Madhusudhan, 2009). The protein content of defatted flaxseed meal ranges from 35-40 
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% (Sammour, 1999). Similar to other oilseeds, albumins and globulins are the major 
storage proteins of flaxseed, contributing about 58-66 % of the total seed protein 
(Chung et al., 2005). Flaxseed proteins are mainly stored in the cotyledons 
(Wanasundara & Shahidi, 1998) 
 
The dietary fibre in flaxseed is comprised of both insoluble and soluble forms. 
Flaxseeds contain about 400 g/kg total dietary fibre (TDF) rich in pentosans and the hull 
fraction contains 2-7 % soluble dietary fibre (SDF) known as mucilage/gum (Bhatty & 
Cherdkiatgumchai, 1990). The mucilage, which is a mixture of acidic and neutral 
polysaccharides consisting primarily of D-galacturonic acid, D-xylose, L-rhamnose, D-
galactose, and L-arabinose (Mazza & Oomah, 1995), occurs mainly in the epidermal 
layer of the seed coat (Dev & Quensell, 1988). 
 
Another important group of constituents in flaxseed are the phenolic phytoestrogens 
called lignans. The major flaxseed lignan is known as secoisolariciresinol diglucoside 
(SDG) which is present at levels 75-800 times higher than any other crop and vegetable 
known to-date (Thompson et al., 1997; Westcott & Muir, 1996). The defatted flaxseed 
flour was shown to contain 1–3 % of SDG (Westcott & Muir, 1996).  
 
2.3 Food and feed uses of flaxseed 
Flaxseed products are found in forms of whole seed, ground (milled), partially defatted 
meal and oil (Bassett et al., 2009). When added to products such as waffles, pancakes, 
breakfast cereals, drinks, biscuits, crackers, soups, and bagels, etc. ground or whole 
flaxseed gives a nutty flavor (Berglund, 2002). The ground flaxseed is presently sold in 
the market under vacuum packaging. Use of ground flaxseed is beneficial over the 
whole flaxseed as the whole seed can pass through the body undigested (Flax Council 
of Canada, 2010). In Southern India, flaxseed is consumed as flaxseed chutney (a pickle 
of Indian origin), which could be preserved for months (Madhusudhan, 2009). 
 
Flax oil is obtained by mechanical pressing of seeds. Traditionally the oil extracted 
from flaxseed (known as linseed oil) was used for industrial purposes such as drying  
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agents in paints and varnish (Judd, 1995). With the discovery of health benefits of ALA, 
oil extracted from cold pressing of flaxseed is now available in super markets and health 
food stores as bottled oil and sealed gel capsules. The oil can be used in fresh salads 
whereas the capsules are sold as dietary supplements (Flax Council of Canada, 2010). 
Use of flax oil for frying is not recommended. Once extracted from the seeds, the 
polyunsaturated fatty acids (PUFAs) in the flax oil may undergo thermal oxidation 
when exposed to high temperatures of cooking resulting in off flavours and odours in 
the finished product (Wanasundara & Shahidi, 1998). 
 
The residue that remains after crushing flaxseed to obtain oil is the flaxseed meal. Most 
of the flaxseed protein is concentrated in the meal. It also contains fibre and lignans and 
is poor in ALA content (Bassett et al., 2009). Historically, the meal was used as a 
livestock feed and fertilizer. Today, the packaged meal is available in health food stores 
or via internet agents as a food ingredient that can be added to cereals, salads, blended 
drinks etc. (NexTag, 2010). Although the meal is rich in proteins it is marketed by 
highlighting its value as a good source of dietary fibre, lignans and mucilage. 
 
Milled whole flaxseed and flaxseed meal are also popular ingredients in animal feed 
rations. Due to its unique ALA content, farmers and animal breeders include flaxseed in 
the diet formulations for cattle, equine and hogs to improve animal health. Also feeding 
hens with poultry feed containing flaxseed is popular to produce eggs rich in ω-3 fats 
that are appealing to consumers (Flax Council of Canada, 2010).  
 
In January 2009, whole and milled flaxseed was given GRAS (generally recognized as 
safe) status by the United States Food and Drug Administration (FDA). To be accepted 
by the food industry in the U.S.A., a new food ingredient has to obtain GRAS status or 
be free of harmful toxins or unsafe side effects. Gaining this status will further expand 
the use of flaxseed by food manufacturers and human food applications worldwide 
(Flax Council of Canada, 2009). 
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2.4 Flaxseed as a functional food 
Foods are now being researched intensively for added physiological benefits that may 
reduce chronic disease risk or otherwise optimize health. Such research efforts have led 
to global interest in the food category known as functional foods. There is no 
universally accepted definition for functional foods. Health Canada defines a functional 
food as a food similar in appearance to a conventional food, which is consumed as a 
part of the usual diet and has demonstrated physiological benefits and/or reduces the 
risk of chronic diseases beyond basic nutritional functions (Health Canada, 1997). Apart 
from naturally occurring functional foods, such foods can be manufactured by the 
addition or enrichment of physiologically active components as ingredients (Erdmann et 
al., 2008). 
 
Flaxseed is one of the most prominent oilseeds studied today as a functional food 
besides soy. During the past decade, potential health benefits associated with flaxseed 
consumption have become more prominent. These health benefits include cardio 
protective effects, anticancer effects, antiviral and bactericidal activity, anti-
inflammatory effect, ion reduction, laxative effects, beneficial effects on renal function 
in patients with lupus nephritis, mediation of bone health, management of diabetes, etc. 
(Cunnane et al., 1995; Jenab & Thompson, 1996; Jenkins et al., 1999; Kurzer & Xu, 
1997; Oomah, 2001; Zhang et al., 2008). Of these, there is an increasing interest in 
using flaxseed to reduce the risk of cardiovascular diseases (CVD). This is mainly based 
on the cardioprotective effects shown by bioactive components in flaxseed. There are 
human and animal studies reporting the cardioprotective mechanisms of flaxseed, which 
include hypolipideimic effects (Cunnane et al., 1993; Cunnane et al., 1995; Jenkins et 
al., 1999), anti-inflammatory effects (Faintuch et al., 2007), antiplatelet effects 
(Bierenbaum et al., 1993) and antioxidant effects (Lee et al., 2008). In a review of 
experimental and clinical research findings on the cardiovascular benefits of consuming 
flaxseed, Bassett et al. (2009) reported that consumption of 1-4 tablespoons of ground 
flaxseed per day can modestly reduce total cholesterol (TC; 6-11 %) and low density 
lipoprotein (LDL) cholesterol (9-18 %) levels and can reduce various markers 
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associated with atherosclerotic CVD in humans. The authors have also reported the 
inconsistency of findings regarding the antioxidative and antiplatelet effects of flaxseed 
in humans. The effects of flaxseed on arterial blood pressure have rarely been studied 
(Bassett et al., 2009). Short term flaxseed consumption was found to exert no effect on 
arterial pressure of humans (Stuglin & Prasad, 2005) However, there are some human 
studies reporting a significant reduction in systolic and diastolic blood pressures (SBP 
and DBP) due to flaxseed (Dodin et al., 2005) and flaxseed oil consumption (Paschos et 
al., 2007). Moderate (30 g ground flaxseed per day) flax consumption has been reported 
to reduce atherosclerosis and irregular heart rhythms and reduce the risk of peripheral 
arteria disease (PAD) (Dewan & Perkins, 2010). 
 
2.5 Health claims for flaxseed in Canada 
A health claim is considered to be any representation in labelling and advertising that 
states, suggests or implies that a relation exists between the consumption of foods or 
food constituents and health (Labbe et al., 2008). Some food labels contain statements 
about the beneficial effects of certain foods on a person's health, such as "a healthy 
diet low in saturated and trans fat may reduce the risk of heart disease". This 
type of statement is an example of a health claim (Health Canada, 2010). There are 
three main categories of health claims allowed in Canada. They are; 
 
1. Disease risk reduction claims: Links the consumption of foods or food 
constituents to a reduced risk of a disease in the context of the total diet 
 
2. Function claims: Statements based on the specific beneficial effects that the 
consumption of a food or a food constituent has on the normal functions or 
biological activities of the body. 
 
e.g. I Nutrient function claims: (formerly called biological role claims) are function 
claims that describe the well-established roles of energy or known nutrients that are 
essential for the maintenance of good health or for normal growth and development. 
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e.g. II Probiotic claims: are health claims about the benefits of probiotic 
microorganisms. 
 
3. General health claims: are broad claims that promote health through healthy 
eating or that provide dietary guidance. These claims can be made on any 
product provided no linkage is made to a specific product or to a health effect, 
disease or health condition (Health Canada, 2010). 
 
Health claims on foods impart benefits to stakeholders including regulatory bodies, 
industrial manufacturers, and consumers as well as to research institutions and 
scientists. For regulatory bodies, health claims provide a means to protect consumers 
from misleading or unsubstantiated information on product labels. For the food 
industry, health claims and nutrition labelling enable communication of health benefits 
of a food or food ingredient to consumers, which can also provide a strategic 
competitive advantage (Jew et al., 2008). It has recently been suggested that consumers 
would be 10–26 % more likely to consume products with proven health claims, which 
may translate to a 20 % increase in sales. In turn, health claims tend to help consumers 
make better food choices and gain a deeper understanding of diet-disease relations (Jew 
et al., 2008). Research institutions and scientists also benefit from conducting research 
on foods and their effects on health stimulated by the ability to develop and utilize 
health claims. In Canada, advertising health claims for foods is regulated under Food 
and Drug Regulations (FDR), whereas Health Canada develops the policies, regulations 
and standards related to health and safety (Labbe et al., 2008). Substantiation of disease 
risk-reduction claims in Canada is based on the two key principles namely the totality of 
evidence and the requirement for a high or convincing level of evidence. First, a 
structured, comprehensive literature review of the totality of relevant evidence based on 
human studies of acceptable quality is required. Second, the strength of evidence must 
be convincing and consistently supports a causal relation between the consumption of 
foods or food constituents and the reduction of a disease risk (Labbe et al., 2008). 
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Canadians are increasingly receptive to the idea of using food to prevent disease and 
improve health (Agriculture and Agri-Food Canada, 2010). Therefore, availability of 
health claims for food products are important to make consumers aware of their health 
benefits. Although there is research supporting the health benefits of flaxseed 
consumption, currently there are no approved health claims available for labelling 
flaxseed and their products in Canada. Small sample sizes, inconsistencies in products 
tested and other failures in study designs make study findings inconclusive. In a recent 
review, Arvanitoyannis and Houwelingen-Koukaliaroglou (2005) stated that research 
into functional foods will not advance public health, unless the benefits of the foods are 
effectively and clearly communicated to the consumer. Furthermore, foods with health 
claims that are supported by solid scientific substantiation have the potential to become 
increasingly important elements of a healthy lifestyle and can be extremely beneficial to 
the public and the food industry. When health claims are clearly supported by sound 
scientific evidence, consumers’ confidence in them shall grow. Therefore, having health 
claims for flaxseed and their products will guide consumers on potential health benefits 
of flaxseed consumption, and will make flaxseed an appealing product in the functional 
food market increasing their market value. The FDA has approved qualified health 
claims for reduced risk of coronary heart disease (CHD) on conventional foods that 
contain ω-3 fatty acids (United States Food and Drug Administration, 2010). The 
approval of such health claims is expected to increase the use of ω-3 fatty acids 
containing foods such as flaxseed by health conscious consumers. Since flaxseed has 
gained GRAS status in the United States, Canada is now trying to develop health claims 
for flaxseed (Flax Council of Canada, 2010). 
 
Sufficient conclusive scientific data that shows the relationship between flaxseed 
constituents and disease risk reduction is essential to obtain health claims for flaxseed 
products. The ample research publications available on cardioprotective functions of 
flaxseed constituents, especially ALA, lignan and mucilage are still controversial and 
inconsistent. Moreover, such information on flaxseed protein is scarce. Extensive, well 
designed studies on flaxseed constituents and heart health will provide necessary  
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information that will support setting health claims for flaxseed. Also it is of importance 
to identify the current information gap on flaxseed and heart health prior to focusing on 
human trials.  
 
According to Health Canada (2010), health claims on foods would require a common 
scientific basis to provide consistent and credible messages to the public. It is important 
that any claimed benefit attributed to a product is justified by appropriate studies that 
are carried out based on sound scientific criteria. Although human studies are weighted 
most heavily in the evaluation of evidence on a substance/disease relationship, data 
from animal models and in vitro studies can also be used to support a substance/disease 
relationship. Animal and in vitro studies permit greater control over variables, such as 
diet and genetics, and permit more aggressive intervention. There is always an 
uncertainty when extrapolating data derived from these studies to physiological effects 
in humans. However, these studies can be useful in providing information on the 
mechanism of action and specificity of a food substance and the process that causes 
disease or health-related condition. Animal and in vitro studies should be considered 
when there are problems designing interventional studies or in the absence of an 
appropriate biomarker. If such studies are used, they are subjected to the same kind of 
assessment as human studies in assessing for health claims (United States Food and 
Drug Administration, 1999). Since human studies are more expensive to conduct, well 
designed in vitro studies that mimic human physiological condition can be used to 
generate supportive data on flaxseed and heart health.  
 
2.6 Flaxseed components and reported cardiovascular benefits 
Most of the studies on health attributes of flaxseed have focused on the bioactive 
constituents of flaxseed such as ALA in flaxseed oil, the lignan SDG and mucilage. 
Flaxseed is unique in its high content of the ω-3 fatty acid ALA, which is reported to 
have significant beneficial effects against heart disease. ALA can be converted in the 
body into cardioprotective ω-3-PUFAs eicosapentaenoic acid (EPA) and  
docosahexaenoic acid (DHA) (Harper et al., 2006). The ω-3 fatty acids have been 
shown to regulate gene transcription and expression, thus altering enzyme synthesis and 
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to modify several risk factors for coronary heart disease including reducing serum 
triacylglycerols and blood pressure (Chen et al., 2007; Dupasquier et al., 2007; 
Waldschlager et al., 2005). It has also been suggested that ALA could decrease blood 
pressure via its regulation of prostaglandin metabolism, which is involved in vascular 
reactivity, control of salt and water balance, regulation of renin release, effects on 
peripheral sympathetic tone, control of renal blood flow and effects on cardiac output 
and baroreceptors (Paschos et al., 2007). 
 
The anti-inflammatory, antioxidant, antiplatelet, hypolipidemic and hypotensive effects 
associated with flaxseed consumption were thought as consequences of ALA in 
flaxseed. However, in a rat feeding study, Bhathena et al., (2003) showed that defatted 
flaxseed meal significantly decreased plasma cholesterol level compared to casein and 
reduced liver weight and hepatic fat deposition of obese rats compared to soy protein. 
The hypocholesterolemic action of defatted flaxseed meal also has been reported in 
human studies conducted by Jenkins et al., (1999). Defatted flaxseed meal does not 
contain appreciable amounts of ALA. Therefore, these findings suggest that the 
hypolipidemic effect of flaxseed is not due to ALA. Recent studies on extracted 
flaxseed oil has further shown that there is no reduction in total cholesterol or LDL 
cholesterol levels in healthy humans upon consumption of flaxseed oil (Kaul et al., 
2008). Although there are animal studies supporting the fact that flaxseed oil is 
antithrombotic (Yamashita et al., 2005) and inhibits platelet aggregation, there are 
human studies showing it has no antiplatelet activity (Vas Dias et al., 1982). Partially 
defatted flaxseed meal has also shown antithrombotic and anti-atherogenic effect in 
mice (Sano et al., 2003). Nestel et al. (1997) has reported no effect of flaxseed oil on 
blood pressure of humans. 
 
The findings of studies on flaxseed suggest that there is a non-lipid component in 
flaxseed, which contributes to CVD protection. In a recent review, Bassett et al. (2009)  
have suggested that the hypocholesterolemic function of flaxseed is due to its dietary 
fibre and lignan content whereas flaxseed oil contributes to antiatherogenicity via anti-
inflammatory and antiproliferative mechanisms. Prasad (2009) has conducted several 
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studies on flaxseed lignans and reported that suppression of atherosclerosis by flaxseed 
was associated with antioxidant activity and lowering of serum cholesterol, and is not 
due to its ALA but due to lignans. Based on animal and in vitro studies the author also 
suggested that flaxseed lignan and not ALA is contributing to the hypotensive activity 
of flaxseed. Also the hypotensive action of lignan was suggested to be mediated by the 
guanylate cyclase enzyme. Flaxseed lignans have chemical structures similar to the 
human hormone estrogen. When flaxseeds are ingested, SDG is converted to protective 
mammalian lignans, enterodiol and enterolactone, by the action of gut microflora (Chen 
et al., 2003). The lignan complex isolated from flaxseed decreased oxidative stress and 
serum cholesterol in animal models (Prasad, 2005) and SDG isolated from flaxseed 
showed hydroxyl radical (OH•) scavenging activity in vitro (Prasad, 1997). However, 
studies done using mice have shown that lignans in defatted flax meal have no effect on 
atherogenesis or thrombosis (Sano et al., 2003). Interestingly, there are recent human 
studies reporting that lignans isolated from flaxseed have no effect on plasma lipid 
concentrations, serum lipoprotein oxidation resistance, plasma antioxidant capacity 
(Hallund et al., 2006) or endothelial function (Hallund et al., 2006). 
 
The controversies regarding the active component present in flaxseed, suggest that there 
has to be a non-lipid and non-lignan component in flaxseed that contributes to the 
cardioprotective function. The mucilaginous soluble fibre in flaxseed is reported to 
provide cardioprotective effects by reducing serum cholesterol and controlling 
hyperglycemia in humans, similar to guar gum, oat gum and other viscous fibre 
(Jenkins, 1995; Thakur et al., 2009). In addition, it prevents development of colon and 
rectal cancer and reduces the incidence of obesity (Cunnane et al., 1995; Oomah & 
Mazza, 1998). In the process of determining the phytochemicals with the most 
biological activity, some components of flaxseed, especially proteins, have received 
very little attention. At present, the official websites of flax organizations (Flax Council 
of Canada, 2010; Flax Canada 2015, 2010; and AmeriFlax, 2010) report 
cardioprotective benefits of flaxseed oil, lignans and fibre but not of proteins. This 
further shows the absence of published scientific evidence on flaxseed protein and CVD 
health. Oomah (2001) has pointed out that there is a lack of clinical studies conducted to 
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identify the bioactive potency of flaxseed gums and protein. This could be due to the 
understanding and belief that the secondary plant substances are the only bioactive 
phytochemicals. Although it has been reported that flaxseed mucilage may lower blood 
glucose, it is unlikely that the mucilage alone has such an effect. It has been observed 
that flaxseed protein may influence blood glucose by stimulating insulin secretion, 
which could result in reduced glycemic response (Nuttal et al., 1984) and by interaction 
with polysaccharides. Lignans and other phenolics are also known to have strong 
protein-binding properties which may suggest some partial chemopreventive effect of 
flaxseed protein in conjunction with phenolics (Setchell et al., 1983). At present there is 
evidence from epidemiological studies that suggests proteins from vegetables, and 
animal sources can prevent CVD (Zhang et al., 2003). These research findings have 
motivated researchers to explore the role of flaxseed protein in the cardioprotective 
benefits exhibited by consumption of flax. To the best of my knowledge, human studies 
on health benefits of flaxseed protein, especially on cardiovascular health, is still in its 
infancy and have not yet been documented.  
 
2.7 Flaxseed proteins 
Flaxseed is a good source of protein. The protein content of flaxseed and defatted meal 
ranges from 10.5-31.0 % (Oomah & Mazza, 1993) and 35-40 % (Sammour, 1999), 
respectively and may varies with the genetic and environmental factors. Cool climates 
usually result in high oil and low protein content in the seeds. However, the genetic 
variation for protein content in flax cultivars is limited (Oomah & Mazza, 1998). While 
several studies have been conducted on extraction methods for flaxseed protein, only a 
few studies have characterized flaxseed proteins. Studies on isolating flaxseed protein  
were first reported by Osborne in 1892. Flaxseed has two major storage proteins, a 
predominant salt soluble fraction with high molecular weight (11-12S; globulin; 18.6 % 
nitrogen) and a water soluble basic component with low molecular weight (LMW) (1.6-
2S; albumin; 17.7 % nitrogen) (Dev et al., 1986; Madhusudhan & Singh, 1983; 
Sammour,1999; Vassel & Nesbit, 1945). Globulins comprise 70-85 % of flaxseed 
proteins, two thirds of which has a molecular mass of 250 kDa. The remainder is of low 
molecular mass in nature (Madhusudhan & Singh, 1983). A reasonably well-balanced 
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amino acid composition has been reported for flaxseed protein (Sammour, 1999). In 
particular, it has a favorable ratio of amino acids with Lys, Thr and Tyr as the limiting 
amino acids. It is a good source of sulfur amino acids (Met and Cys) and is rich in 
branched chain amino acids (BCAA; Ile, Leu and Val) (Oomah & Mazza, 1995). 
Similar to other seed storage proteins (SSPs), the major protein of flaxseed (cultivar: 
NorMan) has high contents of the amino acids Arg, Glu/Gln, and Asp/Aspn (Oomah, 
2001; Oomah & Mazza, 2000). The essential amino acid index of flaxseed meal is 69 
compared to 79 and 75 for soybean and canola meals, respectively. Similarly, the 
protein score based on the most limiting amino acid relative to the Food and Agriculture 
Organization (FAO) requirement is 82 for flaxseed meal and 67 for soybean meal 
(Sosulski & Sarwar, 1973). The Lys to Arg ratio that determines the cholesterolemic 
and atherogenic effects of a protein (Czarnecki & Kritchevsky, 1992) is 0.37 for 
flaxseed, suggesting that it is less lipidemic and atherogenic compared to soybean or 
canola proteins, which have a Lys to Arg ratio of 0.88 (Oomah, 2001; Oomah & Mazza, 
2000).  
 
Although flaxseed proteins show similar properties to other oilseed proteins, the 
nutritional and therapeutic application of flaxseed protein has not yet been fully 
exploited. The present inconclusive findings on CVD protection by ALA and lignan in 
flaxseed is motivating a switch in research into flaxseed protein and investigation of 
whether the protein component of flaxseed is contributing to the cardioprotective 
benefits shown by flaxseed and its meal. However, upon consumption, protein 
undergoes digestion by a series of proteolytic enzymes in the GI tract. Therefore, it is  
important to investigate whether any of the products released during digestion of 
flaxseed protein is cardioprotective. In recent years, there has been a huge interest in the 
phenomenon of bioactive peptides. Apart from providing the amino acid requirement, 
food proteins including seed proteins have the ability to generate bioactive peptides 
possessing various physiological and health benefits (Kitts & Weiler, 2003). Since 
flaxseed protein is currently not considered as a bioactive component, studies on the 
ability of flaxseed proteins to release cardioprotective bioactive peptides during GI 
digestion would be of interest. Such studies would not only help to fill the present 
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information gap on health benefits of flaxseed protein but will support the regulatory 
bodies in the development of health claims for flaxseed and its products. 
  
2.8 Food derived bioactive peptides 
Bioactive peptides are defined as specific protein fragments that have a positive impact 
on body functions or conditions and which ultimately may influence health (Kitts & 
Weiler, 2003). They are inactive within the sequence of the parent protein, and can be 
released during hydrolysis by proteolytic microorganisms and through the action of 
proteolytic enzymes derived from microorganisms or plants (Korhonen & Pihlanto, 
2006). 
 
To date, controlled enzymatic hydrolysis is the most popular method to produce 
bioactive peptides from food proteins. Although peptides can be released from acid 
hydrolysis, which is simple and less expensive, enzymatic hydrolysis is easier to control 
and does not damage the amino acids due to the use of mild reaction conditions (Gilani 
et al., 2008). Proteinases (endopeptidases) such as chymotrypsin, papain, pepsin,  
plasmin, protenase K, subtilisin, Thermolysin, and trypsin, are some of the commonly 
used enzymes for the production of bioactive peptides from food protein (Yamamoto et 
al., 2003).  
 
Gastrointestinal digestion is another important pathway by which bioactive peptides are 
released from food proteins. The bioactive peptides generated during GI digestion of 
food proteins as well as orally administered bioactive peptides following digestion, can 
either be absorbed via the intestine, enter the blood circulation intact and exert systemic 
effects or produce local effects in the GI tract (e.g. by binding directly to epithelial cell 
surface receptor sites). The main mechanisms in the human body by which these 
bioactive peptides can be activated or inactivated include digestion by proteolytic 
digestive enzymes, absorption through the intestinal tract and further hydrolysis by 
serum peptidases (Pihlanto & Korhonen, 2003). Bioactive peptides have been shown to 
possess different activities in vitro and in vivo depending on the sequence of amino 
acids. Such activities include antihypertensive, anti-oxidative, antithrombotic, 
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antimicrobial, hypocholesterolemic, opioid, immunomodulatory and other activities. 
(Erdmann et al., 2008; Pihlanto & Korhonen, 2003; Yust et al., 2003). Many of the 
bioactive peptides are multifunctional and can possess more than one activity. Upon 
oral administration, bioactive peptides may affect the major body systems, namely the 
cardiovascular, digestive, immune and nervous systems, reducing the risk of various 
lifestyle related diseases (Korhonen & Pihlanto, 2006; Yoshikawa et al., 2000). Due to 
the health enhancing properties and safety profiles such as absence of toxicity, these 
peptides have gained interest as components in functional foods and nutraceuticals. The 
most widely used method for yielding bioactive peptides in vitro is the enzymatic 
hydrolysis by pancreatic enzymes, especially trypsin. Once the amino acid sequence of 
the peptide is known, the peptides can be synthesized by chemical synthesis or 
recombinant DNA technology. Chemical synthesis is useful for synthesis of short 
sequences whereas the latter is useful for larger peptides (Moller et al., 2008). 
 
Food-derived bioactive peptides commonly contain two to nine amino acids (Kitts & 
Weiler, 2003). However, this range may be extended to 3-20 or more amino acid 
residues (Korhonen & Pihlanto, 2003). For example lunasin, a food-derived peptide  
with proven anticancer activity, contains 43 amino acids with a molecular weight of 
5400 Da (Joeng et al., 2002). Bioactive peptides have been mainly isolated and studied 
from animal protein sources including bovine milk, cheese and dairy products. (Moller 
et al., 2008). Bioactive peptide sequences are found in other animal and plant proteins 
too. These include bovine blood, gelatin, meat, eggs, fish, wheat, soy, corn, rice, 
sorghum, mushroom, pumpkin and garlic (Darragh, 2002; Moller et al., 2008). Several 
food applications of bioactive peptides, especially those with antihypertensive activity, 
have already evolved; caseinophosphopeptides are currently used as dietary and 
pharmaceutical supplements, and fermented milk products based on antihypertensive 
peptides are on the market in Japan and Finland (Korhonen, 2002; Yamamoto, 2010). 
Antihypertensive peptides prepared from hydrolysis of sardine protein and peptide 
soups containing antihypertensive bonito hydrolysate are currently available in Japan 
(Yamamoto, 2010). However, most of the exogenous bioactive peptides are ineffective 
after oral administration because of their sensitivity to endothelial peptidases or 
 
 
20 
 
difficulty in intestinal absorption. In contrast, some bioactive peptides derived from 
food proteins are active after oral administration even though their specific activities are 
not very high. This is due to their smaller molecular size and resistance to peptidases 
(Yoshikawa et al., 2000). However, research on the absorption of biologically 
functional peptides and digestive enzyme resistant peptides in the intestine is limited 
(Yamamoto et al., 2003). 
 
2.9 Fate of food proteins and bioactive peptides in the human gastrointestinal tract 
Food proteins are extensively hydrolyzed at all stages of GI digestion before being 
transferred as di- or tri-peptides to the basolateral side of the intestinal enterocytes 
(Roberts et al., 1999). The human GI tract secretes a number of peptidases that function 
synergistically to cleave polypeptide chains into amino acids and small peptides. It is 
evident that a significant proportion of dietary nitrogen is absorbed into the body in the 
form of small peptides (Roberts et al., 1999). Due to their specific activities, digestive 
enzymes play a major role in regulating the release of bioactive peptides from food  
proteins. Therefore, the digestibility of a food protein is an indication of its efficacy to 
generate bioactive peptides during GI digestion. Bioavailability is usually defined as the 
fraction of an oral dose of a parent compound or active metabolite from a particular 
preparation that reaches the systemic circulation (Fernandez-Garcia et al., 2009). 
Therefore, when a food protein is ingested, its digestibility as well as bioavailability of 
the end products will play crucial roles in determining whether bioactive peptides can 
be released from the protein and become available to express respective bioactivities in 
the human body. The physical form in which foods are consumed is considered as an 
important factor to be considered in determining the digestibility and bioavailability of 
nutrients (Bjorcket al., 1994). 
 
The food proteins are exposed to various proteolytic enzymes during their passage 
through GI tract. The ingested food, after mastication and bolus formation in the mouth, 
passes into the stomach where the pH is in the range of 1.5-3. The digestion of food 
proteins begins in the stomach where proteolysis is initiated by pepsins that are 
activated at acidic pH. The pepsins catalyze hydrolysis of peptide bonds involving Phe, 
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Tyr and Leu (Erickson & Kim, 1990). This gastric phase results in a mixture of long 
polypeptides, short oligopeptides, and some free amino acids (Erickson & Kim, 1990). 
When the digested products enter into the first part of the small intestine, the duodenum, 
the products are further digested by enzymes (trypsin, chymotrypsin, elastase, 
carboxypeptidase A and B) that are synthesized and released by the pancreas. The 
pancreatic enzymes are activated in the duodenum where the rise in pH to neutral or 
slightly alkaline conditions inactivates the gastric pepsins. Trypsin cleaves the peptide 
bonds on the carboxyl side of the basic amino acids (Arg, Lys). Chymotrypsin 
hydrolyzes peptide bonds where the carbonyl groups are aromatic (Tyr, Phe and Trp). 
Elastases are endopeptidases that cleave the interior peptide bonds of protein and 
polypeptides. Elastase hydrolyzes peptide bonds where the amino acid contributing to 
the carboxylic groups are aliphatic (Ala, Leu, Gly, Val, Ile). Carboxypeptidase A and B 
are major exopeptidases in pancreatic secretion. They remove single amino acid groups 
from the carboxylic ends of proteins and oligopeptides. These pancreatic enzymes 
digest the peptides released from the gastric phase further into a mixture of short 
oligopeptides (2-6 amino acids) and free amino acids (Erickson & Kim, 1990).  
 
In the small intestine, the proteins are exposed to an extensive range of biosurfactants 
including bile acids and phospholipids and the products of lipolysis. Although bile acids 
aid fat digestion, recent studies show that they are important for protein digestion as 
well. Gass et al. (2007) showed that hydrolysis of proteins by trypsin and chymotrypsin 
was significantly enhanced by the presence of conjugated bile acids. It was suggested 
that this was due to the bile acids destabilizing the protein structure and making it more 
susceptible to proteolysis. However, this was not shown for all proteins and the effect of 
bile acids is attenuated in the presence of high levels of fatty acids and monoglycerides 
as the competition for bile acids to get incorporated into the fat based micelles is 
increased. 
 
The small intestine is the principal site of absorption of the end products of protein 
digestion. It is shown that small (di- and tri-peptides) and large (10-51 amino acids) 
peptides generated in the diet can be absorbed intact through the intestine and produce 
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biological effects at the tissue level (Roberts et al., 1999). The free amino acids are 
absorbed via enterocytes of the small intestinal brush border membrane through distinct 
amino acid transport systems. However, the oligopeptides can undergo further 
hydrolysis prior to absorption by brush border peptidases resulting in a mixture of free 
amino acids, di and tri peptides. The intestinal brush border is rich in amino peptidases, 
which provide functional complementation to carboxypeptidases in pancreatic juice. 
The major amino peptidases (N and A) cleave N terminal neutral and anionic amino 
acids, respectively. In addition, the intestinal brush border has endopeptidase and 
dipeptidase activity. For example dipeptidyl amino peptidase IV releases dipeptides 
from the N-terminus of oligopeptides with Pro or Ala in the penultimate position. 
Hence, the dipeptides released by the brush border enzymes are generally of the X-Pro 
type (Vermeirssen et al., 2004). Proline and hydroxyl-Pro-containing peptides are 
generally resistant to degradation by these brush border enzymes. Furthermore,  
tripeptides containing the C-terminal Pro-Pro are reported to be resistant to Pro-specific 
peptidases. Also it has been observed that large polypeptides or proteolysis-resistant 
entire proteins can enter the blood circulation in small amounts (Vermeirssen et al., 
2004). 
 
There are several mechanisms by which peptides are transported through the intestinal 
epithelium. Electrophysiological studies conducted during 1970s and 1980s have 
suggested the existence of a peptide transport system in the intestinal epithelium by 
which peptides would be actively transported through the intestinal membrane (trans 
cellular) under a H+ gradient (Ganapathy & Leibatch, 1985). However, this transport 
mechanism carries only di- and tri-peptides (Daniel et al., 1992) whereas oligopeptides 
with more than four residues are transported through the intestinal epithelium via other 
routes such as pinocytosis or through paracellular channels (Roberts et al., 1999) 
depending on the molecular size and hydrophobicity. Figure 2.1 provides a schematic 
overview of these two pathways. After absorption via the intestinal tract, serum 
peptidase can further hydrolyze the peptide bonds. Therefore, resistance to peptidase 
degradation is a prerequisite for physiological effects of bioactive peptides following 
oral ingestion or intravenous infusion. 
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Figure 2.1 Schematic explanation of potential paths of peptide and amino acid 
absorption in the small intestine 
 
2.10 Use of in vitro methods to assess protein digestibility and release of peptides 
The amounts of essential amino acids in proteins, the digestibility, the ability to release 
amino acids and peptides with biological activities during digestion and the 
bioavailability of the digested products are among the main determinants of the 
nutritional quality and health benefits of food proteins (Gauthier et al., 1986). 
Knowledge of the release of intermediate peptides, amino acid composition and size 
distribution of peptides released during protein digestion is essential for explaining their 
biological actions (Agudelo et al., 2004). Therefore, investigations on digestion of food 
proteins and absorption of digested products in humans are important to understand the 
physiological and nutritional roles of proteins. However, due to ethical reasons and the 
cost involved, it is becoming increasingly difficult to carry out such research using 
humans as subjects. Hence, there is a need for exploring validated animal models and in 
vitro models, which can adequately predict protein digestion and absorption in humans. 
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Pigs and rats have been widely used as animal models. In vitro studies have been 
developed to simulate the physiological conditions and sequence of events that occur 
during digestion in the human GI tract. The features that simulate in vitro models to true 
GI digestion are physiological temperature, mixing or agitation, chemical and 
enzymatic composition of saliva, gastric juice, duodenal juice and bile juice. The in 
vitro GI model is defined as a static model when physical processes that occur in vivo 
are not reproduced. The dynamic models mimic the in vivo physical processes. They 
take into account new variables such as changes in the viscosity of digesta, particle size 
reduction, diffusion and partitioning of nutrients (Fernandez-Garcia et al., 2009). 
 
A more practical and realistic approach to in vitro models is to separately evaluate the 
specific contributions of oral and gastric digestion, intestinal digestion by pancreatic 
enzymes, brush-border hydrolysis, and eventually intestinal absorption and enterocyte 
metabolism (Savoie, 1994). In the commonly used two stage in vitro technique, the 
protein substrate is first digested with pepsin and then by pancreatin. Pancreatin is a 
crude preparation from pancreatic secretions that includes proteases such as trypsin and 
chymotrypsin (Qiao et al., 2005). However, when such enzymatic hydrolysis occurs in a 
batch process, accumulation of hydrolysis products does not reflect what happens in the 
GI tract. The accumulation of the proteolytic reaction products may impede the 
progression of hydrolysis (Stahmann & Woldegiorgis, 1975). Therefore, continuous 
removal of digestion products during in vitro proteolysis represents a more realistic 
model that represent in vivo mechanisms, where the epithelial brush border membranes 
remove the products of protein digestion from the lumen by independent mechanisms 
(Savoie, 1994).  
 
The two-step proteolysis model (digestion cell) developed by Savoie and Gauthier 
(1986) closely simulates the in vivo digestion process. This includes digestion of protein 
with a pepsin-containing reaction mixture in a closed system followed by digestion with 
pancreatin in a dialysis tube of 1 kDa molecular weight cut off. The digestion cell  
apparatus developed to perform the pancreatic digestion is made up of two concentric 
compartments. The enzymatic reaction takes place in the inner cylinder surrounded by 
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the membrane and mixing is provided by a magnetic stirrer. The products released 
during digestion diffuse through the membrane and are collected by the circulation of 
sodium phosphate buffer in the outer cylinder. The entire system is submerged in a 
water bath maintained at constant temperature. Simultaneous removal of hydrolysis 
products is achieved by continuous replacing of the buffer using a peristaltic pump. This 
approach enables direct identification of amino acid composition of the digestion 
products and their release kinetics during the digestion process. Also it allows for 
continuous collection of dialyzable digestion products of low molecular weight (less 
than 1 kDa) that correspond to the end products of luminal digestion (Agudelo et al., 
2004). However, it is important that an in vitro versus in vivo validation process is 
carried out to delineate the reliability of the in vitro models.  
 
2.11 Role of food derived bioactive peptides in reducing cardiovascular diseases  
Cardiovascular disease is the leading cause of death worldwide. In 2004 an estimated 
17.1 million people died from CVDs, representing 29 % of all global deaths. Of these 
deaths, an estimated 7.2 million were due to CHD and 5.7 million were due to stroke 
(World Health Organization, 2009). 
 
There are various factors leading to CVD, which are called CVD risk factors. In order 
to prevent CVD it is important to identify the major modifiable risk factors. They 
include tobacco and alcohol use, high blood pressure (hypertension), high serum low 
density lipoprotein (LDL) cholesterol, elevated glucose, obesity, physical inactivity, and 
unhealthy diets (MacKay & Menash, 2004; Smith et al., 2004). Since diet is a 
significant modifiable risk factor for CVD (World Heart Federation, 2007), choosing 
healthy food plays a major role as it can reduce the occurrence of many of the listed 
modifiable CVD risk factors. The current dietary recommendations to reduce CVD risk 
encourages consumption of diets rich in vegetables, fruits, whole grains and high fibre 
foods, whereas consumption of oily fish at least twice a week is recommended. It is also 
recommended to reduce saturated fat (<7 % energy) and trans fat (<1 % energy) in the 
diet and minimize consumption of foods with added sugars and salt in order to reduce 
the risk of CVD (Lichtenstein et al., 2006). Moreover, there is research evidence to 
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suggest that an increased consumption of protein (e.g. replacing carbohydrates in diet 
with protein), particularly plant protein, may further lower the risk of hypertension and 
CVD (Hu et al., 1999; Stamler et al., 1999). Release of cardio protective bioactive 
peptides upon dietary protein ingestion could be the mechanism behind these findings. 
Major activities of bioactive peptides that are related to CVD health are discussed 
below. 
 
2.12 Bioactivities of food derived peptides 
2.12.1 Antihypertensive effect and angiotensin I-converting enzyme inhibitory 
peptides 
Hypertension or high blood pressure is a major health problem all over the world, 
affecting 50 % of individuals above 55 years in many industrialized countries, and is a 
major risk factor for coronary heart disease, congestive heart failure, stroke and renal 
disease (Hermanson, 2000). A person is said to be hypertensive when SBP >140 mmHg 
or DBP >90 mmHg (140/90 mmHg) or when taking medications for hypertension 
(Wolz et al., 2000). In a recent meta-analysis of clinical trials, Pripp (2008) identified 
that food protein derived peptides play a significant role in blood pressure reduction. 
Many of these clinical trials were done using ACEI peptides.  
 
Angiotensin I-converting enzyme plays a critical role in regulation of blood pressure. It 
is a zinc metalloprotease, a component in the renin angiotensin system (RAS), and a 
dipeptidylcarboxypeptidase that hydrolyzes carboxy terminal dipeptides from 
oligopeptide substrates (Figure 2.2). ACE and other components of RAS coexist locally 
in various tissues including blood vessels, kidney, adrenal glands, heart and brain in 
addition to circulation. High concentrations of ACE are found on epithelial surfaces 
such as intestinal, pulmonary surface, choroid plexus, and placental brush borders 
influencing the fluid and electrolyte balance at these fluid membrane interfaces (Ehlers 
& Riordan, 1989). ACE increases blood pressure by catalyzing the conversion of the 
decapeptide angiotensin I into the potent vasoconstricting octapeptide angiotensin II, 
and also by catalyzing the degradation of bradykinin, a blood pressure lowering 
nonapeptide. 
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Figure 2.2 Summary of renin-angiotensin system indicating major drug inventions 
(ACE inhibitors, Beta blockers and Renin inhibitors) to regulate hypertension  
 
Angiotensin II leads to several effects that are central and causes further increases in 
blood pressure (Figure 2.2). Therefore, inhibition of ACE results in an overall 
antihypertensive effect (Vermeirssen et al., 2002). ACE has two domains (N and C), 
each of which contains an active site with a His-Glu-X-X-His. The His residues are 
considered to participate in Zn binding and Glu residue in the catalytic mechanism. Of 
these, the C domain is the dominant angiotensin I-converting site (Natesh et al., 2003). 
The first available competitive inhibitors of ACE were isolated from venom of Bothrops 
jararaca snake as naturally occurring peptides (Ferreira et al., 1970). The pentapeptide, 
Glu-Lys-Trp-Ala-Pro and the nonapeptide Glu-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro 
isolated from the venom were found to have antihypertensive properties. 
 
There are studies indicating the effect of peptide structure on its ACEI activity. The 
structure-activity correlation studies of analogs of both peptides indicated that their 
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carboxy terminal tripeptide residues (Trp-Ala-Pro) play a predominant role in 
competitive binding to the active site of ACE (Cheung et al., 1980) (Figure 2.3). The 
antihypertensive effect of such peptides led to development of the highly potent ACEI 
drug, Captopril that inhibits ACE by coordinating strongly with the Zn atom in the 
active site of ACE by coupling its sulfhydryl group to the dipeptide Ala-Pro (Figure 
2.3).  
 
Numerous other ACE inhibitors such as Enlapril® and Lisinopril® have also been 
developed (Wei et al., 1992). In addition to ACE inhibitors, renin inhibitors, which 
block the action of renin and thereby prevent formation of both angiotensin I and 
angiotensin II, also have been developed for lowering blood pressure. Renin inhibitors 
do not affect kinin metabolism and are not expected to cause dry cough and 
angioneurotic edema, which are characteristic side effects of ACE inhibitors (Karlberg, 
1993). However, except for Alliskerin (a non-peptide renin inhibitor), most of the renin 
inhibitors identified so far were found to be clinically ineffective when given orally 
(Gradman et al., 2005). 
 
Several studies have been conducted to identify and isolate peptides with ACEI activity 
from food proteins. Trp, Tyr, Phe, and Pro are the most potent C-terminal amino acids 
of these peptides that contribute immensely  to substrate binding at the ACE active site 
and thereby inhibit their activity of ACE (Cheung et al., 1980). Wu et al. (2006), from a 
database containing 168 dipeptides and 140 tripeptides, identified that amino acid 
residues with bulky side chains as well as hydrophobic side chains are preferred for 
ACEI dipeptides. For tripeptides, the most favourable residues for the carboxyl 
terminus are aromatic amino acids, while positively charged amino acids are preferred 
for the middle position, and hydrophobic amino acids for the amino terminus.  
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Figure 2.3 Proposed model for binding of venom nonapeptide and Captopril on to 
the active sites of angiotensin I-converting enzyme (Modified from Cushman et al., 
1981) 
 
Recently, few studies have shown the presence of ACEI activity in hydrolyzed flaxseed 
protein (Wu et al., 2004; Udenigwe et al., 2009). ACEI peptide sequences can be 
liberated from flaxseed protein by proteolytic enzymes as demonstrated with defatted 
flaxseed meal in a recent patent (Wu et al., 2004). Recently, Udenigwe et al. (2009) 
hydrolyzed flaxseed protein using various proteases (alcalase, ficin, pancreatin, papain, 
pepsin, Thermolysin and trypsin) and the resulting hydrolysates were tested for ACEI 
and renin inhibitory activity. In this study, all the protein hydrolysates showed ACEI 
activity whereas <1 kDa fraction of papain and pancreatin hydrolysate did not show 
renin inhibition. However, it is still not known whether these ACEI peptides can be 
released during sequential digestion of flaxseed protein by GI enzymes. 
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Table 2.1 Examples of angiotensin I-converting enzyme inhibitory peptides derived from enzymatic hydrolysis of seed storage 
proteins 
Source of protein Enzymes generating 
ACEI peptides 
Amino acid sequence of peptides Details Reference 
Wheat (Triticum aestivum L.) 
germ 
Bacillus 
licheniformis 
alkaline protease 
 
Ile-Val-Tyr Simulated GI digestion 
increased the activity 
Matsui et al., 
1999 
Buckwheat (Fagopyrum 
esculentum Moench) flour 
 
Pepsin, 
chymotrypsin & 
trypsin 
 
Tyr-Gln-Tyr 
 Pro-Ser-Tyr 
 
Lowered SBP of SHR Li et al., 2002 
Chick pea (Cicer arietinum 
L.) legumin 
Alcalase Met-Asp, Asp-Phe-Leu-Ile, 
Met-Phe-Asp-Leu Met-Asp-Leu 
Met-Asp-Leu-Ala 
 
In vitro study Yust et al., 
2003 
Field pea (Pisum sativum L.) 
protein 
pepsin, 
chymotrypsin & 
trypsin 
 
NR Lowered mean arterial 
blood pressure in SHR 
Vermeirssen et 
al., 2005 
Mung bean (Phaseolus 
radiatus L.) protein 
Alcalase Lys-Asp-Tyr-Arg-Leu 
Val-Thr-Pro-Ala-Leu-Arg 
Lys-Leu-Pro-Ala-Gly-Thr-Leu-
Phe 
 
In vitro study Li et al., 2006 
Soybean (Glycine max L. 
Merr.)  
Alcalase Asp-Leu-Pro, Asp-Gly Stable to in vitro GI 
digestion 
 
Wu & Ding, 
2002 
Pepsin Ile-Ala, Tyr-Leu-Ala-Gly-Asn-
Gln, Phe-Phe-Leu, Ile-Tyr-Leu-
Leu 
Lowered blood 
pressure in SHR 
Chen et al., 
2003 
Cont’d. 
30 
 
 
 
 
31 
 
Table 2.1 contd. Examples of angiotensin I-converting enzyme inhibitory peptides derived from enzymatic hydrolysis of seed 
storage proteins  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 NR: Not reported; SBP: Systolic blood pressure; SHR: Spontaneously hypertensive rats; GI: Gastrointestinal 
 
 
Source  Enzymes generating 
ACEI peptides 
Amino acid sequence of peptides Details Reference 
Soybean (Glycine 
max L. Merr.)  
Pepsin & pancreatin NR In vitro dynamic model 
simulating upper GI tract 
 
Lo et al., 2006 
Rapeseed/Canola 
(Brassica napus) 
protein 
 
Subtilisin® Ile-Ty, Val-Trp, Val-Trp-Ile-Ser Lowered blood pressure 
in SHR 
Marczak et al., 
2003 
Canola meal Alcalase Val-Ser-Val 
Phe-Leu 
 
In vitro study Wu et al., 2008 
Sunflower 
(Helianthus ananus 
L.) protein 
Pepsin and pancreatin Phe-Val-Asn-Pro-Gln-Ala-Gly-Ser In vitro study Megias et al., 2004 
 
Flaxseed protein  
 
Pepsin, ficin, trypsin, 
papain, Thermolysin, 
pancreatin and Alcalase 
 
NR 
 
In vitro study 
 
Udenigwe et al., 
2009 
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2.12.2 Antioxidant activity 
Free radicals such as superoxide (O2•-), OH• and other oxygen-derived species (H2O2, 
and hypochlorous acid) are formed constantly in the human body during oxygen 
metabolism in addition to exposure to oxidants such as air pollutants, ozone, oxides of 
nitrogen, tobacco smoke, and motor vehicle exhaust (Clarkson & Thompson, 2000). 
The free radicals are defined as chemical species that contain an unpaired electron in the 
outer orbital (Cheesman & Slatter, 1993). They are highly reactive as the unpaired 
electron in the outer orbit allows attraction of electrons from other molecules resulting 
in another free radical that is capable of reacting and damaging another molecule 
(Clarkson & Thompson, 2000). Molecules such as hydrogen peroxide (H2O2) that are 
generated in the biological system via free radicals are reactive oxygen species (ROS). 
The ROS includes both oxygen derived free radicals and non-radical oxygen derivatives 
that are involved in oxygen radical production (Cheeseman & Slatter, 1993). For 
example, O2•- arising either through metabolic processes or following oxygen 
“activation” by physical irradiation, is considered the “primary” ROS. Two O2•-
molecules can react together to form hydrogen peroxide and oxygen. H2O2 can break 
down to generate the most reactive OH• via the Haber-Weiss reaction which proceeds 
quickly when metal ions such as Fe2+ or Cu+ are present (Fenton reaction when iron is 
the catalyst) (Benzie, 2000; Cheeseman & Slatter, 1993). The free radicals can attack all 
macromolecules, causing lipid peroxidation (oxidative destruction of PUFAs in cell 
membranes), DNA damage and protein degradation during oxidatively stressful events. 
Of these, unsaturated lipids are the most susceptible (Clarkson & Thompson, 2000). 
Specifically, the oxidative modification of LDL leads to oxidized LDL that can increase 
atherogenesity. Therefore, uncontrolled production of free radicals is associated with 
the onset of various CVDs including atherosclerosis, ischemic heart disease, 
hypertension, cardiomyopathies, cardiac hypertrophy and congestive heart failure 
(Clarkson & Thompson, 2000). 
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The human body has an endogenous antioxidant defense system that consists of various 
enzymes (such as catalase and superoxide dismutase) and antioxidant compounds. 
These antioxidants can prevent or inhibit oxidation by preventing generation or by 
inactivation of ROS. Several naturally occurring antioxidant peptides such as 
glutathione (GSH: Glu-Cys-Gly), carnosine (-Ala-L-His), anserine (-Ala-3 methyl-L-
His), homocarnosine ( aminobutyryl-L-His) with free radical scavenging activity have 
been identified in the human body (Kelly, 1999). Of these, GSH scavenges free radicals 
by donating its H atom and by acting as a co-substrate in reduction of H2O2 and other 
hydroperoxides by GSH peroxidase (Kelly, 1999). Amongst the His-containing 
peptides, carnosine, one of the most abundant (1-20 mM) nitrogenous compounds 
present in the non-protein fraction of vertebrate skeletal muscle and certain other 
tissues, including olfactory epithelium, scavenges OH• , O2•- and chelates Cu, which in 
turn prevents the Haber-Weiss reaction (Gariballa & Sinclair, 2000). However, these 
endogenous defenses are not completely efficient (Jacob & Burry, 1996). When ROS 
are generated excessively or the antioxidative defenses are depressed (oxidative stress), 
a number of pathological events take place (Figure 2.4). Therefore, antioxidants in the 
human diet are of great interest as possible protective agents to help the human body to 
reduce oxidative damage (Wu et al., 2005). 
 
In addition to the well-known dietary antioxidants such as vitamin C, E, polyphenols 
and carotenoids, recent studies have shown that peptides with antioxidant activity can 
be released by food proteins. Some of these food derived antioxidant peptides exert 
antioxidant activity against enzyme (lipoxygenase mediated) and non-enzyme 
peroxidation of lipids and essential fatty acids (Chen et al., 1996). The antioxidant 
mechanism of these peptides has been suggested to be due to metal ion chelation, free 
radical scavenging and singlet oxygen quenching or a combination of these mechanisms 
(Chen et al., 1998; Kitts & Weiller, 2003). Another possible mechanism could be 
induction of genes that protect cells from ROS damage (Erdmann et al., 2008). The 
major examples of food proteins releasing antioxidant peptides are milk casein 
(Suetsuna et al., 2000), whey protein (Hernandez-Ledesma et al., 2005) and egg 
proteins (Davalos et al., 2004). 
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Figure 2.4 Damage to biological molecules by reactive oxygen species leading to 
increased risk of diseases (Modified from Benzie, 2000) 
 
Several studies report the antioxidant activities of food protein hydrolysates in vitro 
operating on multiple antioxidant mechanisms (Table 2.2). The majority of hydrolysates 
have shown multiple antioxidant mechanisms (Table 2.2). However, only few studies 
have attempted to isolate and sequence the antioxidant peptides from the hydrolysates. 
Such studies show the importance of certain amino acids in the peptide sequence to 
exert the antioxidant mechanism. Chen et al. (1995) isolated six antioxidant peptide 
fragments from digestion of soy  conglycinin with protease S. The peptides (P1: Val-
Asn-Pro-His-Asp-His-Gln-Asn; P2: Leu-Val-Asn-Pro-His-Asp-His-Gln-Asn, P3: Leu-
Leu-Pro-His-His, P4: Leu-Leu-Pro-His-His-Ala-Asp-Ala-Asp-Tyr, P5: Val-Ile-Pro-Ala-
Gly-Tyr-Pro, P6:Leu-Gln-Ser-Gly-Asp-Ala-Leu-Arg-Val-Pro-Ser-Gly-Thr-Thr-Tyr- 
Tyr) consisted of 5-16 amino acid residues including hydrophobic amino acids such as 
Val or Leu at the N-terminal position and Pro, His and Tyr in the sequences. Suetsuna et 
al. (2000) isolated O2•-, OH• and DPPH radical scavenging peptide Tyr-Phe-Tyr-Pro-
Glu-Leu from pepsin hydrolyzed casein and observed that the Glu-Leu analog of the 
peptide plays a role in free radical scavenging.  
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Table 2.2 Antioxidant mechanisms of selected food protein hydrolysates 
 
O2•-: Superoxide radical; OH•: Hydroxyl radical; DPPH•: 2, 2-diphenyl-1-picrylhydrazyl radical; ABTS•+: 
2, 2’-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source protein 
 
Enzyme/s Antioxidant Mechanism Reference 
Casein pepsin Scavenging DPPH•, O2•-, OH• Suetsuna et 
al., 2000 
 
Soy  conglycinin microbial enzymes 
(Protease M, N, P 
and S) and Pepsin 
 
Inhibition of linoleic acid 
peroxidation 
Chen et al., 
1995 
Wheat germ protein 
isolate 
Alcalase Inhibition of linoleic acid 
peroxidation, reducing power, 
Fe2+ chelating effect, scavenging 
DPPH•, O2•-, OH• 
 
Zhu et al., 
2006 
Zein from maize Alcalase and 
papain 
Inhibition of liposome oxidation, 
Cu+ chelation, reducing power, 
radical scavenging 
 
Kong & 
Xiong, 2006 
Chick pea protein Alcalase Inhibition of linoleic acid 
oxidation, Reducing power, 
Scavenging DPPH•, O2•-, OH• 
 
Li et al., 
2008 
Rapeseed protein Alcalase Reducing power, Scavenging 
DPPH•, O2•-, OH• 
 
Pan et al., 
2009 
Lima bean 
(Phaseolus lunatus) 
and jamapa bean 
(Phaseolus 
vulgaris) protein 
Alcalase and 
Flavourzyme 
Scavenging ABTS•+ radical 
cation 
Torruco-uco 
et al., 2009 
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The exact mechanism by which peptides exhibit antioxidant potency is not clear. 
However, several research findings show that amino acid composition and structural 
features of the peptide play a role. In a recent review, Erdmann et al. (2008) reported 
that the presence of a high amount of His and some hydrophobic amino acids in the 
peptide is related to their antioxidant potency. The activity of His-containing peptides is 
thought to be due to hydrogen donating ability, lipid peroxy radical trapping, and /or 
metal ion chelating ability of the imidazole group (Erdmann et al., 2008). Also the 
addition of Leu or Pro residues to the N-terminus of a His-His peptide would enhance 
antioxidant activity. Chen et al. (1996) have shown that a soy protein derived peptide 
with a Pro-His-His sequence shows the highest antioxidant capacity. The 
hydrophobicity of the peptide also would play a role due to its increased accessibility to 
hydrophobic targets such as fatty acids (Chen et al., 1998). Furthermore, it is evident 
that the antioxidant effect of certain amino acids are higher when they are incorporated 
into dipeptides suggesting that the peptide bond and specific structural features of the 
peptides also play a crucial role in determining antioxidant potency (Erdmann et al., 
2008). 
 
Udenigwe et al. (2009) recently reported on the ability of isolated flaxseed protein to 
liberate antioxidant peptides (with DPPH•, O2•-, OH•) when hydrolyzed with ficin, 
pancreatin, papain, pepsin, Thermolysin and trypsin. These finding support our 
hypothesis that flaxseed protein consist of amino acid sequences that have antioxidant 
properties. However, whether flaxseed protein can still release these antioxidant 
peptides during the sequential digestion of protein in the GI tract is not known yet. 
 
2.12.3 Cholesterol lowering ability 
Among the dietary proteins, soy protein, has demonstrated cholesterol lowering 
properties in various populations (D’Amico et al., 1992; Laurin et al., 1991). In a meta-
analysis of human studies, Anderson et al. (1995) showed that rather than animal 
proteins, soy protein intake significantly decreased serum concentrations of total 
cholesterol, LDL cholesterol, and triacylglycerols in humans. Soy isoflavones were 
considered as the components that contributed to this cholesterol lowering effect. Sirtori 
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et al. (1997) demonstrated that a marked plasma cholesterol reduction was caused by 
isoflavone–poor soybean products, suggesting the cholesterol lowering ability of a non-
isoflavone component in soy. A few years later the U.S. FDA approved health claims 
for soy protein and CHD based on its cholesterol lowering effect (Messina et al., 2009). 
However, the mechanism responsible for the plasma cholesterol lowering ability of soy 
protein remained questionable until recently. There is evidence suggesting that bile acid 
binding ability of the peptides that are generated during soy protein digestion 
contributes to reduce blood cholesterol level (Park et al., 2005).  
 
Bile acids are acidic steroids synthesized in the liver from cholesterol. They are secreted 
into the duodenum to participate in the digestion process and are actively reabsorbed 
from the terminal ileum to undergo enterohepatic circulation (Kahlon & Shao, 2004). 
Studies on the hypocholesterolemic effect of soy proteins have hypothesized that a 
peptide with high bile acid binding ability could inhibit the reabsorption of bile acids in 
the ileum and stimulate cholesterol transformation into bile acids in plasma and liver, 
which will ultimately reduce plasma cholesterol level (Figure 2.5) (Park et al., 2005). 
Such peptides could also decrease the micellar solubility of cholesterol in the small 
intestinal epithelial cells and decrease the blood cholesterol level.  
 
Leu-Pro-Tyr-Pro-Arg, which is a fragment of soybean glycinin, has reduced serum 
cholesterol in mice after oral administration at a dose of 50 mg/kg for 2 days (25.4 % 
and 30.6 % reduction in total cholesterol LDL-cholesterol, respectively). However, they 
did not increase the excretion of fecal cholesterol and bile acids indicating that the 
mechanism responsible for hypocholesterolemic activity might not be the binding of 
bile acids (Yoshikawa et al., 2000).  
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Figure 2.5 Hypocholesterolemic action of bile acid binding peptides. Bile acids are 
synthesized from cholesterol, conjugated and then excreted into the bile ducts. 
Released bile acids are reabsorbed via intestinal epithelium facilitating the dietary 
cholesterol absorption. Dietary protein derived bile acid binding peptides enhance 
bile acid excretion with feces, reducing the bile acid re-absorption 
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There are studies on soybean glycinin, which support the hypothesis of bile acid binding 
action of soybean peptides. It has been demonstrated that soy 11S globulin has higher 
hypocholesterolemic ability than 7S soy globulin, native soy protein and casein (Park et 
al., 2005). Of the five subunits (group I: A1aBIb, A1bB2, and A2B1a; group II: A3B4, 
and A5A4B3) of hexameric soybean glycinin, Choi et al. (2002) identified a potential 
bile acid binding peptide sequence (Val-Ala-Trp-Trp-Met-Tyr) in acidic polypeptide 
A1a of the A1aB1b subunit. Incorporation of the nucleotide sequence encoding this 
peptide in the DNA code, which corresponds to amino acids of A1a polypeptide has 
improved bile acid binding ability of glycinin indicating the ability to improve the 
physiological functions of SSP by introducing a favorable oligopeptide sequence (Choi 
et al., 2004). Soy protein peptic hydrolysate with phospholipids (SPHP) has shown 
significantly greater in vitro bile acid binding capacity than that of soy protein peptic 
hydrolysate without phospholipids (SPH) (Nagaoka et al., 1999). The cholesterol 
micelles containing SPHP and SPH significantly suppressed cholesterol uptake by 
Caco-2 cells compared to cholesterol micelles containing casein tryptic hydrolysate. 
The in vivo studies conducted using rats have indicated that the fecal excretion of total 
steroids was significantly greater in rats fed with SPHP than SPH. 
 
Currently, there are several studies (in vitro and in vivo) showing the cholesterol 
lowering effect of different protein hydrolysates (Lovati et al., 2000; Ma & Xiong, 
2009; Mendonca et al., 2009; Park et al., 2005; Nagaoka et al., 2001; Yoshie-Stark et 
al., 2004; Yoshie-Stark et al., 2008) (Table 2.3). Of these, several in vitro studies show 
the ability of food protein derived peptides to bind bile acids, which will lead to 
cholesterol lowering (Ma & Xiong, 2009; Park et al., 2005; Yoshie-Stark et al., 2004; 
Yoshie-Stark et al., 2008). In these studies, several proteins such as soy, rapeseed, lupin 
and buckwheat proteins have also shown bile acid binding in the unhydrolyzed state. 
However, there is lack of information on characterization (e.g. amino acid sequence) of 
most of these bioactive cholesterol lowering peptides (Table 2.3).  
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Table 2.3: Cholesterol lowering mechanisms and identified sequences of food 
protein derived bioactive peptides 
 NR: Not reported; LDL: Low density lipoprotein
Source 
Protein 
 
Enzymes Type of 
Study 
Cholesterol 
Lowering 
Mechanism 
Amino 
acid 
Sequence 
of Peptide 
Reference 
Bovine milk 
β 
lactoglobulin 
Trypsin In vivo 
(rats) 
Inhibition of 
micellar solubility 
of cholesterol which 
suppresses 
cholesterol 
absorption  
 
Ile-Ile-Ala-
Glu-Lys 
Nagaoka 
et al., 
2001 
Soy protein 
concentrate 
Pepsin & 
trypsin 
Human 
hepatome 
cells 
 
Up regulation of 
LDL receptors 
NR Lovati et 
al., 2000 
Amaranth 
protein 
- In vivo 
(hamsters) 
Protein digestibility 
and excretion of 
cholesterol and bile 
acids 
 
NR Mendonca 
et al., 
2009 
Rapeseed 
protein 
Pepsin & 
pancreatin 
In vitro  Bile acid binding NR Yoshie-
Stark et 
al., 2008 
 
Lupin protein Pepsin & 
pancreatin 
In vitro  Bile acid binding NR Yoshie-
Stark et 
al., 2004 
 
Buckwheat 
protein 
Pepsin & 
pancreatin 
In vitro Bile acid binding NR Ma & 
Xiong, 
2009 
 
Soy 11S 
globulin 
Pepsin In vitro Bile acid binding Ile-Ala-
Val-Pro-
Gly-Glu-
Val-Ala 
Park et 
al., 2005 
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2.12.4 Antithrombotic activity 
The blocking of a coronary artery by thrombi (blood clots) leading to acute arterial 
thrombosis is the primary cause of most cases of myocardial infarction (heart attack) 
and about 80 % of strokes. These are collectively the most common cause of death in 
the developed world (Xiong et al., 2009; Zhang et al., 2008). A key phase of this blood 
clotting process is the interaction between thrombin and fibrinogen to form the fibrin 
clot (Zhang et al., 2008). The blood contains fibrinogen and the precursor of thrombin, 
known as prothrombin. When blood comes in contact with tissues, as in a wound, 
prothrombin undergoes a series of enzymatic reactions involving Factor VIII, which 
lead to thrombin as a smaller protein product. The thrombin-catalyzed conversion of 
fibrinogen to fibrin consists of three reversible steps. Thrombin is involved only in the 
first step, which is a limited proteolysis to release fibrinopeptides A (FpA) and B (FpB) 
from fibrinogen to produce a fibrin monomer. These fibrin monomers interact non-
covalently to form intermediate polymers (step 2) that aggregate to form the fibrin clot 
(step 3) (Scheraga, 2004). The clots made upon tissue injury consist of activated 
platelets and fibrin (Furie & Furie, 1988). The γ chain of human fibrinogen interacts 
with recognition sites in platelet receptors stimulated by ADP resulting in aggregation. 
There is a significant molecular similarity between milk clotting (due to action of 
chymosin on κ-casein) and blood clotting (Erdmann et al., 2008). 
 
Diet, which inhibits platelet activation and aggregation, may reduce the risk of 
atherothrombosis. Investigations on fruits and vegetables have focused mainly on the 
biochemical instead of the pathophysiological aspects of atherothrombosis (Yamamoto 
et al., 2003; Yamamoto et al., 2006; Yamamoto et al., 2008), but most of them were 
investigated from biochemical aspects, not pathophysiologically. In addition, studies on 
foods of animal origin are rare. However, there are a few studies showing the 
antithrombotic effect of casein derived peptides (in vitro and in vivo). The casoplatelins, 
which are casein-derived peptides, are inhibitors of both the aggregation of ADP-
activated platelets and the binding of human fibrinogen to a specific receptor region on 
the platelet surface. The peptide Met-Ala-Ile-Pro-Pro-Lys-Lys-Asn-Gln-Asp-Lys 
derived from bovine κ-casein inhibited platelet aggregation and binding of fibrinogen to 
 
 
42 
 
platelets (Jolles et al., 1986). The amino acids Asp, Ile and Lys seem to be important for 
antithrombotic effect of this peptide as they are homologous in position to the γ chain of 
human fibrinogen (Erdmann et al., 2008). Therefore, the antithrombotic activity could 
be the result of competition between the casoplatelin and γ chain of human fibrinogen to 
bind with platelet receptors. In an in vitro and ex vivo study using guinea pigs, κ-
caseinoglycopeptide (CGP) from sheep, derived from hydrolysis of κ-casein by 
chymosin, was shown to decrease thrombin- and collagen-induced platelet aggregation. 
Three peptides obtained from trypsin hydrolysis of CGP (Lys-Asp-Gln-Asp-Lys, Gln-
Val-Thr-Ser-Thr-Glu-Val, Thr-Ala-Gln-Val-Thr-Ser-Thr-Glu-Val) were shown to have 
antithrombotic effects in guinea pigs (Qian et al., 1995). Also, after breast feeding or 
ingestion of cow's milk-based formulae, antithrombotic CGPs were detected in 
newborn’s plasma, which had been derived from human and bovine κ-caseins, 
respectively (Chabance et al., 1995). These CGPs are suggested to be released from κ-
caseins during the milk digestion process and absorbed into blood circulation. There are 
a few in vitro studies showing the antithrombotic activity of plant derived peptides. 
Peptides in Alcalase digested rapeseed protein have been shown to inhibit thrombin 
catalyzed coagulation of fibrinogen (Zhang et al., 2008). Tryptic digests of amaranth 
glutelin were found to contain antithrombotic peptides (Pro-Pro-Gly, Pro-Gly, and Gly-
Pro) that had anticoagulant and fibrinolytic potential of blood plasma (Silva-Sanchez et 
al., 2008) 
 
2.13 Research evidence on bioactive peptides derived from flaxseed protein 
There are reports on the availability of naturally occurring cyclolinopeptides (cyclic, 
hydrophobic peptides) in flaxseed. These peptides have been identified as Pro-Pro-Phe-
Phe-Leu-Ile-Ile-Leu-Val, Pro-Pro-Phe-Phe-Val-Ile-Met-Ile-Leu, Pro-Phe-Phe-Trp-Val-
Met-Leu-Met, Pro-Phe-Phe-Trp-Ile-Met-Leu-Met and they are mostly found in the oil 
fraction (Stefanowicz, 2001). They are reported to be immunosuppressive, 
hepatoprotective and antimalarial (Stefanowicz, 2001). There are a few recent in vitro  
studies showing the availability of ACEI, renin inhibitory (Udenigwe et al., 2009) and 
antioxidative (Udenigwe et al., 2009) bioactive peptide sequences within flaxseed 
protein, which can be released by enzymatic hydrolysis. In these studies, flaxseed 
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protein was hydrolyzed by proteolytic enzymes such as pepsin, ficin, papain, 
Thermolysin and pancreatin to release bioactive peptides. Wu et al. (2004) reported in a 
patent that proteolytic digestion of defatted flaxseed meal generates a hydrolysate with 
ACEI activity. Apart from these studies, there are a few other in vitro studies showing 
calmodulin (CaM) binding activity of flaxseed protein hydrolysates. CaM is an 
important soluble protein in human platelets that binds with Ca2+ and regulates the 
activity of many cellular enzymes involved in cyclic nucleotide metabolism, Ca2+ 
transport, protein phosphorylation-dephosphorylation cascades, ion transport, 
cytoskeletal function and cell proliferation (Gnegy, 1993). Omoni and Aluko (2006) 
reported the ability of flaxseed protein isolate hydrolyzed by Alcalase to yield peptides 
that can bind to calmodulin. The flaxseed protein hydrolysate inhibited CaM dependent 
neuronal and endothelial nitric oxide synthase (nNOS). Although nNOS is 
physiologically important for neurotransmission, vasodilatation, immune response, 
smooth muscle contraction and relaxation, excessive activity can lead to acute and 
chronic disorders such as stroke, Alzheimer’s, Parkinson’s as well as migraine 
headaches, convulsions and pain (Omoni & Aluko, 2006). 
 
2.14 Information gap on flaxseed protein derived bioactive peptides 
The available research evidence shows the presence of bioactive peptide sequences in 
flaxseed protein that can be released via enzymatic hydrolysis. Of these, especially the 
ACEI and antioxidant peptides are important to study further as both are related to CVD 
protection. To the best of my knowledge there is no published information available on 
the ability of flaxseed protein to generate cardioprotective bioactive peptides during GI 
digestion. Therefore, it is of interest to investigate whether flaxseed protein possesses 
bioactive peptide sequences that can be released during GI digestion. Available research 
data suggest the presence of non-fat and non-lignan constituent in flaxseed that is 
antiatherogenic. Therefore, it is interesting to investigate whether this constituent is  
flaxseed protein. None of the published studies have explored the possible amino acid 
sequence of bioactive flaxseed protein derived peptides. Solid data on bioactivity of 
products generated upon GI digestion of flaxseed protein obtained by well controlled 
and well designed in vitro studies, in vivo animal and human studies will enable the 
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development of health claims for flaxseed and flaxseed products. Since in vivo studies 
are more expensive to conduct, controlled in vitro simulated GI digestion studies on 
flaxseed protein will be important to generate information on any potential of the 
protein to release bioactive peptides.  
 
At present flaxseed is consumed as whole seeds, ground or as defatted meal. In whole 
flaxseed the protein is present with other seed matrix components such as mucilage and 
oil whereas in the meal the oil is expelled. It is not known which form of flaxseed 
consumption can provide the health benefits of protein derived bioactive peptides, if 
any. Such studies will also support bridging the information gap in health benefits of 
flaxseed constituents. In addition, to improve the demand for flaxseed as a functional 
food ingredient, there is a need to generate protein products with bioactivities. The 
flaxseed protein products with bioactive peptides could be used as food ingredients in 
functional foods or beverages. Since mostly the small peptides will be bioavailable to 
the human body, there is a need to assess the bioactive nature of peptides released upon 
hydrolysis of flaxseed protein by commercial microbial enzymes that can cause 
extensive protein hydrolysis.  
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3. MATERIALS AND METHODOLOGY 
 
3.1 Materials 
Flaxseed of the cultivar Valour was used as the starting material throughout the study. 
All the enzymes including ACE (from porcine kidney), Flavourzyme®, pancreatin, and 
pepsin, and most of the chemicals were purchased from Sigma Chemical Co. Canada. 
The total bile acid analysis kit and the total dietary fibre analysis kit were purchased 
from Bio-Quant Diagnostic Kits, U.S.A. and Megazyme International Ireland Ltd., 
Ireland, respectively. All the chemicals used were of analytical grade. 
 
3.2 Preparation of different flaxseed protein sources 
3.2.1 Milled whole flaxseed 
The whole flaxseed was milled using a home style coffee grinder and passed through # 
35 mesh (500 µm) to obtain milled whole flaxseed. 
  
3.2.2 Milled and demucilaged flaxseed 
The mucilage of flaxseed was removed (demucilaging) before milling using water or 
0.5 M NaHCO3 solution as the solubilizing aid. Demucilaging with 0.5 M NaHCO3 
yielded the lowest amount of soluble carbohydrates remaining in the outer seed coat of 
whole seeds and therefore was used throughout the study for the mucilage removal. 
 
3.2.2.1 Methods of demucilaging 
(a) Demucilaging with water 
Flaxseeds were soaked in distilled water (1:20, w/v) at room temperature in a beaker 
overnight with continuous stirring using a magnetic stirrer. The water with extracted 
mucilage was filtered under suction and discarded. The seeds were rubbed 
46 
 
against a metal mesh using a stainless steel spoon for further removal of mucilage. The 
seeds were washed with distilled water (1:10, w/v) five times, drained and dried in a 
forced air oven at 45 C for 24 h (Alzueta et al., 2002; Wanasundara & Shahidi, 1997).  
 
b) Demucilaging with NaHCO3  
The flaxseeds were stirred in 0.5 M NaHCO3 (1:8, w/v) in a double jacketed glass 
vessel at 50 °C for 1 h. The glass vessel was connected to a circulating water bath 
(VWR, U.S.A.) to maintain a constant temperature. After 1 h, the liquid with mucilage 
was removed by filtering under suction. Thereafter, the seeds were rubbed against a 
metal mesh, washed with distilled water, drained and the extraction and washing was 
continued for two more times. Then the demucilaged seeds were dried as discussed 
under section 3.2.2.1 (a).  
 
The demucilaged flaxseeds were milled using a coffee grinder and passed through a 500 
µm mesh screen to obtain milled and demucilaged flaxseed. 
 
3.2.3 Milled, demucilaged and defatted flaxseed  
Two methods of defatting were carried out for demucilaged flaxseed. They were hexane 
extraction alone and screw pressing using an oil expeller followed by hexane extraction. 
The method that yielded the lowest residual oil content remaining in the meal was 
selected and used throughout the study for the removal of oil from demucilaged 
flaxseeds. 
 
3.2.3.1 Methods of defatting  
(a) Hexane extraction 
The milled and demucilaged flaxseed was subjected to hexane extraction using n-
hexane (milled and demucilaged flaxseed: hexane ratio was 1:3, w/v) for 2 h at room 
temperature with continuous stirring using a magnetic stirrer. Then the hexane with 
extracted oil was discarded by filtering under suction and new hexane was introduced. 
This process was repeated three times (total extraction time: 6 h). The resulting milled, 
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demucilaged and defatted flaxseed was allowed to dry at room temperature overnight 
under a fume hood prior to use.  
 
(b) Screw pressing followed by hexane extraction                                                                                   
The demucilaged flaxseeds (before milling) were pressed using an oil expeller (Komet, 
IBG Monforts Oekotec GmbH & Co., Germany) for partial removal of oil. The resulting 
meal was milled using a home style coffee grinder, passed through a 500 µm mesh 
screen and subjected to hexane extraction using n-hexane as discussed under section (a) 
of 3.2.3.1. 
 
3.2.4 Isolated form of flaxseed protein 
The flaxseed protein was extracted from milled, demucilaged and defatted flaxseed 
using alkali solubilization followed by acid precipitation. The pH at which flaxseed 
protein precipitates was determined by investigating the protein solubility profile of the 
milled, demucilaged and defatted flaxseed. 
 
3.2.4.1 Determination of protein solubility profile at different pH values 
This determination was carried out for milled, demucilaged and defatted flaxseed. Fifty 
mL dispersions of 0.25 % (w/v) sample were prepared at pH values between 1.0 and 
10.0. Soluble protein in the sample was extracted with vigorous stirring on a magnetic 
stirrer at room temperature for 30 min while maintaining the pH using a pH meter 
(Accumet, Fisher Scientific, U.S.A.) at predetermined values. The solution was then 
centrifuged using a Beckman J2-HC centrifuge (Beckman Instruments Inc., U.S.A.) at 
4220 × g for 15 min. The extract was filtered by vacuum filtration through a #1 
Whatman filter paper. The final volume of the filtrate was recorded. The filtrates were 
frozen at -20 °C until further use. The soluble protein content of the filtrate was 
determined by the modified Lowry method (Markwell et al., 1978) as described in 
section 3.3.3. The soluble protein content (%) was plotted against the pH of each flour 
dispersion to determine the pH, which gives minimum solubility of flaxseed protein. 
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3.2.4.3 Extraction of proteins  
The milled, demucilaged and defatted flaxseed was used for protein extraction. 
Solubilization of proteins was carried out at pH 8.5 using sample: water of 1:10 w/v and 
extraction time of 1 h. The pH of the extraction solution was adjusted using 0.1 M and 1 
M NaOH. The slurry was then centrifuged at 9820 × g for 20 min to recover solubles 
and insolubles. After extraction, the residue was subjected to two more extractions 
(sample: water 1:10 w/v at pH 8.5; time of extraction 1 h) followed by centrifugation 
similar to above. The supernatants were pooled and the pH was adjusted to 3.8 (the pH 
that gives minimum soluble protein level). The precipitated proteins were separated by 
centrifugation at 9820 × g for 20 min and washed once with distilled water. The slurry 
was centrifuged again as mentioned above. The precipitate was re-dissolved in distilled 
water and pH was adjusted to 7.0 using 0.1 M NaOH. The protein solution was then 
dialyzed against distilled water using a dialysis membrane [Spectra/Por, molecular 
weight cutoff (MWCO): 3.5 kDa] at 4 C for 48 h to remove any small molecules. 
During the dialysis period the distilled water used was renewed three times/d. The 
dialyzed protein solution was then freeze dried. The freeze-dried protein isolate was 
stored at 4 C till used for further studies.  
 
3.3 Analysis of composition 
3.3.1 Proximate composition 
The analysis of moisture (AOAC method 925.09), ash (AOAC method 923.03), crude 
protein (AOAC method 920.87; N × 6.25) and crude fat (AOAC method 920.85) was 
carried out using standard AOAC (1990) procedures. The total dietary fibre (TDF), 
insoluble dietary fibre (IDF) and soluble dietary fibre (SDF) of samples were analyzed 
using Megazyme total dietary fibre analysis kit and calculated as % values (AOAC 
method 985.29). 
 
3.3.2 Nitrogen analysis 
The total N content of the samples (liquid and solid) were determined according to 
kjeldhal method (AOAC, 1990; method 920.87) or using combustion N analysis 
(AOAC, 1997; method 988.05) with a N analyzer (Flash EA® 1122, Thermo, U.S.A.) 
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using EDTA as the standard. The N values obtained were converted to protein content 
using a conversion factor of 6.25 (N % × 6.25) when needed. 
 
3.3.3 Modified Lowry method for protein determination 
This method was used for liquid samples that were expected to have low levels of 
protein. If frozen, samples were brought to ambient temperature by immersing in water 
at same temperature. One milliliter of the sample was mixed with 3 mL of reagent C 
[prepared by mixing 100 parts of reagent A (2 % Na2CO3, 0.4 % NaOH, 0.16 % sodium 
tartarate, 1 % SDS, w/v) with 1 part of reagent B (4 % CuSO4.5H2O, w/v)] in a test 
tube. The contents in the tube were incubated for 30 min at room temperature, then 
mixed with 0.3 mL of Folin-Ciocalteu reagent, vortexed and incubated at room 
temperature for another 45 min. The absorbance of the resulting solution was measured 
at 660 nm (Ab660) using a diode array spectrophotometer (HP-8453, Agilent 
Technologies Canada Inc., Canada). (A standard curve was constructed using bovine 
serum albumin (BSA; concentration range: 1 µg/mL to 36 µg/mL) by plotting its Ab660 
against different known concentrations of BSA. The soluble protein content of the 
filtrate was determined by reading the concentration corresponding to the measured 
Ab660 of the sample from the standard curve (Markwell et al., 1978). 
 
3.3.4 Amino acid analysis 
The samples were oxidized with performic acid and hydrolyzed with HCl as previously 
described by Llames and Fontaine (1994) for analysis of amino acids except for Trp. 
Amino acids were separated using an AMINOSep ion exchange column (particle size: 
5µM; Capacity: 2 meq/g; Transgenomics Inc., U.S.A.) and post column derivatized 
with O-pthalaldehyde (OPA) using a HPLC system (Agilent 1100 series, Agilent 
Technologies, Germany) attached to a fluorescence detector (RF551, Shimadzu, 
U.S.A.). 
  
For the analysis of Trp, samples (approximately 100 to 200 mg) were weighed in 50 mL 
Pyrex bottles, and 100 mg of preservative (proprietary formula) was added to each 
bottle. These preparations were pre-digested in 5 mL of 5 N NaOH for 5 h at room 
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temperature. Next, the bottles were degassed under vacuum for 5 min, and gently 
flushed with a constant stream of pure nitrogen for 5 min. Following this, the bottles 
were loosely capped with screw-cap closures and placed in the oven set at 110 oC. After 
1 h of incubation the screw-caps were tightened, and the samples were hydrolyzed at 
110 oC for 23 h. The hydrolyzed samples were cooled to room temperature, neutralized 
to pH between 2.5 to 3.5 with 6 N HCl, and diluted as required. These preparations 
were centrifuged at 14,000 × g, filtered through 0.45 μm syringe filters, and analyzed 
for Trp content using a HPLC system (Agilent 1100 series, Agilent technologies, 
Germany). Quantitative analyses were performed using an analytical reversed phase 
column, (250 x 4.6 mm, 5 µ, Luna, Phenomenex, CA). The mobile phase was 50 mM 
borate buffer/methanol 70:30 v/v, adjusted to pH 2.8 with 6 N HCl. The mobile phase 
was delivered at a rate of 1 mL/min and samples were introduced into the column using 
an auto sampler. Detection was performed using a fluorescence detector set at excitation 
233 nm and emission 351 nm. The method was validated for precision, accuracy, 
reproducibility, and analyte recovery (Olkowski, unpublished).  
 
3.3.5 Determination of soluble carbohydrate content 
The soluble carbohydrate content was determined according to the phenol-sulphuric 
acid method using rhamnose as a standard (Dubois et al., 1956). The water-soluble 
polysaccharides were extracted from flaxseed by mixing the whole seeds with 
potassium phosphate buffer (pH 7.0) (1:13 w/v) in a double jacketed glass spinner flask 
connected to a circulating water bath. The mixture was stirred on a magnetic stirrer for 
2 h at 85 C. The resulting solution was filtered under suction to separate the seeds from 
the extract. Two mL of the solution was pipetted into a glass test tube and 0.05 mL of 
80 % (v/v) phenol was added into the tube. Then 5 mL of concentrated sulfuric acid was 
transferred into the tube rapidly. The stream of acid was directed against the liquid 
surface rather than against the side of the test tube in order to obtain a good mixing. The 
tubes were allowed to stand for 10 min at room temperature. Then they were vortexed 
and placed in a water bath (Isotemp, Fisher scientific, U.S.A.) at 30 °C for 15 min. The 
absorbance of the characteristic yellow-orange color was measured at 480 nm against a 
blank prepared by substituting the polysaccharide extract with distilled water. The 
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soluble carbohydrate content was determined against a standard curve constructed using 
rhamnose and was expressed as % of the seed weight.  
 
3.3.6 SDS- PAGE of flaxseed protein  
The polypeptide profiles of milled whole flaxseed, milled and demucilaged flaxseed, 
milled, demucilaged and defatted flaxseed, isolated protein and the residues remaining 
after simulated gastric and GI digestion/Flavourzyme catalyzed hydrolysis were 
determined using sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) under reducing and non-reducing (NR) conditions (Laemmli, 1970). The 
remaining pellet after centrifugation of the digestion/hydrolysis mix represent the 
unhydrolyzed protein and partially digested protein during the simulated gastric and GI 
digestion/ Flavourzyme catalyzed hydrolysis. The N content of the freeze dried 
undigested residue was determined using a N analyzer prior to SDS-PAGE. The 
samples (5 mg protein/mL) were dispersed in 0.1 M Tris buffer (pH 8.0) containing 5 % 
(w/v) SDS in Eppendorf tubes by vortexing vigorously for 2 min. When reducing 
conditions were required, β-mercaptoethanol (β-ME) was added to the solution to 5 % 
(v/v) concentration. When NR conditions were required β-ME was not included in the 
sample buffer. The samples were then placed in an Eppendorf Thermomixer 
(Brinkmann Instruments Services Inc., Canada) at 99 °C for 10 min with mixing at 
1,300 rpm, cooled to room temperature for 10 min and centrifuged (Spectrafuge; 
Mandel Scientific Inc., Canada) for 10 min at 1,500 × g prior to application. Gradient 
mini gels (resolving 8-25% T and 2% C, stacking zone 4.5 % T and 3 % C, 43×50×0.45 
mm, polyacrylamide gels cast on GelBond® plastic backing, buffer 0.112 M acetate, 
0.112 M Tris, pH 6.4) were used to separate proteins on a PhastSystem equipped with 
separation and development capabilities (Amersham Pharmacia, Sweden). Sample of ~5 
µg protein was applied into each well and molecular weight standards (Fermentas pre-
stained protein ladder ranging from 10 to 170 kDa) were also applied into a separate 
well. Following separation, the proteins were fixed and stained using PhastGel blue R 
(Coomasie R-350) and developed to obtain a suitable background color. The gels were 
scanned and the acquired images were analyzed by the ImageQuant® (version 3.0, 
Pharmacia Biotech) software. 
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3.4 Simulated gastrointestinal digestion of flaxseed protein 
The GI digestion was simulated in vitro using two models; static and dynamic. The 
static model of digestion was used for milled whole flaxseed, milled and demucilaged 
flaxseed, milled, demucilaged and defatted flaxseed and isolated protein. The dynamic 
model was only used for the isolated flaxseed protein. The presence of mucilage, oil and 
other non-protein constituents in the milled whole, milled and demucilaged and milled, 
demucilaged and defatted flaxseed products limited the use of the dynamic model for 
simulated GI digestion. Both models involved a simulated gastric digestion (with 
pepsin) and a simulated intestinal digestion (with pancreatin and bile) at physiological 
temperature and pH.  
 
3.4.1 Preliminary studies on simulated gastrointestinal digestion 
Two preliminary digestion trials (Static model I and II) were conducted using casein as 
the standard protein to identify the enzyme to substrate ratios (E/S) that best mimic 
human GI digestion. The in vitro digestion process used in the preliminary trials was the 
static model of digestion with two phases; gastric phase and intestinal phase. The GI 
conditions used in the trials were based on published literature. Salivary amylase was 
not used in any of these trials due to lack of starch in the starting material. The static 
model I differed from static model II in terms of E/S ratios, volumes of digestive fluids 
used, pH of the intestinal phase and composition of simulated bile juice. All the other 
conditions were similar in both models. Details of the preliminary trial using static 
model I are explained under Appendix I. The methodology used for static model II is 
explained herein. The most suitable E/S for simulated GI digestion of flaxseed protein 
was determined based on the digestibility of casein.  
 
3.4.2 Preparation of digestive juices 
The simulated digestive fluids were prepared fresh daily as described in the United 
States Pharmacopeia (USP, 1995) with slight modifications.  
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3.4.2.1 Simulated gastric control solution and simulated gastric fluid (SGF) 
Two grams of NaCl was dissolved in 500 mL of deionized water and the pH was 
adjusted to 2.0 by adding concentrated HCl. Then water was added to a final volume of 
1 L to make the simulated gastric control solution and stored at 4 °C. The cold 
simulated gastric control solution was mixed with pepsin from porcine mucosa (Sigma, 
2490 units/mg solid or 3410 units/mg protein) to a concentration of 4 mg/mL and the 
resulting solution was used as the SGF.  
 
3.4.2.2 Simulated intestinal control solution and simulated intestinal fluid (SIF) 
The intestinal control solution was prepared by mixing 6.8 g of monobasic potassium 
phosphate in 250 mL of deionized water. Then, 77 mL of 0.2 M NaOH and 500 mL of 
water was added. The pH of the solution was adjusted to 6.8 by adding 0.2 M HCl/0.2 
M NaOH. The resulting solution was then diluted to 1 L with deionized water. The 
solution was stored at 4 °C. The intestinal control solution was mixed with pancreatin 
from porcine pancreas (Sigma, 8 x USP) to a concentration of 10 mg/mL to prepare the 
SIF.  
 
3.4.2.3 Simulated bile solution 
The bile solution was prepared by mixing sodium taurocholate and sodium 
glycodeoxycholate at a concentration of 4 mM each into the simulated intestinal control 
solution prepared as discussed in section 3.4.2.2. The solution was sonicated at room 
temperature for 10 min to aid in dissolving bile salts.  
 
3.4.3 Simulated gastrointestinal digestion: Static model  
The static model II that does not simulate absorption of small molecules in the intestinal 
phase was used for digestion. 
 
3.4.3.1 Simulated gastric digestion  
The protein (1 g of flaxseed protein or casein) was incubated with gastric control 
solution (25 mL) in a 50 mL Erlenmeyer flask for 10 min (167 rpm) at 37 °C in a 
shaking water bath (OLS2000, GRANT, U.S.A.) as shown in Figure 3.1. The solution 
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was brought to pH 2.0 with 1 M HCl and the total volume was made up to 29 mL with 
gastric control solution. Freshly prepared SGF (1 mL) was added into this solution to 
have pepsin: protein ratio (E/S) of 1:250 w/w and the mixture was subsequently 
incubated in a shaking water bath at 37 °C for 2 h. An enzyme blank was prepared by 
incubating the enzyme under the described conditions with the substrate omitted. A 
sample blank was prepared for each sample by incubating the protein under the 
described conditions without the enzyme. At the end of gastric phase digestion the 
pepsin activity was inactivated by immediately raising the pH to 6.8 with addition of 1 
M NaOH. The solution was then subjected to intestinal phase digestion.  
 
3.4.3.2 Simulated intestinal digestion  
The volume of the pH adjusted sample predigested with pepsin was raised to 35 mL by 
addition of intestinal control solution. The sample was mixed well for 5 min at 37 °C. 
To this mixture, 1 mL of bile solution and 4 mL of SIF containing pancreatin was 
added. The trials for digestion of casein with pancreatin were performed using two 
levels of E/S; 1:/25 and 1/250 w/w. The E/S for digestion of flaxseed protein was 
selected based on the digestibility of casein. The samples were incubated for 4 h at 37 
°C using a shaking water bath. The protocol was also carried out for sample blanks and 
enzyme blanks as described under gastric phase digestion. 
 
3.4.3.3 Collection of samples  
During simulated GI digestion, samples were collected at zero time (unhydrolyzed 
protein; initiation of digestion), at the end of gastric phase (gastric digest) and at the end 
of gastric + intestinal phase (gastric + intestinal digest). At the end of each phase the 
digestive enzymes present in the digested protein samples were inactivated by heating 
in a water bath at 98 ºC for 15 min. The digested samples were then cooled to room  
temperature and adjusted to the pH at which protein shows minimum solubility (3.8 for 
flaxseed protein and 4.6 for casein). The samples were then centrifuged at 13,800 × g 
for 15 min and the supernatant (digest) as well as the pellets (undigested residues) were 
recovered. The pellets were freeze dried and stored at -20 ºC for further analysis. The 
recovered volume of the digest was recorded and pH was adjusted to 7 using 1 M 
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NaOH. The resulting solution was adjusted to a known volume using deionized water in 
a volumetric flask. Aliquots of this solution were stored at -20 °C for the analysis of 
degree of hydrolysis (DH) and the rest was freeze dried for the determination of 
bioactivities. The freeze dried gastric and the GI digests were analyzed for ACEI and 
OH• scavenging activities as discussed in sections 3.9.1 and 3.9.2, respectively. All the 
freeze dried samples were stored at -70 °C until use. 
 
 
Figure 3.1 Schematic diagram of digestion of flaxseed protein using the static 
model  
 
3.4.4 Simulated gastrointestinal digestion: Dynamic model  
In this model, small intestinal absorption of small peptides was simulated in the 
intestinal phase. 
 
3.4.4.1 Simulated gastric digestion 
The simulated gastric phase used in this method was same as in the static model 
discussed above.  
 
3.4.4.2 Development of dynamic model for simulated intestinal digestion 
In the digestion chamber, a dialysis membrane was used to remove LMW digested 
products to simulate small intestinal absorption of small peptides and free amino acids. 
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A preliminary study was conducted to determine the suitability of different dialysis 
membranes for this study. Two dialysis tubings were tested, namely Spectra/Por® Float- 
A-Lyzer® (MWCO: 1 kDa, diameter 10 mm, volume: 10 mL) and Spectra/Por® dialysis 
membrane (MWCO: 1 kDa, flat width 45 mm, diameter: 29 mm, volume: 5 mL) 
(Spectrum Laboratories Inc., Canada). The ability of these membranes to diffuse 
digested products was tested using amino acids and peptides of <1 kDa. The amino acid 
used was Phe (165.19 Da), and the peptides used were glutathione (Glu-Cys-Gly; 307.3 
Da) and Gly-Gly-Tyr-Arg (451.5 Da) all prepared separately as 1mg/mL in simulated 
intestinal control solution. The dialysis tubings with the samples were placed in a 
double jacketed glass container filled with simulated intestinal control solution (Figure 
3.2). The temperature of the system was maintained at 37 °C by connecting the double 
jacketed container to a circulating water bath set at 37 °C. When Float-A- Lyzers were 
used, both the contents in the dialysis tube and outer buffer compartment were stirred 
using a magnetic stirrer. In case of the dialysis membrane, only the outer solution was 
stirred using a magnetic stirrer. The diffusion of amino acids and peptides from both 
models were determined by measuring the absorbance of solution inside the membrane 
at zero time and after 4 h of dialysis. The absorbance was monitored at 280 nm for Phe 
and at 214 nm for peptides. 
 
 
Figure 3.2 Schematic diagram showing the small intestinal digestion in the  
dynamic model 
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3.4.4.3 Simulated intestinal digestion 
Based on the findings of the preliminary study discussed under the section 3.4.4.2, a 
dialysis bag made of Spectra/Por® dialysis membrane (MWCO: 1 kDa, flat width 45 
mm, diameter 29 mm) was used to simulate the intestinal phase of the dynamic model. 
The dialysis bag was immersed in intestinal control solution (pH 6.8, 1000 mL) in a 
double jacketed glass vessel which was placed on a magnetic stirrer and connected to a 
feeding reservoir containing intestinal control solution (maintained at 37 °C) and a 
receiver flask (Figure 3.3). Feeding fresh intestinal control solution to the vessel 
containing the dialysis bag and collection of solution containing dialyzed products was 
done using two peristaltic pumps (variable flow mini pumps, VWR, U.S.A.) providing a 
constant flow to the system (1.6 mL/min). The temperature of double jacketed container 
was maintained at 37 °C using a circulating water bath (VWR, U.S.A.).  
 
After the simulated gastric phase digestion the pH of the pepsin digest was adjusted to 
pH 6.8 and the total volume of the digest was adjusted to 35 mL using intestinal control 
solution. This digest was transferred to the prepared dialysis bag. One mL of bile salt 
solution and 4 mL of SIF containing pancreatin previously maintained at 37 °C were 
added to the digest and further digestion was continued for 4 h with continuous stirring. 
During the intestinal phase of digestion the dialysate was removed continuously using a 
peristaltic pump (flow rate: 1.6 mL/min) and collected in the receiving flask. Fresh 
buffer was pumped into the reaction vessel to replace removed dialysate.  
 
3.4.4.4 Collection of samples  
The samples of both dialysate and retentate were collected at the initiation of gastric + 
intestinal digestion and after 4 h, in addition to the samples of unhydrolyzed protein and 
gastric digest. The collected samples were heated in a water bath at 98 ºC for 15 min to 
heat inactivate the enzymes. The volume of the collected dialysate was recorded, the pH 
was adjusted to 7.0 using 1 M NaOH and brought up to a known volume using a 
volumetric flask by adding water. Aliquots of the dialysate was stored at -20 °C for DH 
determination and the rest was freeze dried and stored at -70 °C for bioactivity 
assessment. The retentate (material that was not dialyzed and retained inside the dialysis 
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bag) was treated similarly to the gastric + intestinal digests collected from static model 
as discussed above. The recovered pH adjusted supernatant of retentate obtained after 
centrifugation was used for assessment of DH and bioactivities.  
 
The freeze dried retentate and dialysate of GI digests obtained from the dynamic model 
were analyzed for ACEI and OH• scavenging activities as discussed in sections 3.9.1 
and 3.9.2 respectively. 
 
Figure 3.3 Schematic diagram of digestion of flaxseed protein using the dynamic 
model 
 
3.5 Determination of digestibility  
The digestibility of different sources of flaxseed protein was determined as release of 
TCA soluble N (%) due to pepsin and pancreatin digestion using casein as the standard. 
A portion of the digest (10 mL) was mixed with equal volumes of 20 % (w/v) TCA. The 
resulting solution was centrifuged at 13,800 × g for 15 min. The volume of the 
recovered supernatant was recorded and its pH was adjusted to 7 using 1 M and 0.1 M 
NaOH. The pH adjusted supernatant was analyzed for N content using a N analyzer 
using EDTA as the standard (Section 3.3.2). The same procedure was carried out for the 
enzyme blanks and sample blanks. The % TCA soluble N released during digestion was 
calculated as follows.  
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 
100
 N Total
 N solTCA -  N solTCA  - N solTCA 
 N solubleTCA %
digest
blank enzymeblank sampledigest   (3.1)
           
3.6 Flavourzyme assisted hydrolysis of flaxseed proteins 
3.6.1 Experimental design 
This experiment was carried out as a two factor central composite rotatable design 
(CCRD) as described in Kellner et al. (1998). The design was used to determine the 
responses namely DH, and bioactivities of the hydrolysates in relation to the two 
independent variables, E/S: X1 and time of hydrolysis (X2), each at five levels. The 
variables with the coded and actual levels are given in Table 3.1.  The design included 
nine hydrolysis experiments with different combinations of E/S and time of hydrolysis.  
Each experiment was carried out in duplicate and the central point of the design (E/S: 
47.5 and time of hydrolysis: 12 h/0,0), was repeated four times for reproducibility. 
  
Table 3.1 Experimental design of protein hydrolysis  
Variable Symbol Levels 
- -1 0 +1 + 
E/S (LAPU/g of protein) X1 1.5 15 47.5 80 93.5 
Time of hydrolysis (h) X2 0.7 4 12 20 23.3 
LAPU: Enzyme activity of Flavourzyme as expressed in Leucine amino peptidase units 
α=1.414 
 
3.6.2 Hydrolysis of flaxseed protein 
Flaxseed protein was subjected to hydrolysis by the commercially available, food-grade 
fungal proteolytic enzyme Flavourzyme (Sigma; Activity of 554 LAPU/g) at conditions 
of its optimum activity (temperature 50 C; pH 5-7). The combinations of E/S and time 
of hydrolysis as defined in Table 3.1 were used in the hydrolysis procedure. Each 
hydrolysis combination was carried out in duplicate in glass double-jacketed spinner 
flasks, which were placed on magnetic stir plates (Figure 3.4). Prior to protein 
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hydrolysis, a suspension of isolated flaxseed protein was prepared in deionized water. 
The pH of the suspension was adjusted to 7.0 by addition of 0.1 M NaOH and thereafter  
further deionized water was added to maintain the protein: solvent ratio at 1:50 (w/v). 
The temperature of the hydrolysis mixture was maintained at 50 oC using a circulating 
water bath (VWR, Canada). At the end of hydrolysis the enzyme was inactivated by 
heating in a water bath at 95 oC for 10 min. Thereafter the hydrolysate was centrifuged 
at 8,820 × g for 15 min. Both the supernatant and the unhydrolyzed residue were 
recovered. The supernatant was freeze dried and stored at –20 oC. The unhydrolyzed 
residue was stored at –70 oC for further analysis. In addition to the combination of 
hydrolysis parameters explained in the experimental design, non-hydrolyzed flaxseed 
protein as well as untreated flaxseed protein (zero level of Flavourzyme and five levels 
of time of hydrolysis) were also subjected to hydrolysis experiment as explained above. 
The freeze-dried crude flaxseed protein hydrolysate (denoted as FPH hereafter) was 
analyzed for DH and range of bioactivities including % inhibition of ACE, OH• and O2•- 
scavenging activities, ability to inhibit linoleic acid peroxidation, metal chelating 
activity, antithrombotic activity and bile acid binding ability as discussed in section 3.9. 
 
 
Figure 3.4 Schematic diagram of flaxseed protein hydrolysis with Flavourzyme 
 
3.7 Measurement of degree of hydrolysis and average peptide chain length  
The DH, defined as the percentage of peptide bonds cleaved was calculated by 
analyzing the free amino groups of the reaction mixture according to the OPA method 
as described by Wanasundara et al. (2002), based on a modified procedure of Church et 
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al. (1983). The OPA reagent was prepared daily by mixing 6 mM OPA (first dissolved 
in 95 % ethanol, v/v) and 5.7 mM DL-dithiothrietol in 0.1 M sodium tetra borate 
decahydrate containing 2 % w/v SDS. Samples (0.4 mL) were then added to 3 mL of 
OPA reagent, vortexed , incubated for 2 min at room temperature and the absorbance 
was monitored at 340 nm using a HP-8453 (Agilent Technologies Canada Inc., Canada) 
diode array spectrophotometer. The amount of free amino groups was calculated as 
serine-NH2 moieties. Total number of amino groups in the flaxseed protein was 
estimated using acid hydrolysis (6 N HCl at 110 C for 24 h) assuming complete 
hydrolysis of all peptide bonds of the protein. The DH and PCL in the hydrolysates 
were calculated according to the following equations. 
 
   
    100NHNH
NHNH
DH %
To2Total2
To2Tx2 
        (3.2) 
 
  To2NH = Number of free -NH2 groups at zero min of hydrolysis. 
 Tx2NH = Number of free -NH2 groups at the end of enzymatic hydrolysis 
 Total2NH = Number of -NH2 groups liberated by acid hydrolysis (assuming complete 
protein hydrolysis)  
DH
100lengthchainpeptideAverage   (Adler-Nissen, 1986)   (3.3) 
 
3.8 Determination of bioactivities 
The freeze dried gastric and gastric + intestinal digests of flaxseed protein as well as 
FPHs were analyzed for bioactivities. The samples were dissolved in respective assay 
buffers, sonicated for 10 min at room temperature and filtered using 0.45 m filters 
(Acrodisc syringe filters, Gelman Laboratory, U.S.A.) prior to determination of 
bioactivities. 
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3.8.1 Angiotensin I-converting enzyme inhibitory activity 
Angiotensin I-converting enzyme releases hippuric acid from hippuril-L-histidyl-L-
leucine (Hip-His-Leu) by hydrolytic removal of the dipeptide, His-Leu (Cushman & 
Cheung, 1971). Angiotensin I-converting enzyme buffer (ACE buffer; 100 mM Tris 
HCl, 300 mM NaCl, 10 M ZnCl2 in deionized water, pH: 8.3) was used to solubilize 
the enzyme, substrate, digest/FPH (2 mg/mL) and the standard (Captopril: ACEI drug). 
The ACEI activity of the digests/FPHs was assessed with Hip-His-Leu as the substrate. 
The initial assay mixture consisted of 50 L of the substrate (3 mM), 50 L of the 
enzyme (ACE from porcine kidney) solution containing 1.25 milli units of declared 
enzyme activity and 50 L of the digest. The reaction components were separately 
incubated in glass vials at 37 oC for 30 min using a water bath (Fischer isotope, Fischer 
Scientific, Canada). Thereafter, the components were mixed and incubated again for 30 
min at 37 oC. The reaction was stopped by adding glacial acetic acid (150 L). The 
reaction mixture was then filtered with 0.2 m filters (Acrodisc CR 13 mm syringe 
filters, Gelman Laboratory, U.S.A.) before subjecting to HPLC. The amount of hippuric 
acid released due to uninhibited ACE activity was determined as described by 
Wanasundara et al. (2002) with modifications in the mobile phase and detection 
wavelength. A reversed-phase C18 column (Bond clone C18, 5 µ, 250 × 4.6 mm) 
protected by a guard column (Bond clone C18, 10 µ, 50 × 1.0 mm; Phenomenex, 
Canada) was used for separation. The isocratic mobile phase, consisted of 25 % (v/v) 
acetonitrile in deionized water, was adjusted to pH 3.0 by adding glacial acetic acid. 
The injection volume used was 10 µL with a flow rate of 1 mL/min. Elution of hippuric 
acid was detected by monitoring the absorbance at 238 nm. A standard curve was 
constructed using a series of pure hippuric acid of known concentration in order to 
quantify the released hippuric acid in the assay mixture. The HPLC system consisted of 
a solvent delivery system pump (Agilent 1100 series), an auto sampler, LC detector 
(diode array) and was supported by Chemstation A 10.01 software. The hippuric acid 
content of a control reaction mixture and a mixture consisting of Captopril (2 mg/mL of 
ACE buffer) instead of the digests were also determined. The control assay mixture had 
ACE buffer instead of the hydrolysate. The percent inhibition of enzyme activity was 
calculated as follows. 
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   
  100acid Hippuric
acid Hippuricacid Hippuric
inhibitionACE % 
Control
SampleControl  (3.4) 
 
3.8.1.1 Determination of inhibition pattern of angiotensin I-converting enzyme 
To investigate the inhibition pattern of ACE, the gastric and gastric + intestinal 
digests/FPHs (0, 0.17 and 0.67 mg/mL) were added to the assay mixture containing 
different substrate (HHL) concentrations (0.5, 1, 2, 4 and 8 mM). The ACE assay was 
performed as described above. The Lineweaver-Birk plots were generated to analyze 
the ACEI pattern of the samples. 
 
3.8.2 Hydroxyl radical scavenging activity 
The ability of the gastric and gastric + intestinal digests of flaxseed protein/FPHs to 
scavenge OH• was determined using a 2-deoxy D-ribose (DR) assay, originally 
described by Halliwell et al. (1987) with some adaptations as described by Burits & 
Bucar (2000). The oxidation of 2-Deoxyribose by OH• formed by the Fenton reaction 
degrades into malonaldehyde (Gutteridge, 1984; 1987), which can form adducts with 2-
thiobarbituric acid (TBA). In this method the ability of digests of flaxseed protein/FPHs 
to suppress breakdown of 2-deoxy D-ribose (induced via Fenton reaction) into TBA 
reactive substances (TBARS) was determined. All solutions were prepared fresh. The 
freeze-dried digests/FPHs were dissolved in KH2PO4-KOH buffer (1.34 mg/mL of 
buffer, pH 7.4). One mL of the reaction mixture contained 100 µL of 28 mM 2-deoxy 
D-ribose in KH2PO4-KOH buffer (pH 7.4), 500 µL solution of the digest/FPH, 200 µL 
of 200 µM FeCl3 and 1.04 mM EDTA (1:1 v/v), 100 µL H2O2 (1.0 mM) and 100 µL 
ascorbic acid (1.0 mM) in glass tubes. After an incubation period of 1 h at 37 °C in a 
water bath the samples were mixed with 1.0 mL of TBA (1 % in 50 mM NaOH) and 1.0 
mL of 2.8 % TCA. The tubes were then heated at 100 °C for 20 min in a water bath, and 
cooled to room temperature. The extent of TBARS development was measured by 
recording the absorbance at 532 nm (Ab532) against a blank using a HP-8453 (Agilent 
Technologies Canada Inc., Canada) diode array spectrophotometer. Carnosine was used 
as the standard antioxidant in this assay. A blank sample was prepared by adding all the 
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reagents except the sample, which was replaced with KH2PO4-KOH buffer and TBA 
and TCA were added with no incubation at 37 °C. 
 
    
  100Ab
AbAb
activityscavengingOH%
Control532
Sample532Control532    (3.5) 
 
3.8.3 Inhibition of linoleic acid oxidation 
The thiocyanate assay, with a linoleic acid model system, was used to determine lipid 
peroxide value of linoleic acid as described by Yen and Hseih (1998). The time taken to 
form the maximum amount of lipid peroxides was determined using the thiocyanate 
assay. During the oxidation process peroxides are gradually degraded to form lower 
molecular compounds. Such degradation products were measured using the TBARS 
assay. The linoleic acid emulsion was prepared by mixing 560 µL linoleic acid with 
equal volumes of Tween 20 and 100 mL sodium phosphate buffer (0.1 M, pH: 7.0). The 
mixture was homogenized using a polytron homogenizer (Kinematica AG, Switzerland) 
for 10 sec in an ice bath to form the emulsion. A control sample consisting of 1 mL of 
linoleic acid emulsion, and 1 mL of sodium phosphate buffer was prepared in a screw 
capped vial in duplicate and incubated in an oven at 40 °C in dark. Aliquots of 0.1 mL 
were taken from this mixture at 24 h interval during incubation. The peroxide formation 
was measured according to the thiocyanate method by sequentially adding ethanol (4.7 
mL, 75 % v/v), ammonium thiocyanate (0.1 mL; 30 % w/v), control solution (0.1 mL) 
and ferrous chloride (0.1 mL, 0.02 M in 3.5 % v/v HCl) to the sample. The mixture was 
allowed to stand precisely for 3 min and the peroxide value was determined by reading 
the absorbance at 500 nm using a spectrophotometer (Agilent Technologies Canada 
Inc., Canada). Ascorbic acid was used as the standard. The time of incubation needed 
for the TBARS assay was determined one day after the absorbance of the control 
reached maximum value in the thiocyanate method.  
 
For the TBARS assay, the FPH samples were prepared by suspending the freeze dried 
hydrolysates in sodium phosphate buffer (6.7 mg/mL). Three mL of the emulsion 
prepared as described for the thiocyanate assay was mixed with 2.4 mL of sodium 
 
 
65 
 
phosphate buffer and 600 μL of hydrolysate sample (final concentration 0.67 mg/mL). 
The samples were incubated at 40 °C in the dark for 75 h. To 1 mL of sample solution, 
was added 1 mL of 20 % (w/v) TCA and 1 mL of 0.67 % (w/v) TBA. The mixture was 
placed in a boiling water bath for 10 min and after cooling was centrifuged at 3000 rpm 
(2,060 × g) for 20 min. Absorbance (Ab532) of supernatant was measured at 532 nm 
(Chen et al., 2007). A control sample was prepared by replacing the FPH with buffer. 
The blank consisted of all the reagents in the control sample to which TCA and TBA 
were added at zero time of incubation. Ascorbic acid was used as the standard. 
 
 
(3.6) 
 
 
3.8.4 Superoxide radical scavenging activity 
The O2•- scavenging ability of FPHs was determined using hypoxanthine-xanthine 
oxidase (HPX-XOD) system as described by Saint-Cricq de Gaulejac et al. (1999). 
Active oxygen free radicals can be generated by the HPX -XOD system. At pH 7.4, O2•- 
reduces the tetrazolium blue into formazan blue (maximum 560). After addition of 
radical scavengers, the formation of formazan blue is restricted and absorbance at 560 
nm (Ab560) decreases. Absorbance at 560 nm is proportional to the amount of residual 
O2•- (Saint-Cricq de Gaulejac et al., 1999). 
 
For the assay, Nitro blue tetrazolium or Tetrazolium blue (NBT; 0.001 M), XOD (1.67 
U/mL) and HPX (0.005 M) were solubilized in sodium phosphate buffer (prepared by 
mixing 4 volumes of 0.1 M Na2HPO4 with 1 volume of 0.1 M NaH2PO4; pH 7.4). The 
FPHs tested were solubilized in water. The reagent volumes used for blank, control and 
sample assays were as in Table 3.2. The final concentration of the FPHs in the assay 
mix was 0.67 mg/mL. The absorbance (Ab560) of control and samples were monitored at 
560 nm for 10 min using the kinetic mode of the diode array spectrophotometer 
(Agilent Technologies Canada Inc. Canada). Standard antioxidants used were carnosine 
and ascorbic acid at the same concentration as hydrolysates. 
    
  100Ab
AbAb
onperoxidati acid linoleic of Inhibition %
Control532
Sample532Control532 
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Table 3.2 Reagent volumes used for the determination of superoxide radical 
scavenging activity 
NBT: Nitro blue tetrazolium; HPX: Hypoxanthine; XOD: Xanthine oxidase 
 
The O2•- scavenging activity of the FPHs was determined using the following equation. 
    
  100bA
AbAb
activity scavenging O%
Control560
Sample560Control560-·
2 

 (3.7) 
 
 560Ab = 560Ab at 10 minutes- 560Ab at zero time     (3.8) 
 
3.8.5 Metal chelating activity 
The chelation of ferrous ions by the FPHs was estimated by the method of Dinis et al. 
(1994). Divalent iron reacts with ferozine to form a stable magenta complex, which has 
a maximum absorbance at 562 nm (Ab562) (Dinis et al., 1994). Reduction of 
concentration of divalent Fe ions due to chelation was assessed using the reduction of 
the intensity of the color complex.  
 
In a cuvette 50 μL of FPH in distilled water (final concentration 0.67 mg/mL), 25 μL of 
2 mM ferrous chloride and 1375 μL of distilled water were mixed. The mixture in the 
cuvette was incubated for 5 min at room temperature. Ferrozine (50 μL) was transferred 
into the cuvette and it was incubated further for 10 min at room temperature. The 
absorbance of the resulting solution was read at 562 nm (Ab562) against deionized water 
blank. The control consisted of all the reagents prepared by replacing the FPH with 
deionized water. The % metal chelation of the FPHs was determined as follows.  
    
  100Ab
AbAb
activity chelating Metal%
Control562
Sample562Control562 
  (3.9)
 
 Na phosphate 
buffer, 0.1 M, pH 
7.4 
NBT (μL) HPX (μL) XOD (μL) Hydrolysate 
(μL) 
Blank 2400 100 500 - - 
Control 2300 100 500 100 - 
Sample 2200 100 500 100 100 
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3.8.6 Antithrombotic activity 
The inhibition of fibrin clot formation by thrombin was measured at 420 nm using a 
 spectrophotometer as described by Szewczuk et al. (1992). Bovine fibrinogen (0.1% 
w/v, 3 mL) in 0.05 M Tris-HCl buffer (pH 7.6) containing 0.1 M NaCl and 0.1 % (v/v) 
polyethylene glycol 8000 were mixed in a cuvette with FPHs in Tris-HCl buffer at a 
final concentration of 0.67 mg/mL. The volume of the solution was adjusted with 0.98 
mL using Tris-HCl buffer. Human thrombin (20 µL; final concentration: 0.2 U/mL) was 
added to the cuvette, mixed and the absorbance at 420 nm (Ab420) was recorded with 
time. The control reaction consisted of Tris-HCl buffer in place of the hydrolysate. A 
blank was prepared by including all the reagents present in the control except thrombin. 
Antithrombin was used as the standard. The antithrombotic activity was determined 
using the following equation. 
  
    
  100activity oticAntithromb  % 420
420420 
Control
SampleControl
Ab
AbAb
        (3.10)
 
 
3.8.7 Bile acid binding ability 
The in vitro bile acid binding capacity of FPHs was assessed as described by Yoshie-
Stark and Wasche (2004). In the presence of NAD the enzyme 3-α hydroxyl-steroid 
dehydrogenase (3-α HSD) converts bile acids to 3-keto steroids and NADH. The 
NADH formed reacts with NBT to form a formazan dye in the presence of diaphorase 
enzyme. The dye formation is monitored by measuring the absorbance at 540 nm and is 
directly proportional to the bile acid concentration in the sample.  
 
The bile acids tested were sodium cholate (SC), sodium glycocholate (SGC), sodium 
taurocholate (STC), sodium deoxycholate (SDC) and sodium chenodeoxycholate 
(SCDC). The flaxseed protein isolate and FPHs were dissolved in 0.1 M sodium 
phosphate buffer (pH 7.0) at a concentration of 6.7 mg/mL, prior to the assay. One 
hundred µL of sample suspension was mixed with 900 L of 2 mM bile acid solution in 
sodium phosphate buffer in a micro-centrifuge tube. The mix was incubated at 37 C for 
2 h, centrifuged at 16,000 × g for 5 min using a micro centrifuge (Brinkmann, 
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Germany). The recovered supernatant was then transferred into a 25 mL volumetric 
flask. The remaining residue was mixed with 500 L of sodium phosphate buffer and 
centrifuged again. The supernatants were pooled in the volumetric flask and the final 
volume was adjusted to the mark using sodium phosphate buffer. A control reaction 
mixture consisting of 100 L of sodium phosphate buffer and 900 L of 2 mM bile acid 
solution was incubated along with samples and treated similarly. The blank consisted of 
all the reagents used for final spectrophotometric analysis except the test sample, which 
was replaced by the sodium phosphate buffer. Bio-Quant total bile acid analysis kit 
(Bio-Quant Inc., U.S.A.) was used to quantify free bile acids in the supernatants. All the 
bile acids were monitored at absorbance 540 nm (Ab540). Calibration curves were 
constructed for each of the bile acid tested. Cholestyramine resin (0.67 mg/mL), which 
is the clinically approved bile acid binding agent, was used as the standard. The bile 
acid binding ability for each bile acid was tested separately.  
 
    
  100Ab
AbAb
bindingacidBile%
Control540
Sample540Control540 
                            (3.11) 
540Ab =Change in 540Ab after 5 minutes of incubation with reagents in the enzyme 
assay kit 
 
3.8.8 Determination of IC50 value for the bioactivities 
The IC50 value was defined as the concentration of digests/FPHs (mg/mL) required to 
achieve 50 % of the control value resulted in for each bioactivity. The IC50 values were 
calculated for each bioactivity tested by using different concentrations of digests 
possessing the tested bioactivities. 
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3.9 Purification and characterization of the bioactive peptides  
3.9.1 Purification of angiotensin I-converting enzyme inhibitory peptides using 
angiotensin I-converting enzyme immobilized to glyoxyl-agarose 
3.9.1.1 Immobilization of angiotensin I-converting enzyme into glyoxyl-agarose 
Angiotensin I-converting enzyme was immobilized, through amino groups of Lys, to 4 
% cross-linked (4 BCL) glyoxyl-agarose beads. The immobilized ACE was used to 
purify ACEI peptides in FPHs as described by Megias et al. (2006).  
 
3.9.1.2 Activation of agarose beads 
The agarose beads were activated according to Megias et al. (2006) before ACE 
immobilization. Ten mL of agarose was washed using 5 volumes of deionized water 
and 1 volume of 1 M NaOH containing 0.5 M NaBH4 to remove the ethanol, which had 
been used as a preservative in agarose. Five milliliters of 1 M NaOH + 0.5 M NaBH4 
was added to agarose at a bead to solution ratio of 2:1 v/v. While keeping this mixture 
on an ice bucket, glycidol was added drop wise in order to reach a 2 M final 
concentration, and the resulting suspension was gently stirred overnight at room 
temperature. The beaker was kept open while stirring to release hydrogen gas. The 
agarose beads were washed with 200 mL of deionized water using a scintered bottom 
funnel under very mild vacuum. Then the agarose beads were suspended in water (100 
mL) in a beaker containing NaIO4 (0.64 g) and stirred for 3 h at room temperature. The 
oxidation with NaIO4 converts diol groups into aldehyde groups making multipoint 
attachment of protein molecules to the gel possible. The resulting activated agarose 
beads were washed with 300 mL water, mixed with 5 mL of water (10 mL beads in 15 
mL suspension) and stored at 4 °C until further use. 
 
3.9.1.3 Immobilization of angiotensin I-converting enzyme to activated agarose 
The activated agarose bead suspension (1.5 mL) was centrifuged (2,285 × g for 30 sec) 
using a micro centrifuge (Brinkmann, Germany) to remove water. The beads were 
washed twice with 0.5 mL of 0.2 M NaHCO3 (pH 10) and transferred into a beaker. It 
was added with 14 µg of ACE from porcine kidney and 0.2 M NaHCO3 (pH: 10) 
(Agarose beads: NaHCO3, 1:10 v/v). The mixture was stirred gently for 30 min at room 
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temperature. NaBH4 (0.011 g) was added to the mixture and stirred for another 30 min. 
The solution was filtered using a scintered bottom funnel under mild vacuum. The 
resulting agarose gel with immobilized ACE was washed five times with 10 mL 
deionized water to remove any unimmobilized ACE. The filtrates were collected, freeze 
dried and checked for ACE activity (method described in section 3.9.1) to determine the 
presence of any unimmobilized ACE. The ACE activity of immobilized ACE was 
determined using unimmobilized ACE as the control. The agarose gel with ACE 
(approximately 0.8 mL of recovered packed gel) was stored in 0.02 % (w/v) sodium 
azide at 4 °C.  
 
3.9.1.4 Identification of peptides with angiotensin I-converting enzyme inhibitory 
activity 
The ACE immobilized to agarose beads was used to purify ACEI peptides in the FPH 
with the highest ACEI activity. The FPH was incubated with the immobilized ACE. 
Before this, the immobilized ACE was washed with water (700 µL portions) five times 
and with 700 µL portions of ACE buffer twice to remove any sodium azide present. 
One hundred µL of ACE immobilized to agarose was mixed with equal volume of ACE 
buffer. Thereafter 100 µL of this suspension (50 µL packed gel) was pipetted into an 
Eppendorf tube and was incubated with FPH for 2 h at 37 °C in a water bath. The 
immobilized ACE: FPH ratio used was 1:2800 (w/w). This ratio was calculated based 
on the ratio between ACE and hydrolysate used in the ACE assay. After incubation, the 
supernatant was recovered by centrifuging at 2,285 × g for 30 sec in a micro centrifuge. 
The agarose beads were washed 4 times with 400 µL portions of ACE buffer to remove 
any unbound material by mixing with buffer and centrifuged at 2,285 × g for 30 sec. 
The supernatant and FPH used for incubation was injected to Superdex peptide HR 
10/30 column (column size 10 × 300 mm, Amersham Pharmacia Biotech, Sweden) 
coupled with AKTA fast protein liquid chromatography (FPLC) system to identify any 
missing peaks due to binding with ACE. The chromatographic conditions used were 
same as described under the following section (3.9.2). The immobilized ACE upon 
incubation with FPH was used for assay of ACE activity as described previously. The 
immobilized ACE without incubation with FPH was used as the control. 
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3.9.2 Peptide fractionation using fast protein liquid chromatography (FPLC) 
The freeze dried gastric and gastric + intestinal digests of isolated flaxseed protein 
obtained from both simulated digestion models as well as FPHs that possessed 
bioactivities were fractionated on a Superdex peptide HR 10/30 size exclusion column 
(SEC) (column size 10 × 300 mm, Amersham Pharmacia Biotech, Sweden) using an 
AKTA Explorer FPLC system (Amersham Pharmacia Biotech, Sweden). Of the digests 
obtained from gastric + intestinal phase of dynamic model, only the dialysate was 
subjected to fractionation. A solution of the digests/FPHs were prepared in the mobile 
phase (20 % v/v acetonitrile + 0.05 % v/v trifluoroacetic acid /TFA) to a concentration 
of 20 mg/mL, and filtered through a 0.45 µm membrane before application. An aliquot 
of this solution (150 µL) was injected on to the column manually and eluted using 
isocratic conditions (20 % v/v acetoinitrile + 0.05 % v/v TFA) at a flow rate of 0.5 
mL/min at room temperature. The column eluent was monitored at 214 nm and 280 nm. 
The standards of known molecular masses (insulin chain A, angiotensin II and Hip-His-
Leu) were also separated on the same column to determine the distribution of molecular 
masses of the peptides in the digests. Fractions of eluent (1 mL) were collected using a 
fraction collector. The collected fractions were pooled based on the molecular mass 
distribution as determined by comparing with the standards and then freeze dried. The 
freeze dried fraction of each digest/FPH was assessed for the bioactivities after re-
dissolving in respective buffers. The fraction(s) exhibiting the most activity was 
selected for further purification and characterization of bioactive peptides. 
 
3.9.3 Concentration and purification of peptides  
The lyophilized bioactive FPLC fractions of flaxseed protein digests/ FPHs were further 
purified using PepCleanTM C-18 spin columns (Pierce, U.S.A.) prior to peptide 
sequencing. The spin column was placed in a receiving tube (Eppendorf tube) and the 
resin in the spin columns were activated with 200 µL of 50 % v/v acetonitrile, 
centrifuged at 1500 × g for 1 min and the flow through was discarded. The resin was 
then equilibrated with 200 µL of 5 % (v/v) acetonitrile having 0.5 % (v/v) TFA, 
centrifuged at 1500 × g for 1 min and the flow through was discarded. The activation 
and equilibration steps were carried out twice as instructed by the manufacturer. A 
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solution was prepared by mixing the sample (1 mg) with sample buffer (100 µL, 5 % 
v/v acetonitrile + 0.5 % v/v TFA). This solution was sonicated for 10 min and the 
solution (100 µL) was loaded on to the column. The column was centrifuged as before 
and the flow through was recovered and loaded back to the column to ensure sample 
binding. The binding process was carried out four times. The resin bound with peptides 
were then washed with 200 µL of 5 % (v/v) acetonitrile having 0.5 % (v/v) TFA 
centrifuged as before and the flow through was discarded. The washing step was 
repeated four times to remove as much contaminants as possible from the sample. The 
purified peptides were then eluted into a new receiving tube using 20 µL of elution 
buffer (50 % v/v acetonitrile + 0.1 % v/v formic acid). The elution step was carried out 
four times or until sufficient volume of eluate was collected. The eluate was then freeze 
dried. The dried samples were suspended in 0.1 % (v/v) formic acid at a concentration 
of 0.8 mg/mL prior to de novo sequencing. 
 
3.9.4 De novo sequencing of peptides  
The sequence analysis of peptides in the concentrated and purified bioactive fractions of 
flaxseed protein digests/FPHs was carried out using liquid chromatography (LC) 
connected to a mass spectrometer (MS). The solvent delivery and sample introduction 
was performed using Waters Acquity ultra performance LC (UPLC) system (Waters, 
U.K.). The samples were separated on a 2.1 mm x 50 mm Acquity reverse phase 
column (BEH, C18, 1.7µm) connected to a UPLC using 1 % (v/v) formic acid (solvent 
A) and acetonitrile (solvent B) as the mobile phases. A gradient elution was employed 
starting at 10 % (v/v) B and rising linearly to 90 % (v/v) within 15 min. The 
composition was returned to initial conditions within 2 min and thereafter to 5 % (v/v) 
B within another 2 min giving a total run time of 19 min. The injection volumes of the 
sample were 10 µL. The column was maintained at 65 °C. The standard peptides used 
were Gly-Gly-Tyr-Arg (451.22 Da) and Phe-Phe (312.15 Da). 
 
Flow from the UPLC column was entered into a high definition mass spectrometer 
(SYNAPT HDMS, Waters, UK) interfaced with electrospray ionization (ESI) source. 
The ESI source was operated in the positive ion mode at a capillary voltage of 3.5 V. 
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Cone voltage and collision energy for peptides were 40 V and 30 eV, respectively. The 
ion source and desolvation temperature was maintained at 100 °C and 150 °C, 
respectively. The MS/MS spectra were obtained for the most abundant peptides in the 
total ion current chromatogram (TIC). The amino acid sequencing of the abundant 
peptides was performed using Masslynx/MASCOT distiller programs (Micromass, UK) 
as de novo sequencing. 
 
3.10 Statistical analysis 
All the experiments and analyses were conducted in duplicate or triplicate. All the 
values were reported as mean  standard deviation. The results of the simulated GI 
digestion study were evaluated using a generalized linear model (one way analysis of 
variance-ANOVA) with multiple comparisons of means (Tukey’s pair wise 
comparisons) with probability (P) at 0.05.  
 
The data obtained from CCRD experiment of Flavourzyme catalyzed hydrolysis of 
flaxseed protein was analyzed by ANOVA assuming a general linear model. Response 
surface methodology and multivariate analysis allowed the determination of the 
optimum hydrolysis time and E/S combinations that yield the highest level of DH 
values and bioactivities. Statistical analysis was performed using SAS 9.1 software 
(SAS Institute Inc., U. S. A.). 
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4. RESULTS AND DISCUSSION 
 
4.1 Study 1: Release of cardioprotective bioactive peptides during simulated 
gastrointestinal digestion of flaxseed protein 
4.1.1 Materials used for protein extraction 
The flaxseed (variety: Valour) used in the present study consisted of 5.74 ± 0.1 % 
moisture, 4.04 ± 0.0 % ash, 40.62 ± 0.5 % lipid, 22.18 ± 0.4 % protein (N % x 6.25) and 
9.84 ± 0.2 % soluble carbohydrates on a fresh weight basis (Table 4.1). The soluble 
carbohydrate content was mainly analyzed to estimate the mucilage content of the 
flaxseed. Prior to protein extraction the seeds were subjected to both demucilaging and 
defatting to remove the mucilage from the seed coat and oil from the seed kernel.  
 
Table 4.1 Proximate composition of flaxseed (cultivar: Valour) used  
 
 
 
 
 
 
 
 
 
1Values are means ± standard deviations of triplicate analyses expressed on as is basis 
 
The results of preliminary studies revealed that mild conditions such as soaking in water 
at room temperature as well as stirring in 0.5 M NaHCO3 at 50 °C assisted in mucilage 
removal from the seed coat (Table 4.2).  
Component Value (%)1 
Lipid 40.62 ± 0.5 
Protein 22.18 ± 0.4 
Water soluble carbohydrates 9.84 ± 0.2 
Moisture 5.74 ± 0.1 
Ash 4.04 ± 0.0 
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The flaxseed demucilaged with water as well as with 0.5 M NaHCO3 had significantly 
lower (P<0.05) soluble carbohydrate content than the whole flaxseed. The use of 0.5 M 
NaHCO3 removed a significantly higher (P<0.05) level of flaxseed mucilage (88 %) 
than extraction with water (68 %). 
Table 4.2 Estimated soluble carbohydrate levels in flaxseed after treatments 
1 Values are means ± standard deviations of triplicate analyses expressed on as is basis (g/100g of seed) 
abcMeans in the same column followed by the same letter are not significantly different (P<0.05) 
 
The isolation of protein from oil-free meals often uses alkali solubilization followed by 
acid precipitation. This method, suitable for the isolation of protein from soybean, 
however is not effective for flaxseed because of the polysaccharide gums (mucilage) in 
the hulls/seed coat (Mazza & Biliaderis, 1989). Flaxseed mucilage is a mixture of 
polysaccharides present in the epidermal cell layer of the seed coat (Diederichsen et al., 
2006), which can be extracted by treating with cold water (Erskine & Jones, 1957). 
According to Wanasundara and Shahidi (1997), determination of total sugars and 
pentoses solubilized from the seed coat of flaxseed gives an indirect measurement of its 
mucilage content. The mucilage of flaxseed seriously interferes with the settling of the 
aggregated protein due to its swelling and increase in viscosity in the aqueous medium 
(Smith et al., 1946). Therefore, removal of mucilage from the flaxseed coat was 
considered as important prior to isolation of proteins. Various methods reported in 
literature for mucilage removal include soaking seeds with 1 % (v/v) HCl (Mandokohot 
& Singh, 1979), water followed by passage through a fruit pulper (Madusadhan & 
Singh, 1983), boiled distilled water (Bhatty, 1993), NaHCO3 followed by 0.1 N HCl as 
well as using commercially available carbohydrases (Wanasundara & Shahidi 1997). 
Treatment Remaining soluble carbohydrate content 
(%)1 
Whole flaxseed (no treatment) 12.16 ± 0.6a 
Flaxseed, mucilage removed with water  3.84 ± 0.1b 
Flaxseed, mucilage removed with NaHCO3 2.14 ± 0.1c 
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Use of NaHCO3 in the soaking medium improves removal of mucilage as the alkali pH 
leads to depolymerization of polysaccharides (Wanasundara & Shahidi, 1997). 
The mucilage removal of flaxseeds with NaHCO3 did not require use of specific 
equipment, acids or high temperature and maintained the protein at its native state. It 
was also found to be more effective in removing mucilage from flaxseed compared to 
use of water. Therefore, demucilaging with 0.5 M NaHCO3 was chosen as the suitable 
method for mucilage removal throughout the study.  
 
The demucilaged flaxseed was defatted to obtain demucilaged and defatted flaxseed 
meal. Oil was removed from the demucilaged seeds to improve the recovery of proteins. 
Of the two methods (hexane extraction of milled whole flaxseed and expeller pressing 
followed by hexane extraction) used for removing oil from demucilaged flaxseed, it was 
evident that a product containing <1 % of oil can be obtained using a combination of 
both methods (Table 4.3). Although hexane extraction and expeller pressing when used 
alone significantly reduced (P<0.05) the oil content in flaxseed, the amount of residual 
oil remained in the resulting demucilaged and defatted flaxseed was considerably higher 
compared to that when both methods were combined.  
 
Flaxseed demucilaged with NaHCO3 and defatted by expeller pressing followed by 
hexane extraction was selected as the most suitable meal for protein extraction due to 
low levels of mucilage and oil present (Tables 4.2 and 4.3). 
 
4.1.2 The protein solubility profile of milled, demucilaged and defatted flaxseed 
against pH 
The results shown in Figure 4.1 were used to establish the pH, which provides 
minimum protein solubility in milled, demucilaged and defatted flaxseed. Solubility of 
proteins in milled, demucilaged and defatted flaxseed was changed by extraction 
medium pH as shown in Figure 4.1. The protein solubility curve (Figure 4.1) was a 
typical ‘U’ shaped curve similar to most other SSPs, exhibiting a minimum solubility 
between the pH 3.5 to 4. 
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Table 4.3 Oil content of whole flaxseed and demucilaged and defatted flaxseed 
1Values are means ± standard deviations of triplicate analyses expressed on as it is basis 
abcdMeans in the same column followed by the same letter are not significantly different (P<0.05) 
 
The protein solubility values were greater below and above the pH range of 3.5-4. 
Therefore, during the extraction of flaxseed protein, the pH of the alkali soluble extract 
of milled, demucilaged and defatted flaxseed was adjusted in the range of 3.5-4 in order 
to precipitate maximum amount of proteins. This range is in accordance to the findings 
of flaxseed protein studies carried out by Painter and Nesbitt (1946), but deviates from 
findings (pH 4.9-5.8) of Krause et al.(2002), Madhusadhan and Singh, (1983) (pH 3-6), 
Martinez-Flores et al. (2006) (pH near 5) and Smith et al. (1946) (pH 5.1). It is reported 
that the solubility of flaxseed nitrogenous compounds are dependent on the composition 
and ionic strength of the solvent used, solvent/meal ratio and temperature in addition to 
pH (Dev & Quensel, 1986, Madhusudhan & Singh, 1983). Moreover, the different 
varieties of flaxseed used in these previous studies also could have an effect on the pH 
that provides minimum protein solubility.  
 
A protein carries a net positive or net negative charge at pH values below and above its 
isoelectric pH, respectively. Electrostatic repulsion and hydration of these charged 
residues promote interaction with water, causing solubilization of the proteins. 
Seed treatment                                     Oil content 
                                       (%)1 
Whole  flaxseed 
Demucilaged and defatted flaxseed 
40.62 ± 0.46a 
     Water demucilaged + Hexane extracted   18.57 ± 0.7c 
     Water demucilaged  + Expeller pressed   23.06 ± 0.3b 
     Water demucilaged  + Expeller pressed + Hexane extracted   0.65 ± 0.0d 
     NaHCO3 demucilaged +  Expeller pressed + Hexane extracted   0.23 ± 0.0d 
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Figure 4.1 Solubility of proteins of milled, demucilaged and defatted flaxseed as 
changed by medium pH (Mean values of 3 extractions are plotted) 
 
At alkaline pH, the proteins exhibit maximum solubility. When proteins are near their 
isoelectric pH (IEP), there is an absence of electrostatic repulsion due to charge 
neutralization in proteins, causing minimum solubility. This condition causes 
aggregation and precipitation of proteins via hydrophobic interactions (Damodaran, 
1996). Therefore, the IEP of flaxseed proteins should lie between the pH of 3.5-4. 
However, according to the curve (Figure 4.1), approximately 10 % of the proteins in the 
milled, demucilaged and defatted flaxseed were soluble at the pH range (3.5-4) 
indicating that all proteins are not exhibiting their charge neutrality at this pH range and 
likely would not be present in the protein isolate produced.  
 
4.1.3 Protein content of milled, demucilaged and defatted flaxseed and isolated 
proteins 
For the present study, protein was extracted from milled, demucilaged and defatted 
flaxseed using alkali solubilization followed by precipitation at pH 3.8. It has been 
reported that several extractions can recover more protein from flaxseed meal than a 
single extraction (Painter & Nesbitt, 1946). Therefore, two extractions were carried out 
using water adjusted to pH 8.5 to isolate proteins from milled, demucilaged and defatted 
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flaxseed. Table 4.4 shows a comparison of the crude protein content of the isolated 
proteins obtained from different types of milled, demucilaged and defatted flaxseed. 
The protein content of milled, demucilaged and defatted flaxseed ranged from 30.61 ± 
0.2 % (water demucilaging + hexane extraction) to 40.81 ± 0.4 % (NaHCO3 
demucilaging + expeller pressing + hexane extraction). The protein content of isolated 
flaxseed proteins obtained from different types of milled, demucilaged and defatted 
flaxseed ranged from 63.48 ± 0.9 to 86.01 ± 0.2 %. The demucilaged and defatted 
flaxseed obtained from NaHCO3 demucilaging + expeller pressing + hexane extraction 
resulted in the protein material with the highest crude protein content (86.01 ± 0.2 %), 
which was a significantly higher (P<0.05) level than proteins isolated from other 
demucilaged and defatted flaxseed. These values further revealed that the yield of 
protein in the isolate increases with the reduction of mucilage and residual oil from the 
starting material. In a recent report, Udenigwe et al. (2009) have reported protein 
extraction from industrially crushed and defatted flaxseed meal. They have demucilaged 
flaxseed meal with cellulase enzyme prior to protein extraction using alkali 
solubilization and acid precipitation. The protein content in the resulting flaxseed 
protein isolate reported by these authors was 78.9 %, which was lower than the protein 
content (86.01 ± 0.2 %) of the isolated protein obtained in the present study. 
 
There is a possibility for a certain amount of retained mucilage to be precipitated along 
with protein during the protein extraction procedure. Presence of a high amount of 
mucilage (3.31 ± 0.3 %) and oil (23.55 ± 0.2 %) in the protein isolate extracted from 
water demucilaged and hexane extracted meal can be considered as an important factor 
which led to lower protein yield. The results of the present study further revealed that 
the milled, demucilaged and defatted flaxseed prepared by NaHCO3 assisted 
demucilaging and expeller pressing combined with hexane extraction was the most 
suitable material for protein extraction. This term “milled, demucilaged and defatted 
flaxseed” refers to the above material hereafter. The protein isolated from this material 
was used throughout the study and will be referred as isolated flaxseed protein. 
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Table 4.4 Crude protein content of different milled, demucilaged and defatted 
flaxseed and isolated proteins 
1Values are means ± standard deviations of triplicate analyses expressed on as is basis 
abcMeans in the same column followed by the same letter are not significantly different (P<0.05) 
 
4.1.4 Composition of isolated flaxseed protein 
The proximate composition of flaxseed protein isolated by alkali solubilization followed 
by acid precipitation is given in Table 4.5. Of the non-protein constituents, the lipid 
content was found to be relatively low (<1 %), whereas the TDF content was around 
8.01 ± 0.6 %. The SDF, which comprised the majority of the TDF was expected to be 
the soluble polysaccharides (mucilage) from seed coat and cell wall that still remained. 
Of the dietary fiber in flaxseed, which is concentrated in the hull, two thirds is insoluble 
fibre consisting of cellulose, hemicellulose and lignin (Tarpila et al., 2005). The results 
revealed the solubilization and co-precipitation of both soluble and insoluble fibres 
remained in milled, demucilaged and defatted flaxseed during the protein extraction 
(See section 4.2.1). The extent of solubilization and co-precipitation with protein was 
found to be higher in SDF compared to TDF as expected. 
 
The amino acid composition of the milled, demucilaged and defatted flaxseed and 
isolated protein was also analyzed and is presented in Table 4.6. Both were found to be 
rich in acidic amino acids such as Glu and Asp as well as the basic amino acid, Arg. 
The other amino acids found in abundance were the neutral, hydrophobic amino acids, 
Gly and Leu. Except for Arg, slightly lower levels of all the other amino acids were 
found in the isolated protein compared to the milled, demucilaged and defatted flaxseed. 
 Protein content (%)1 
 
Treatment  Milled, demucilaged 
and defatted flaxseed 
Isolated protein  
Water demucilaged + Hexane extracted  30.61 ± 0.2c 63.48 ± 0. 9b 
Water demucilaged + Expeller pressed + 
Hexane extracted  38.67 ± 0.5
b 68.76 ± 0.3b 
NaHCO3 demucilaged + Expeller pressed + 
Hexane extracted  40.81 ± 0.4
a 86.01 ± 0.2a 
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Table 4.5 Proximate composition of the isolated flaxseed protein  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1Values are means ± standard deviations  of triplicate analyses expressed on as is basis 
 
The most limiting amino acids in the milled, demucilaged and defatted flaxseed were 
His, Trp, Tyr and the sulphur containing amino acids (Cys and Met), whereas in the 
isolated protein, Lys and Pro were also limiting in addition to these amino acids. These 
results were in accordance to the amino acid pattern of flaxseed proteins reported by 
others (Chung et al., 2005, Oomah & Mazza, 1993). According to Oomah and Mazza 
(1993) the amino acid pattern of flaxseed protein is comparable to that of soy, with both 
oilseeds having relatively high levels of Asp, Glu, Leu and Arg. Protein sources rich in 
Arg and Glu have recently gained popularity due to the preventive function of Arg 
against heart diseases and Glu in supporting the immune system (Oomah, 2001) and 
improving athletic performance (Blenford, 1996). L-Arg is the substrate of nitric oxide 
synthase (NOS) generateing nitric oxide (NO) that acts as a vasodialator and an 
inhibitor of platelet aggregation (Maxwell & Cooke, 1998). Therefore, the low Lys:Arg 
is suggested to be the causal factor for the antiatherogenic  and antithrombotic effects of 
many plant proteins (Kritchevsky et al., 1981). 
Constituent Value (%)1 
Protein 86.01 ± 0.2 
Lipid 0.55 ± 0.1 
Total dietary fiber (TDF) 8.01 ± 0.6 
     Soluble dietary fiber (SDF) 5.41 ± 0.8 
     Insoluble dietary fiber (IDF) 2.59 ± 1.4 
Moisture 5.98 ± 0.9 
Ash 4.13 ± 0.3 
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Table 4.6 Amino acid composition (g/100 g protein) of milled, demucilaged and 
defatted flaxseed and isolated protein  
 1Values are means ± standard deviations of duplicate analyses 
2 Branched chain amino acids, 3 Conditionally essential (Food and Nutrition Board, 2005) 
 E/T: Percentage ratio between essential amino acids and total amino acids 
Amino acid   Milled, demucilaged and defatted 
flaxseed1 
Isolated  protein1 
Essential    
His 2.22 ± 0.0 1.59 ± 0.0 
   
Ile2 3.91 ± 0.1 3.37 ± 0.0 
 
Leu2 6.23 ± 0.1 4.67 ± 0.0 
 
Lys 3.56 ± 0.0 2.12 ± 0.0 
 
Met 2.40 ± 0.0 1.69 ± 0.1 
 
Phe 4.97 ± 0.1 4.52 ± 0.1 
 
Thr 4.19 ± 0.1 2.83 ± 0.1 
 
Trp 1.19 ± 0.0 1.10 ± 0.0 
 
Val2 5.18 ± 0.1 3.75 ± 0.0 
 
Non-essential    
Ala 4.96 ± 0.0 3.77 ± 0.1 
 
Arg3 9.47 ± 0.4 9.71 ± 0.0 
 
Asp 9.56 ± 0.1 9.02 ± 0.1 
 
Cys 2.75 ± 0.1 2.04 ± 0.0 
 
Glu 21.26 ± 0.2 19.75 ± 0.4 
 
Gly 6.61 ± 0.1 5.19 ± 0.1 
 
Pro 3.27 ± 0.2 2.45 ± 0.1 
 
Ser 5.31 ± 0.1 4.53 ± 0.1 
 
Tyr 2.28 ± 0.1 1.49 ± 0.1 
 
Lys/Arg 
 
0.38 0.22 
E/T (%) 
 
43.61 42.28 
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The Lys:Arg of the milled, demucilaged and defatted flaxseed and isolated flaxseed 
protein prepared in the present study was 0.22 and 0.38, respectively. The Lys:Arg of 
isolated protein from Norman flaxseed is reported as 0.34 (Chung et al., 2005) and is 
greater than the value of isolated protein obtained in the present study. It was interesting 
to note that flaxseed protein isolated in the present study had a lower Lys:Arg when 
compared to that of soy and canola (0.88 for both) (Oomah & Mazza, 2000). The results 
of the amino acid profile suggest that flaxseed protein has more potential for 
antiatherogenic and antithrombotic effect than soy or canola protein. 
 
The percentage ratio between essential to total amino acids (E/T %) was also calculated 
for both milled, demucilaged and defatted flaxseed and isolated protein (Table 4.6). The 
E/T (%) of isolated protein (42.28 %) and of milled, demucilaged and defatted flaxseed 
(43.61 %), showed that flaxseed protein in isolation or intact form can contribute 
significantly to the supply of essential amino acids in the diet. The E/T (%) of flaxseed 
protein is fairly close to the value (44.4 %) obtained for soybean (Kuri et al., 1991). 
 
4.1.5 Simulated gastrointestinal digestion of flaxseed protein 
4.1.5.1 Development of simulated gastrointestinal model (Static model) 
In the present study, human GI digestion was simulated in vitro using a static model and 
a dynamic model. The static model simulated major physiological parameters (pH, E/S, 
temperature, time of digestion) of human GI digestion, except the absorption of digested 
products via the small intestinal brush border membrane, which was simulated in 
dynamic model.  
 
In the present study, digestion in the mouth by salivary amylase was not simulated as 
flaxseed has not been reported to contain starch which is a substrate for salivary 
amylase. The choice of proteolytic enzymes was considered important because the 
specific action of enzymes on protein generally influence the composition of digested 
products. The importance of using crude enzymes corresponding to those found in the 
gut instead of using purified proteolytic enzymes have been reported for in vitro 
digestion studies (Marable & Sanzone, 1981). Since food proteins occur mainly in close 
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association with carbohydrates and lipids, it was considered desirable to keep lipases 
and amylases in the enzymatic preparations. The activity of these nonproteolytic 
enzymes will influence the proteolytic enzymes, mainly by modifying their substrates 
(Gauthier et al., 1986). For these reasons, the simulated GI digestion model included 
pepsin as the gastric phase enzyme and pancreatin as the intestinal phase enzyme. The 
pancreatin used was a mixture of amylase, trypsin, lipase, ribonuclease and protease 
(Sigma). Savoie and Charbonneau (1990) have reported the importance of using 
pancreatin for in vitro digestion protocols as the pure enzymes such as trypsin and 
chymotrypsin are less stable in a mixture.  
 
Another important aspect that was considered in the development of the GI digestion 
model was selecting a suitable E/S ratio. The E/S ratio is one of the most important 
variables in digestion studies since the enzymatic release of amino acids and small 
peptides varies with the ratio (Gauthier et al., 1986). The search of E/S ratio in the 
published in vitro digestion protocols encountered wide range of values. Also humans 
show a wide variation in their amount and composition of gastric and pancreatic 
secretions making it more difficult to select an optimal E/S ratio. For example, pepsin in 
human gastric samples can vary over 10,000 fold (da Silva Gomes et al., 2003) and 
varies with the type of food consumed (Moreno, 2007). Results of rat studies have 
shown that dietary proteins can increase the synthesis and secretion of digestive 
enzymes (both proteolytic and non-proteolytic) and retard the rate of breakdown of 
these enzymes within the intestine. Products of protein digestion were also found to 
stimulate pancreatic secretion (Snook & Meyer, 1964). Moreover, many of the 
published simulated GI studies do not specify the activity of enzymes and the E/S of 
such studies are estimated on weight basis, which made the comparison between 
digestion protocols not possible.  
 
Two preliminary studies (Static model I and II, which are described in detail under 
Appendix I and section 3.4.3 of the Materials and Methodology chapter, respectively) 
were conducted using casein to identify the most physiologically relevant digestion 
protocol for protein. Casein is regarded internationally as a standard for protein 
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digestibility and has been widely studied in in vitro systems (Gauthier et al., 1986; 
Savoie et al., 1988). In the static model I (Appendix I), the human digestive system was 
simulated considering parameters such as daily protein intake, different volume of 
digestive juices secreted and their ratios as well as the E/S ratios. All the calculations 
used in the static model I were based on the human physiological conditions published 
in the literature (Armand et al., 1995; Okefee et al., 2006). The calculated volumes 
were scaled down to laboratory scale GI digestion process. In the static model II, the 
E/S ratios most commonly used by other authors for in vitro digestion were 
investigated. In both studies the digestion was carried out at physiological temperature, 
mimicking the different pH values and continuous mixing of digest. The major aim of 
these studies was to identify a suitable E/S ratio for a workable in vitro model for 
flaxseed protein digestion that simulates gastric and intestinal digestion of humans. 
 
The digestibility values obtained for casein from the in vitro simulated GI digestion 
trials (Table 4.7) were compared with the in vivo digestibility values available for casein 
based on human studies (Deglaire et al., 2009). The parameters of the model that 
contributed to casein digestibility closest to the published in vivo values were used to 
develop the simulated GI digestion model for the study on flaxseed protein digestion. 
 
4.1.5.1.1 Digestibility of casein in static models I and II 
The results of both preliminary studies revealed that under the simulated conditions 
casein digestibility at the end of gastric + intestinal phase increased significantly 
(P<0.05) compared to that of gastric phase (Table 4.7). The static model I showed the 
lowest digestibility for casein (23.43 ± 2.7 %) at the end of the gastric + intestinal 
phase. In static model II, the use of pancreatin:casein of 1/25 w/w yielded the highest 
digestibility for casein (65.46 ± 1.7 %) and it was significantly higher (P<0.05) than 
when pancreatin:casein of 1/250 w/w (37.28 ± 0.9 %) was used. Savoie et al (1988) 
reported a 97 % digestibility for casein after 24 h proteolysis in vitro. Although the 
digestibility values obtained in the present study were lower than those reported by 
Savoie et al. (1988), the present study considered an intestinal digestion period of 4 h, 
which could have contributed to the different values. 
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Table 4.7 In vitro digestibility (%) of casein using static digestion models I and II 
Digestion phase Time 
(h) 
Static model I  Static model II 
E/S 
(Units/g 
protein) 
In vitro 
digestibility 1,2 
 E/S 
(g enzyme/g 
protein) 
In vitro 
digestibility 1,2 
Initiation of 
digestion 
 
0 - No digestion   - No digestion 
Gastric phase 2 12890 13.45 ± 1.9b  1/250 11.71 ± 1.9c 
Gastric + intestinal 
phase 
6 1303 23.43 ± 2.8a  1/250 37.28 ± 0.9b 
     1/25 65.46 ± 1.7a 
1Measured as net % TCA soluble N remaining at the end of each phase 
2Values are means ± standard deviations of duplicate analyses 
abcMeans in the same column followed by the same letter are not significantly different (P<0.05) 
 3USP units/ g protein 
 
A study carried out using human volunteers has shown that digestibility of casein was 
64.5 % in human after 140 min (Baglieri et al., 1995). Considering the digestibility 
values of casein observed at the end of gastric phase as well as gastric + intestinal 
phase, the E/S in the static model II (pepsin/protein: 1/250 w/w, 10 units/mg of protein; 
pancreatin/protein: 1/25 w/w, 0.32 × USP units/mg of protein) was selected and used 
throughout the study as the E/S ratios for flaxseed protein digestion. The static model II 
will be hereafter referred to as static model throughout the results and discussion 
section. 
 
These E/S (based on weights) identified in the current study are similar to the enzymatic 
conditions proposed by Gauthier et al. (1986) for in vitro digestion of proteins. These 
authors digested casein in a static gastric phase and a dynamic intestinal phase in a 
digestion cell, where casein digestion was measured using percent TCA soluble N for 
gastric phase digestion and percent dialyzed N for intestinal phase. They reported TCA 
soluble N of 48 % for casein at the end of gastric phase digestion (30 min), and dialyzed 
N of 27 % after 4 h of pancreatin catalyzed digestion. The digestibility values for casein 
during gastric phase digestion reported by these authors were greater than that observed 
in the present study (11.71 % in the selected static model). The specific activities of 
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pepsin used by Gauthier et al. (1986) was slightly lower (3152 units/mg of protein) than 
that used in the present study (3410 units/mg of protein). The difference in the type of 
casein used may have contributed for the differences in results. The digestibility value 
of casein in the simulated intestinal phase of the present study was not comparable with 
the study of Gauthier et al. (1986) due to the differences in the digestion models. 
 
4.1.5.1.2 Amino acid composition of flaxseed protein digests 
The amino acid profile of flaxseed protein digests obtained at the end of gastric phase 
and gastric + intestinal phase using the static model is presented in Table 4.8. There was 
no pronounced difference between the amino acid profiles of the digests. Similar to the 
flaxseed protein used (Table 4.8), both digests were rich in Asp, Glu, and Arg. Tyr, a 
limiting amino acid in isolated flaxseed protein (1.49 %, Table 4.8), was not detected in 
both digests. This indicates the inability of pepsin or pancreatin to release Tyr 
containing peptides from flaxseed protein during simulated GI digestion (static model).  
 
4.1.5.1.3 Degree of hydrolysis and average peptide chain length of digested flaxseed 
protein  
Degree of hydrolysis indicates the number of peptide bonds cleaved during the course 
of GI digestion. Before being subjected to simulated GI digestion, the isolated flaxseed 
protein in solution showed a low value for DH (3.31 ± 0.0 %) and average peptide chain 
length (PCL) of 30.2 (Table 4.9).  
 
During digestion with pepsin (gastric phase) and pancreatin (intestinal phase), the DH 
significantly increased (P<0.05) up to 7.96 ± 0.2 % and 43.95 ± 0.8 %, respectively 
with further break down of protein giving PCL of 12.5 and 2.3, respectively. Pepsin 
caused ~5 % increase in DH of flaxseed protein compared to that of undigested. The 
simulated intestinal phase digestion further increased the DH (~36 %) of the gastric 
digested flaxseed protein. Results for DH and average PCL suggested that enzymes 
employed in the simulated intestinal phase contributed more to protein digestion than 
the gastric phase enzymes.  
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 Table 4.8: Amino acid composition (g/ 100 g protein) of isolated flaxseed protein, 
gastric and gastric + intestinal digest -Static model 
1Branched chain amino acids 
2Conditionally essential (Food and Nutrition Board, 2005) 
 
 
 
Amino acid  Isolated protein Gastric digest Gastric + intestinal digest 
Essential     
His 1.59  2.32 2.65 
 
Ile1 3.37  
 
4.00           4.22 
 
Leu1 4.67  
 
5.74 5.57 
 
Lys 2.12  2.42 2.76 
 
Met 1.69  1.62 1.64 
 
Phe 4.52  5.30 5.34 
Thr 2.83  3.68 3.49 
 
Trp 1.10  1.14 1.17 
 
Val1 3.75  4.45 5.39 
 
Non-essential     
Ala 3.77  4.53 4.43 
 
Arg2 9.71  11.36 11.38 
 
Asp 9.02  11.74 11.13 
 
Cys 2.04  
 
2.16 2.42 
 
Glu 19.75  
 
23.78 22.72 
 
Gly 5.19  
 
6.03 6.81 
 
Pro 2.45  2.77 2.28 
 
Ser 4.53  5.66 5.28 
 
Tyr 1.49  0.00 0.00 
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Table 4.9 Degree of hydrolysis and average peptide chain length of flaxseed 
protein and gastrointestinal digests-Static model 
 
 
 
1Values 
are means ± standard deviations of duplicate analyses 
abcMeans in the same column followed by the same letter are not significantly different (P<0.05) 
DH: Degree of hydrolysis 
PCL: Peptide chain length 
 
According to Gauthier et al. (1986), pepsin hydrolysis facilitates activity of pancreatin 
on proteins by increasing the solubility and opening the molecular structure, which 
improves accessibility of peptide bonds. The pancreatin used in the SIF, is a mixture of 
trypsin, chymotrypsin, elastase, and carboxypeptidase that catalyze collectively to 
cleave peptide bonds (Ma & Xiong, 2009) causing improved DH. As a result, the 
peptides with an average of 12 amino acid residues generated during the gastric phase 
(Table 4.9) were further broken down into small peptides (mainly dipeptides) at the end 
of intestinal phase digestion (Table 4.9). Even after 4 h of intestinal digestion, DH did 
not reach 100 %, indicating mostly dipeptides were dominant among the flaxseed 
protein digestion products, rather than amino acids in free form.  
 
4.1.5.1.4 Bioactivities of the digested flaxseed protein  
(a) Angiotensin I-converting enzyme inhibitory activity  
The activity of ACE was determined based on the ability of ACE to catalyze the release 
of hippuric acid from Hip-His-Leu. A reduced amount of hippuric acid was released and 
detected when ACE was inhibited by the test sample. Figure 4.2 indicates the 
chromatograms obtained for hippuric acid, which was eluted and detected at a retention 
time of 5 min under the HPLC conditions used. 
 
 
 
Sample DH (%)1 Average PCL 
Initiation of digestion 3.31 ± 0.0c 30.2 a 
Gastric digest 7.96 ± 0.2b 12. 6 b 
Gastric + intestinal digest 43.95 ± 0.8a 2.3 c 
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Figure 4.2 HPLC chromatogram for hippuric acid (Concentration: 1 mg/mL, 
Column: C18, 5 µ, 250 × 4.6 mm, Flow rate: 1 mL/min, Wave length: 238 nm) 
 
The ACE assay mixture without any digest gave uninhibited release of hippuric acid 
[Figure 4.3 (a) ] whereas those with gastric digest and with gastric + intestinal digest of 
flaxseed protein showed inhibited release of hippuric acid as shown in Figure 4.3 (b) 
and (c), respectively. The reduction in released hippuric acid level in the presence of 
both gastric digest as well as gastric + intestinal digest shows the ACEI activity of these 
digested protein products. The inhibition by gastric digest was found to be greater than 
that of the gastric + intestinal digest [Figure 4.3 (b) and (c)]. 
Hippuric acid 
91 
 
 
                    (a)                                     (b)             (c) 
Figure 4.3 HPLC separation of hippuric acid in the assay mix with no ACE inhibitor (a), with gastric digest (b) and with 
gastric + intestinal digest of flaxseed protein (c) obtained using the static model. HPLC conditions were as follows; Column 
C18, 5 µ, 250 × 4.6 mm, Flow rate of 1 mL/min, detection wave length of 238 nm 
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The undigested flaxseed protein (or sample taken at the initiation of digestion) did not 
possess any ACEI activity although there was limited hydrolysis (Table 4.10). 
Interestingly, both gastric and gastric + intestinal digest of flaxseed protein exhibited 
ACEI activity suggesting that the simulated GI digestion generated peptides with ACEI 
activity (Table 4.10). This means that the GI digestion released ACEI peptides, which 
were inactive within the flaxseed protein sequence.  
 
Table 4.10 Angiotensin I-converting enzyme inhibitory activity of flaxseed protein 
and gastrointestinal digests (static model) in relation to average peptide chain 
length 
1Values are means ± standard deviations of duplicate analyses 
abc Means in the same column followed by the same letter are not significantly different (P<0.05) 
2Concentration of the digest was 0.67 mg/mL in the final assay mixture 
PCL: Peptide chain length, ACEI: Angiotensin 1-converting enzyme inhibitory, N.D: Not determined.  
 
The ACEI activity of flaxseed protein digests generated during different digestion 
phases were compared. Flaxseed protein derived peptides generated from gastric phase 
digestion were long chain peptides (PCL: 12.5) and was significantly higher (P<0.05) in 
the ACEI activity (81.32 ± 1.9 %) than that of the digest of gastric + intestinal phases 
(52.01 ± 1.9 %), which consisted mainly of short peptides (PCL: 2.3). 
 
Mullally et al. (1997) showed that it was the specificity of enzymes and not the final 
DH that determines the development of ACEI peptides. Several studies have explained 
the possible reasons for high ACEI activity of peptides generated by pepsin digestion.
Sample Average 
PCL 
ACEI  activity 
(%)1,2 
IC50 
(mg solids /mL)1 
IC50  
(mg N/mL)1 
Initiation of  digestion 30.2 a 0c N.D. N.D. 
Gastric digest 12.6 b 81.32 ± 1.9a 0.25 ± 0.0 b 0.16± 0.0 b 
Gastric + intestinal 
digest 
 
2.3 c 52.01 ± 1.9b 0.69 ± 0.0 a 0.39± 0.0 a 
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The C-terminal residue of ACEI peptides plays a predominant role in competitive 
binding to the active site of ACE (Cheung et al., 1980). Peptides with hydrophobic and 
aromatic amino acids as well as the imino acid Pro at the C-terminal are among the 
most favorable for strong competitive binding to ACE (Clare & Swaisgood, 2000; 
Cushman et al., 1987; Je et al., 2004). Because pepsin cleaves at the carboxyl end of 
hydrophobic and aromatic amino acids (Phe, Tyr, Trp, and Leu), it results in peptides 
with hydrophobic and aromatic amino acids at the C-terminal (Nelson & Cox, 2000). 
Such peptides bind tightly to ACE at its active site and compete with angiotensin I for 
occupancy; therefore, ACE cannot bind to angiotensin I and convert it to angiotensin II 
(Cushman et al., 1987). 
 
The results of the present study showed that further hydrolysis by pancreatin in the 
intestinal phase reduced the ACEI activity of peptides generated by pepsin assisted 
hydrolysis (Table 4.10). Similar results were reported for the digests of isolated soy 
protein (Lo et al., 2006), sunflower protein (Megias et al., 2004) and other food proteins 
where peptides produced during pepsin digestion had a greater ACEI activity than those 
produced during pancreatin digestion (Hernandez-Ledesma et al., 2004; Yang et al., 
2004). This could be explained by the hypothesis that digestive enzymes in pancreatin 
split within the sequence of ACEI peptides that were generated by the activity of pepsin 
on flaxseed proteins. Therefore, the activity of pancreatin caused degradation of pepsin 
hydrolysis generated ACEI peptides to less inhibitory peptides rather than releasing new 
peptides with ACEI activity. Moreover, Pripp et al. (2004), based on quantitative 
structure activity relationship (QSAR) modeling, reported that the absence of positive 
charge at the C-terminal position also increased ACEI potential of milk protein derived 
peptides. Of the proteases in pancreatic secretions, chymotrypsin cleaves peptide bonds 
at the carboxyl end of aromatic and hydrophobic amino acids similar to pepsin while 
pancreatic trypsin preferentially cleaves at the carboxyl end of arginyl and lysyl 
residues (Neslon & Cox, 2000). Therefore, further cleavage of ACEI peptides in the 
gastric digest by pancreatic trypsin could have released peptides with positively charged 
residues at the C-terminal position, causing reduced ACEI activity of gastric + intestinal 
digest. Maeno et al. (1996) have reported an increase in ACE inhibition of casein 
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derived peptides after pancreatin digestion, which indicates that proteins can behave 
differently in generating ACEI peptides upon GI digestion. 
 
However, the gastric + intestinal digest of flaxseed protein still showed considerable 
ACEI activity, which was greater than 50 %. This could be attributed to combined 
action of proteases in pancreatin. Of the two digests, the ACEI activity of the gastric + 
intestinal digest is considered more important as it contained a pool of peptides 
resembling those generated during stomach and small intestinal digestion in the human 
digestive system. Peptides of the gastric + intestinal digest may be resistant to further 
hydrolysis by proteases in GI tract and are readily available via small intestine. 
 
The IC50 value, the concentration of inhibitory compounds necessary to inhibit 50 % of 
the activity of ACE, was calculated to further confirm the ACEI potential of the digests. 
The digest with the lowest IC50 possesses highest ACEI activity. The results further 
showed that the gastric digest exerted the most potent inhibition of ACE with an IC50 of 
0.25 ± 0.0 mg of solids /mL (0.16 ± 0.0 mg of N/mL) (Table 4.10). The IC50 value for 
gastric + intestinal digest (0.69 ± 0.0 mg of solids /mL; 0.39 ± 0.0 mg of N/mL) was 
significantly higher (P<0.05)  than that of the gastric digest and was higher than that of 
soy protein digests (0.28 mg/mL) reported by Lo et al. (2006). Recent simulated GI 
digestion studies have reported the IC50 for ACEI activity of GI digests of yellow pea 
protein (0.16 mg/mL; Barbana & Boye, 2010), pea protein isolate (0.07 mg/mL; 
Vermeirssen et al., 2005) and chick pea (Desi) protein (0.14 mg/mL; Barbana & Boye, 
2010). The IC50 for flaxseed protein gastric + intestinal digest (0.69 mg of solids/mL) 
was higher than these values indicating that flaxseed protein digests have low ACEI 
potency compared to these digests. However, the IC50 for flaxseed protein gastric + 
intestinal digest was within the range (0.35 to 1.73 mg/mL) reported for ACEI activity 
of GI digested whey protein (Pihlanto-Leppalla et al., 2000). Moreover, ingestion of 
Thermolysin treated bovine gelatin hydrolysate, which showed an IC50 value (0.71 
mg/mL) similar to that of flaxseed protein (0.69 mg/mL) upon simulated gastric + 
intestinal digestion (static model), showed a significant reduction in blood pressure in 
SHR (Herregodds et al., 2011). Therefore, the ACEI potency of digested flaxseed 
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protein might be sufficient to cause in vivo antihypertensive effects. However, the 
differences in assay conditions (especially E/S, enzyme activity and time of hydrolysis) 
as well as units used to express IC50 values make it difficult and complicated to 
compare the values reported in literature with those obtained in the present study.  
 
The ACEI potential of gastric + intestinal digested flaxseed protein was found to be 
lower than that of Captopril, which showed 100 % ACE inhibition (no hippuric acid 
released) at the concentration (0.67 mg/mL) used (results not shown). Many studies 
indicate that ACE inhibitors in protein digests have much higher in vivo 
antihypertensive activity than predicted from in vitro assays. This was suggested due to 
higher affinity of peptides to tissues and slower elimination than synthetic Captopril 
(Fujita & Yoshikawa, 1999; Marczak et al., 2003). Moreover, under in vivo conditions 
the mode of action of ACEI peptides could be different than that under in vitro 
conditions. Therefore, the ACEI potential of gastric + intestinal digest of flaxseed 
protein should not be under estimated by comparison with that of Captopril. 
 
The ACEI activity and release of hippuric acid in the presence of flaxseed protein 
digests in the ACE assay mix was plotted against the concentration of digests and 
presented in Figure 4.4. The ACEI activity of both digests increased with the increasing 
concentration of the digest exhibiting a dose dependent relationship.  
 
The ACEI pattern of the gastric and gastric + intestinal digests of flaxseed protein were 
estimated using Lineweaver-Birk plots (Figure 4.5). The 1/V (1/rate of hippuric acid 
released) by the action of ACE on Hip-His-Leu was plotted against the 1/S (1/Hip-His-
Leu concentration) in the presence of different levels of digests and the absence of 
digests. For both digests, the straight lines crossed at the same Y intercept in the 
presence of different levels of inhibitor, which indicated that both digests possessed a 
competitive ACE inhibition pattern (Figure 4.5). Therefore, the peptides in the gastric 
and gastric + intestinal digests could compete with substrate molecules for binding to 
the active site of ACE enzyme. 
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Figure 4.4 Release of hippuric acid and generation of angiotensin I-converting 
enzyme inhibitory activity by the (a) gastric digest and (b) gastric + intestinal 
digest in the assay mixture 
(b) 
Concentration of gastric + intestinal digest of flaxseed protein isolate (mg/mL)
0.0 0.5 1.0 1.5 2.0 2.5 3.0A
m
ou
nt
 o
f h
ip
pu
ric
 a
ci
d 
re
le
as
ed
 (m
ic
ro
gr
am
s/
m
L)
0
2
4
6
8
10
12
14
16
A
C
EI
 a
ct
iv
ity
 (%
)
0
20
40
60
80
100
Amount of hippuric acid released
ACEI activity
Concentration of gastric digest  of flaxseed protein isolate (mg/mL)
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8A
m
ou
nt
 o
f h
ip
pu
ric
 a
ci
d 
re
le
as
ed
 (m
ic
ro
gr
am
s /
m
L)
0
5
10
15
20
25
A
C
EI
 a
ct
iv
ity
 (%
)
0
20
40
60
80
100
(a) 
(b) 
 
 
97 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 The Lineweaver-Burk plots of Hip-His-Leu hydrolysis by angiotensin I-
converting enzyme in the presence of different levels of (a) gastric digest and (b) 
gastric + intestinal digest of flaxseed protein 
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Most of the food protein derived ACEI peptides are competitive whereas some peptides 
inhibit ACE activity in non-competitive or uncompetitive mode (Nakagomi et al., 
1998). 
 
 (b) Angiotensin I-converting enzyme inhibitory activity of flaxseed protein digests 
under simulated intestinal conditions (No gastric digestion involved) in the static 
model  
An in vitro digestion was carried out involving only the small intestinal phase without 
the gastric phase digestion in order to investigate whether blocking of gastric phase 
digestion would generate peptides with higher ACEI activity from flaxseed protein than 
that of gastric + intestinal phase. The resulting digest had a DH (43.71 ± 2.6 %) similar 
to that of the digest obtained upon simulated GI digestion (Table 4.11). This reveals that 
small intestinal enzymes alone can break flaxseed protein into small peptides without 
prior hydrolysis by pepsin. However, the ACEI activity of such digests (46.46 ± 1.7 %) 
was lower compared to that of flaxseed protein obtained upon simulated GI digestion. 
This further supports the hypothesis that the mixture of proteolytic enzymes in 
pancreatin is breaking the ACEI peptides in flaxseed protein within their sequence 
decreasing the ACEI activity of the released peptides. It also indicates that pepsin 
digestion prior to small intestinal phase plays a critical role in releasing peptides with 
ACEI activity from flaxseed protein. When the DH of flaxseed protein increased during 
GI digestion, the ACEI peptides seems to be further hydrolyzed decreasing the ACEI 
activity, which was indicated by the increased DH of the GI digested protein. 
 
Recent studies (Marambe et al., 2008; Udenigwe et al., 2009) have reported the ACEI 
activity of enzymatic hydrolysates from flaxseed protein using food grade proteases. In 
these two studies, flaxseed protein hydrolysates have been prepared using food grade 
proteases. To the best of my knowledge, there are no published in vitro or in vivo 
studies that report ACEI activity of GI digested flaxseed protein. 
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Table 4.11 Angiotensin I-converting enzyme inhibitory activity of flaxseed protein 
under simulated intestinal digestion without gastric phase digestion in the static 
model  
1Values are mean ± standard deviation of duplicate analyses 
2 Concentration of the digest was 0.67 mg/mL in the final assay mixture 
3Flaxseed protein was subjected to digestion with pancreatin (E/S: 1/25’ 37 °C, 4 h) without gastric phase 
digestion 
PCL: Peptide chain length, ACEI: Angiotensin 1-converting enzyme inhibitory 
 
 
Angiotensin I-converting enzyme plays a key role in regulating blood pressure. 
Therefore, inhibition of ACE is important in preventing the hypertensive condition, a 
risk factor for CVD. The results of the present study clearly indicate that flaxseed 
protein has potential as a food source of antihypertensive agents. So far, ALA and 
lignans in flaxseed were considered to be the antihypertensive components in flaxseed 
(Prasad, 2009; Singer et al., 1990). However, there has been no attempt to investigate 
whether there is any contribution from the protein fraction to the hypotensive effect of 
flaxseed. The findings of the present study suggest that the antihypertensive agent in 
flaxseed could be the digested products of proteins. In a recent review, Basch et al. 
(2007) reported that available literature on flaxseed and health includes poor quality 
studies and do not support recommendation for any health related condition or claims. 
The authors emphasized the importance of well-designed high quality clinical trials on 
flaxseed before such recommendations. The present study provides useful information 
on antihypertensive potential of flaxseed protein at in vitro level, which warrants 
appropriate in vivo studies. 
 
(c) Hydroxyl radical  scavenging activity  
The OH• scavenging activity of flaxseed protein digests were determined using an assay 
containing OH• generated by the Fenton reaction between Fe3+ and H2O2 similar to the 
physiological conditions. The OH• scavenging activity of GI digests is shown in Table 
Sample DH (%)1 Average 
PCL 
ACEI activity  
(%)1,2 
 
Intestinal digest3 43.71 ± 2.6 2.3 46.46 ± 1.7 
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4.12. Similar to ACEI activity, the undigested protein did not show any OH• scavenging 
activity. However, in contrast to the ACEI activity, OH• scavenging activity was not 
present in the digest at the end of simulated gastric digestion of flaxseed protein (Table 
4.12). The recent study by Udenigwe et al. (2009) also reported similar OH• scavenging 
activities of <1 kDa fraction of pepsin hydrolyzed flaxseed protein. In the present study, 
4 h digestion of simulated intestinal phase with pancreatin caused a rise in 
OH•scavenging activity to 45.56 ± 1.1 % with an IC50 value of 0.70 ± 0.1 mg of 
solids/mL (0.40 ± 0.0 mg of N/mL) (Table 4.12). 
 
Table 4.12 Hydroxyl radical scavenging activity of digested flaxseed protein in 
relation to degree of hydrolysis and average peptide chain length 
1Values are mean ± standard deviation of duplicate analyses 
abcMeans in the same column followed by the same letter are not significantly different (P<0.05) 
2Concentration of the digest was 0.67 mg/mL in the final assay mixture 
DH: Degree of hydrolysis, PCL: Peptide chain length, OH•: Hydroxyl radical 
N.D.: Not determined 
 
 
You et al. (2009) have reported similar increase in OH• scavenging activity when 
gastric digestion was followed by intestinal digestion. The digest generated in the 
simulated gastric + intestinal phase exhibited an increase in OH• scavenging activity 
with an increase in concentration (Figure 4.6). The results revealed that the small 
peptides (average PCL: 2.3) generated by the pancreatin digestion of flaxseed protein 
have potential to scavenge OH• whereas no OH• scavenging potency was displayed by 
the long chain peptides (PCL:12) generated by pepsin. Udenigwe et al. (2009) digested 
flaxseed protein with pancreatin and reported that <1 kDa ultrafiltered fraction of the 
Sample DH(%)1 Average 
PCL 
OH• 
scavenging 
activity (%)1,2 
IC50  
(mg of 
solids /mL)1 
IC50  
(mg of N 
/mL)1 
Initiation of 
digestion 
3.31 ± 0.0 c 30.2 0 b N.D.  N.D. 
Gastric digest 7.96 ± 0.2 b 12.6 0 b  N.D.  N.D. 
Gastric + 
intestinal digest 
43.95 ± 0.8 a 2.3 45.56 ± 1.1 a 0.70 ± 0.1 0.40 ± 0.0 
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resulting hydrolysate had a OH• scavenging activity with an IC50 of 0.06 mg protein/mL. 
However, their study was not conducted under simulated GI digestion conditions and 
therefore flaxseed protein had been hydrolyzed without a pre-digestion step with pepsin, 
making it difficult to compare the values for OH• scavenging activity with the findings 
of the present study. 
 
Figure 4.6 Hydroxyl radical scavenging activity of gastric + intestinal digest of 
flaxseed protein in relation to the concentration of digest in the assay mixture 
 
Carnosine (0.67 mg/mL), the standard antioxidant used, had a OH• scavenging activity 
of 63.50 % (results not shown) that was greater than that of the gastric + intestinal 
digest of flaxseed protein (45.56 ± 1.1%). According to Chen et al. (1996; 1998), the 
antioxidant activity of protein hydrolysates is related to the amino acid composition and 
sequence, the size and configuration of the peptides present. The presence of amino acid 
residues such as His, Lys, Tyr, Met and Pro were significantly correlated with radical 
scavenging activity of peptides (Pena Ramos et al., 2004; Saito et al., 2003; Tsuge et 
al., 1991). Tripeptides with Trp or Tyr at their C-terminus exhibited very strong radical-
scavenging activity (Saito et al., 2003). Since radical-scavenging is likely due to the 
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hydrogen donor activity of the hydroxyl groups of aromatic amino acids, the presence 
or absence of such amino acids in the peptide would affect its radical scavenging 
capacity. Based on a study on porcine myofibrillar protein, Saiga et al. (2003) reported 
that short peptides rich in acidic amino acid residues (Asp, Glu) exhibited strong 
antioxidant activity. There is also evidence showing that the antioxidant activity of 
certain amino acids is enhanced when incorporated into dipeptides (Erdmann et al., 
2008), suggesting the crucial role of the peptide bond and/or specific structural features 
of the peptides regarding antioxidant potential. Contradictory results have been reported 
by Hernandez-Ledesma et al. (2005). Based on results of a study on antioxidant 
peptides in hydrolyzed whey protein, these authors suggested that peptide bond or 
structural confirmation of peptides reduced the antioxidant activity of constituent amino 
acids. It was also noted that when in a peptide, antagonistic effect between amino acids 
would reduce their own radical scavenging activity (Hernandez-Ledesma et al., 2005). 
 
The aromatic amino acid content of the gastric and gastric + intestinal digest of flaxseed 
protein showed no pronounced differences (Table 4.8). The aromatic amino acid Tyr 
was absent in both digests but present in isolated protein. However, both gastric and 
gastric + intestinal digests of flaxseed protein were rich in Asp and Glu (Table 4.8). The 
significant improvement in OH• scavenging activity observed for the gastric + intestinal 
digest of flaxseed protein compared to the gastric digest may be attributed to the short 
PCL (dipeptides) in the gastric + intestinal digest or the difference in amino acid 
composition in the peptides caused by cleavage specificity of different digestive 
enzymes. 
 
Previous studies have reported the antioxidant potency of flaxseed non-protein 
components, in which SDG is thought to be the responsible component. Prasad (1997) 
showed that isolated SDG has OH• scavenging in vitro. However, human studies 
conducted by Hallund et al. (2006) suggested that lignan may not be the antioxidant 
component in flaxseed. In the present study we did not analyze the SDG level of 
isolated flaxseed protein. However, the absence of OH• scavenging activity in the digest 
collected at the initiation of digestion of flaxseed protein (Table 4.11) and sample 
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blanks (results not shown) suggested that there was no contribution of SDG to the 
antioxidant activity of flaxseed protein digests and the observed OH• scavenging activity 
was solely due to the products generated during GI digestion of flaxseed protein. Recent 
in vitro studies conducted by Marambe et al. (2008) as well as Udenigwe and Aluko 
(2010) using fungal proteases and Udenigwe et al. (2009) using individual proteolytic 
enzymes also confirmed the presence of antioxidant peptide sequences in flaxseed 
protein, which can be released upon hydrolysis (These results are further discussed in 
the section 4.3.2.2.1 in this thesis). 
 
The OH• are the strongest radical scavengers among ROS, which easily react with any 
biomolecule. In the myocardial cell membrane, OH• can initiate lipid peroxidation or 
oxidation of protein sulfhydryl groups. Lipid peroxidation leads to fragility of lysosome 
membrane and causes leakage of hydrolytic enzymes. This leads to cell damage and 
death leading to cardiovascular injury (Horwitz & Rosenthal, 1999). Therefore, the 
results suggest that upon human consumption flaxseed protein may act as a source of 
antioxidant peptides that will fight against OH• formation thereby preventing CVD. 
 
4.1.5.2 Digestion of flaxseed protein in the dynamic model 
The dynamic model of GI digestion contained gastric and intestinal phases in separate 
reaction chambers. The gastric phase of digestion in this model was similar to that of 
the static model. The intestinal phase differed from the static model due to continuous 
removal of digested products that simulated absorption in the small intestine.  
 
Preliminary experiments were carried out using a Float-A-Lyzer® (ready to use 
cylindrical dialysis tubing made of cellulose ester) and a dialysis bag for the 
determination of their suitability as the small intestinal compartment in the dynamic 
model and the results are as in Table 4.13. Both the Float-A Lyzer and the dialysis bag 
were tested for their ability to diffuse amino acids and LMW peptides that mimic 
products of GI digestion as described in section 3.4.4.2 (Materials and Methodology 
chapter of this thesis). Although both were made of dialysis membranes of 1 kDa 
MWCO, the Float–A-Lyzer was found to be less efficient when compared to the 
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dialysis bag with respect to diffusion of molecules within 4 h (the time used for 
intestinal phase digestion). Among the molecules tested, Phe was the only molecule that 
was able to diffuse out of the Float-A-Lyzer during the 4 h period, whereas Phe and the 
peptides (glutathione and Gly-Gly-Tyr-Arg) were able to diffuse out of the dialysis bag 
as indicated by the reduction of optical density (O.D.) of substances in the membrane 
(Table 4.13). Therefore, the dialysis bag (MWCO: 1 kDa) was used for the further 
studies on simulated GI digestion using the dynamic model. 
 
Table 4.13 Diffusibility of selected amino acids and peptides through the Float-A-
Lyzer and dialysis bag 
1Optical density was measured at 280 nm 
2Optical density was measured at 214 nm 
MW: Molecular weight 
 
Use of dialysis membrane with a MWCO less than 5 kDa would be the reasonable 
approach for mimicking in vivo absorption, considering the pore diameter and the 
permeability characteristics of the human intestine (Ekmekcioglu, 2002). In the 
development of a digestion cell for determining protein digestibility, Gauthier et al. 
(1982) chose a dialysis membrane with a MWCO of 1 kDa. The end product of protein 
digestion in the gut is a mixture of amino acids and short peptides of 2-6 amino acids 
(Peters, 1970). The dialysis membrane with 1 kDa MWCO selects nitrogenous material 
ranging from free amino acids to peptides possibly 8-10 amino acids long, which is very 
close to the end products of intestinal digestion (Gauthier et al., 1982). Therefore, in the 
present study the dialysis bag of MWCO 1 kDa was used to simulate the intestinal 
compartment and was expected to closely mimic absorption in vivo. 
Amino 
acid/peptide 
 Optical density 
 
Float-A-Lyzer 
  
Dialysis bag 
 Initial After 4 h  Initial After 4 h 
L-Phe 
(MW: 165.19)1 
 
0.192 0.071  0.278 0.05 
Gly-Gly-Tyr-Arg 
(MW: 451.5)2 
3.0 3.0  3.0 2.7 
 
Glutathione 
(MW: 307.3)2 
 
3.0 
 
3.0 
  
3.0 
 
0.128 
 
 
105 
 
Filter grown Caco-2 cells or dialysis membranes are usually used as tools in 
experimental models for studying the transport of nutrients between two compartments 
mimicking human intestine (Ekmekcioglu, 2002). In the human gut, nutrients are 
transported by a transcellular and/or paracellular route (Figure 2.1) from the intestinal 
lumen to the interstitial fluid and afterwards to the blood. The paracellular transport is 
accomplished by passive diffusion, which mainly depends on the concentration gradient 
between the intestinal lumen and the interstitium (Ekmekcioglu, 2002). Other factors 
like transepithelial potential difference, the pore radius of the tight junctions at the 
epical poles of the cells and the molecular size of the substances influence passive 
paracellular transport of nutrients (Ekmekcioglu, 2002).  
 
Over 90 % of the peptides absorbed via transcellular route are further hydrolyzed in the 
absorptive cells (Heyman & Desjeux, 1992). For example, the intestinal brush border 
membrane is rich in aminopeptidases, which cleave N- terminal amino acids of 
peptides. Aminopeptidase N and A are found in intestinal brush border and cleave N-
terminal neutral and anionic amino acids, respectively. In addition to these, the 
intestinal brush border contains endopeptidases and dipeptidases (Vermeirssen et al., 
2004). Therefore, the peptides absorbed can be further hydrolyzed by the brush border 
enzymes degrading them into a mixture of amino acids, di- and tri- peptides.The 
paracellular pathway of peptide absorption is known as a non degradative transport 
route, which keeps the transported peptide intact. Whichever the route, peptides longer 
than di- or tri- peptides even in small amounts could get into the body and demonstrate 
physiological functions (Shimizu, 2004). In the studies based on membrane dialysis, 
passive diffusion is considered as the way for nutrients to move between the luminal 
and serosal chamber (Miller et al., 1981). It is important to note that intestinal brush 
border enzymes were not used in the present study and the dynamic model represented 
the absorption of peptides only via passive diffusion.  
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4.1.5.2.1 The amino acid composition of dialysate and retentate of gastric + 
intestinal digest of flaxseed protein 
Table 4.14 shows the amino acid profile obtained for the dialysate and retentate of the 
gastric + intestinal digest obtained from the dynamic model of flaxseed protein 
digestion. The amino acid profile for the gastric digest in the dynamic model was the 
same as that of the static model and therefore is not shown in Table 4.14.  
 
A comparison was made between the amino acid profile of dialysate (absorbable 
fraction) and retentate (non-absorbable fraction) as well as between that of gastric + 
intestinal digests of flaxseed protein obtained from the static and dynamic models. The 
dialysate and retentate showed considerable differences in terms of their amino acid 
profile. The dialysate had higher levels of Met, Ser, Ala, Leu, Tyr, Phe, Lys, Arg and 
Trp compared to that of the retentate (Table 4.14). The dialysis bag, which simulated 
the intestinal lumen, was expected to contain a mixture of peptides and amino acids 
generated from flaxseed protein digestion. It was hypothesized that the dialysate had 
amino acids and peptides with a potential to absorb via passive diffusion, whereas the 
retentate consisted of peptides and amino acids that could not be absorbed via the small 
intestinal epithelium. The results showed a clear difference between the amino acid 
composition of absorbable and non-absorbable fractions during the 4 h intestinal 
digestion. Interestingly, the amino acid profile of gastric + intestinal digest obtained 
from the static model was different than that of the dynamic model. A major difference 
was the presence of the aromatic amino acid Tyr in the digests of the dynamic model, 
which was absent in the digest of the static model (Table 4.14).  
 
The dynamic model of GI digestion is one step closer to the human digestive system 
compared to that of the static model. As stated by Savoie (1994), in simulating GI 
digestion in vitro, the removal of digestion products is of prime importance since their 
accumulation is likely to affect the efficiency and rate of hydrolysis of the substrate. 
The proteolysis and absorption processes that occur in the small intestine are 
simultaneous. 
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Table 4.14 Amino acid composition (g/100 g protein) of gastric + intestinal digest 
of flaxseed protein obtained from the dynamic model in comparison with the static 
model  
 
1Branched chain amino acids; 2 Conditionally essential (Food and Nutrition Board, 2005) 
Amino acid  Static model Dynamic model 
  Dialysate Retentate 
Essential     
His 2.65 
 
1.86 1.93 
 
Ile1 4.22 
 
3.93 4.46 
 
Leu1 5.57 
 
6.20 4.34 
 
Lys 2.76 
 
3.72 2.71 
 
Met 1.64 
 
1.86 1.29 
 
Phe 5.34 
 
7.02 3.56 
 
Thr 3.49 
 
3.51 3.80 
 
Trp 1.17 2.07 0.98 
 
Val1 5.39 
 
5.17 5.29 
 
Non –essential     
Ala 4.43 
 
4.55 4.24 
 
Arg2 11.38 
 
18.8 10.57 
 
Asp 11.13 
 
8.88 13.79 
 
Cys 2.42 0.62 1.59 
 
Glu 22.72 
 
13.43 20.9 
 
Gly 6.81 
 
4.75 6.27 
Pro 2.28 
 
2.69 4.14 
 
Ser 5.28 
 
5.99 5.85 
 
Tyr 0.00 
 
4.13 2.13 
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As hydrolysis proceeds, enzymes, mainly endopeptidases, are constantly exposed to 
different substrates that vary from complex proteins to oligopeptides of smaller sizes. 
Kinetics of these enzymatic reactions are favored when the reaction products are 
removed from the medium. In the static model, the digested products were not removed 
from the reaction medium. The accumulated digested products could inhibit the action 
of enzymes thereby decreasing the degree of proteolysis in the intestinal phase 
(Gauthier et al., 1982). The dialysis allows simultaneous elimination of digested 
products and reduces the possibility of enzyme inhibition by products (Gauthier et al., 
1986). Therefore, continuous elimination of digested products by dialysis in the 
dynamic model was expected to eliminate the influence of products on the enzyme 
activity. As a consequence, a higher degree of proteolysis occurred than with the static 
model (Table 4.9 of section 4.1.3.2.2). The improved efficiency of digestive enzymes in 
the dynamic model, which led to increased proteolysis could be the major reason for the 
differences in amino acid composition compared to the static model.  
 
4.1.5.2.2 Degree of hydrolysis and average peptide chain length of digested flaxseed 
protein 
The DH of intestinal digest obtained from the dynamic model was calculated by taking 
the free amino groups in both dialysate and retentate into consideration. According to 
Savoie (1994), a higher DH was expected in the dynamic model of intestinal digestion 
than that of the static model. In the dynamic model, the DH was 46.78 ± 0.3 %, whereas 
the average PCL was 2.1. The DH obtained for the gastric + intestinal digest of flaxseed 
protein in the dynamic model was greater than that of the static model (43.95 ± 0.8%, 
Table 4.9) as expected. However, the average PCL calculated based on the DH was still 
around 2.  
 
4.1.5.2.3 Bioactivities of the digested flaxseed protein  
When flaxseed protein was digested using the dynamic model, both dialysate and 
retentate were analyzed for the bioactivities. The results shown for the bioactivities of 
dialysate and retentate are the net values obtained after deducting the values of enzyme 
and sample blanks from the sample values. The dialysate was in a large volume of 
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buffer. Therefore, the freeze dried dialysate had a significantly lower N % (0.77 ± 0.0 
%) than that of the retentate (7.96 ± 0.0 %). Due to this reason the IC50 values for 
dialysate and retentate were calculated based on the N % to provide a more accurate 
comparison.  
 
(a) Angiotensin I-converting enzyme inhibitory activity  
Both dialysate and retentate obtained from flaxseed protein digestion had ACEI activity 
(Table 4.15). Interestingly, the presence of ACEI activity in the dialysate showed that 
the ACEI peptides in gastric + intestinal digest of flaxseed protein have potential to be 
absorbed through the small intestine making them bioavailable. The ACEI peptides in 
the retentate had higher molecular mass (>1 kDa) and did not pass through the dialysis 
membrane. ACEI activity in the retentate indicated that GI digestion of flaxseed protein 
releases ACEI peptides with different molecular masses. Of those, the ACEI peptides 
having <1 kDa may have the potential to be absorbed through the small intestinal wall.  
 
The freeze dried dialysate had lower N levels (0.77 ± 0.0 %) compared to the retentate 
(7.96 ± 0.0 %) and gastric digest (10.68 ± 0.1 %). Therefore, a higher concentration of 
dialysate (6.85 mg/mL) was used in the assay mixture for screening of ACEI activity 
compared to that of the retentate and gastric digest (0.67 mg/mL) to obtain equal N 
levels. The calculated IC50 values were based on N content (mg N/mL) and not the 
weight concentration of the digests. The IC50 values also showed that the overall ACEI 
potential was numerically greater in the dialysate when compared to the retentate (Table 
4.15). However, the results were not significantly different (P<0.05). The retentate 
showed higher, but not significantly different ACEI activity than the dialysate. 
Although the ACEI activity of both dialysate and retentate were significantly lower 
(P<0.05) than the gastric digest at the used concentration, the IC50 values indicated that 
dialysate and retentate (IC50: 0.04 ± 0.0 and 0.05 ± 0.0 mg N/mL, respectively) had 
significantly higher (P<0.05) ACEI potency than that of gastric digest (IC50: 0.16 ± 0.0 
mg N/mL) (Table 4.15). This was in contrast to the static model, which showed lower 
ACEI potency of gastric + intestinal digest (IC50: 0.39 ± 0.0 mg N/mL) than the gastric 
digest (IC50: 0.16 ± 0.0 mg N/mL) (Table 4.10).  
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Table 4.15 Angiotensin I-converting enzyme inhibitory activity of digested flaxseed 
protein (dynamic model) in relation to average peptide chain length 
Sample Average PCL ACEI activity 
(%)1 
IC50  
(mg of N/mL) 1 
 
Initiation of digestion 30.2 a 0 N.D. 
 
Gastric digest 
 
12.6 b 
 
81.32 ± 1.9a 
 
0.16 ± 0.0a 
 
Gastric + Intestinal digest, retained 
fraction, >1 kDa 
 
Gastric + Intestinal digest, dialyzed 
fraction, <1 kDa2 
 
 
2.1 c 
 
59.12 ± 2.0b 
 
 
52.96 ± 1.8b 
 
0.05 ± 0.0b 
 
 
0.04 ± 0.0b 
1Values are means ± standard deviations of duplicate analyses 
abcMeans in the same column followed by the same letters are not significantly different (P<0.05) 
2Concentrations of the digests was 0.67 mg/mL in the final assay mixture except for gastric + intestinal 
digest, dialyzed fraction (6.85 mg/mL) 
PCL: Peptide chain length’ ACEI: Angiotensin 1-converting enzyme inhibitory, N.D.: Not determined 
 
The static model of digestion leads to accumulation of hydrolysis products that may 
impede the progression of hydrolysis due to enzyme inhibition by products (Stahmann 
& Woldegiorgis, 1975; Gauthier et al., 1986). Dialysis used in the dynamic model 
allowed simultaneous elimination of digested products and reduced the possibility of 
any enzyme inhibition by the generated products. Therefore, differences were expected 
in the kinetics of digestive enzymes used in the intestinal phase of the static model and 
the dynamic model. The reduced activity of proteases in pancreatin caused by 
accumulated digestion products could have caused the hydrolysis of gastric phase 
generated ACEI peptides within the ACEI sequence, reducing their ACE activity. In the 
dynamic model, continuous removal of digestion products could have enhanced the 
activity of pancreatic proteases, especially chymotrypsin, which cleaves peptide bonds 
at the carboxylic end of aromatic and hydrophobic amino acids (Nelson & Cox, 2000). 
This may have generated peptides with C-terminal aromatic and hydrophobic amino 
acids that are reported as competitive ACE inhibitors leading to improved ACEI activity 
in the gastric + intestinal digest of the dynamic model. The results of the current study 
further showed that the commonly used two stage proteolysis with no absorption for 
simulated GI digestion underestimates the ACEI activity of digested food protein.  
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The IC50 values showed that the ACEI potency of the dialysate (0.04 mg N/mL; 0.23 
mg of protein/mL; 4.77 mg of solids /mL) was within the range reported for several 
cheese varieties (0.16-27.6 mg of solids/mL; Sieber et al., 2010) and similar to that of in 
vitro GI digested proteins from amaranth seeds (IC50: 0.44 mg protein/mL; Tiengo et 
al., 2009). However, the ACEI potency of the dialysate was lower than that of isolated 
protein from soy (IC50: 0.28-0.38 mg of solids/mL; Lo et al. 2006), pea (IC50: 0.076 mg 
of solids/mL; Vermeirssen et al., 2003) and whey (IC50: 0.048 mg of solids/mL; 
Vermeirssen et al., 2003) digested by simulated GI digestion using static digestion 
models. The present study indicated that the ACEI activity of in vitro GI digests could 
differ with the type of digestion model used therefore comparison of IC50 value of 
dialysate of the dynamic model with  protein digests obtained from static digestion 
models may not be appropriate.  
 
The study of Akillioglu & Karakaya, (2009) reported poor ACEI activity of the 
dialysates of common bean (IC50: 0.83 mg protein/mL), pinto beans (IC50: 0.69 mg 
protein/mL) and green lentil (IC50: 0.89  mg protein/mL) protein obtained from a 
dynamic digestion model consisted of 6-8 kDa MWCO dialysis membrane. Considering 
the present study and these reported values, the absorbable flaxseed protein digest may 
be a better source of ACEI peptides than these legume proteins.  
 
The % ACEI activity of both dialysate and retentate was plotted against their 
concentrations as shown in Figure 4.7. Both dialysate and retentate showed a dose 
dependent relationship with ACEI activity, whereas the % ACEI activity increased with 
increased concentration. At low concentrations, the ACEI activity of both dialysate and 
retentate was similar. However, at higher concentrations, the ACEI activity of retentate 
increased at a slower rate compared to that of dialysate (Figure 4.7).  
 
To exert physiological effects in vivo after oral ingestion, it is of crucial importance that 
ACEI peptides retain their activity during GI digestion and absorption and reach the 
cardiovascular system (Vermeirssen et al., 2004). 
 
 
112 
 
Figure 4.7 Angiotensin I-converting enzyme inhibitory activity of dialysate and 
retentate of gastric + intestinal digest of flaxseed protein obtained using the 
dynamic model in relation to the digest concentration in the assay mixture 
 
Most of the studies on bioavailability of ACEI peptides (in vitro and in vivo) are carried 
out using milk protein derived peptides. The in vitro studies used Caco-2 cell 
monolayers as models for the small intestine epithelium to express many intestinal 
enzymes and transport mechanisms (Lopez Fandino et al., 2006). Of the studies 
showing in vivo bioavailability of ACEI peptides, Masuda et al. (1996) detected the 
ACEI peptide Val-Pro-Pro in the abdominal aorta of SHR after administering sour milk. 
This suggested the ability of Val-Pro-Pro to be transepithelially transported. Satake et 
al. (2002) reported that a significant amount of Val-Pro-Pro is transported via Caco-2 
cells. Since the transport via the short-peptide carrier, PepT1, led to a quick hydrolysis 
of the internalized peptide, they suggested paracellular transport through the 
intercellular junctions as the main mechanism for absorption of ACEI peptide Val-Pro-
Pro via the intestine. Several milk protein derived peptides have been tested for 
antihypertensive effect in humans. Reduction in blood pressure after consumption of 
ACEI peptide containing commercial milk products such as Calpis™ (sour milk) 
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(Mizushima et al., 2004), Ameal peptide@ (casein hydrolysate produced with 
Aspergillus oryzae containing Ile-Pro-Pro and Val-Pro-Pro) (Mizuno et al., 2005) and 
Evolus™ (milk fermented with Lactobacillus helveticus) (Seppo et al., 2003) have been 
proven using human subjects. Two other commercial products, a casein hydrolysate 
containing the peptide Phe-Phe-Val-Ala-Pro-Phe-Glu-Val-Phe-Gly-Lys (αs1-casein f23-
34) and a whey protein hydrolysate have also claimed lowering of blood pressure in 
humans (FitzGerald et al., 2004). 
 
The bioavailable potential shown by ACEI flaxseed protein digest as shown in the 
present in vitro study is a good starting point for in vivo experiments and clinical trials 
focussing on antihypertensive effect of flaxseed protein.  
 
(b) Hydroxyl radical scavenging activity  
When flaxseed protein was digested using the static model where there was no 
simulated absorption, only the gastric + intestinal digest showed OH• scavenging 
activity (45.56 ± 1.1%, Table 4.12). In contrast to the static model, OH• scavenging 
activity of the gastric + intestinal digest of flaxseed protein was absent in the dialysate 
and the retentate obtained from the dynamic model. This may be due to further 
alteration or cleavage of the OH• scavenging peptide sequence resulting from changes in 
pancreatin digestion in the dynamic model.  
 
Previous studies on hydrolysates from Allaska pollack skin gelatin (Kim et al., 2001), 
bovine serum albumin (Hatate et al., 1990) and soy protein (Chen et al., 1996) indicate 
that antioxidant peptides exhibit synergistic effect with non- peptidic antioxidants such 
as butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT) and tocopherol. 
Chen et al. (1996) demonstrated that peptides with no antioxidative activity enhance 
antioxidative activity of non-peptidic antioxidants due to synergistic effects when in a 
mixture. Therefore, another hypothesis could be the OH• scavenging activity of gastric + 
intestinal digest obtained from the static model was due to the synergistic effect 
between peptides and a non-peptide antioxidant, which was fractionated in the dynamic 
model. However, there was no OH• scavenging activity in the undigested flaxseed 
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protein (Table 4.12). Therefore, it showed that the isolated flaxseed protein used for the 
digestion studies did not contain any non-peptidic antioxidants unless formed as a result 
of flaxseed protein digestion.  
 
Hayes et al. (1977) reported that amino acids such as Cys and Met can act as 
antioxidants or prooxidants depending on the environment. Bishov and Henick (1975) 
reported the synergistic antioxidant activity between peptides and amino acids when 
present in a mixture. In the present simulated GI study (both static and dynamic 
models), the gastric + intestinal digests were expected to contain a mixture of amino 
acids and peptides. In the dynamic model, amino acids were expected to be in the 
dialysate with peptides <1 kDa. This separation may have caused the loss of any 
synergistic effect between peptides and amino acids on OH• scavenging activity. 
Therefore, it is suggested that separation of amino acids from peptides in the dynamic 
model could be the reason for the loss of OH• scavenging activity of gastric + intestinal 
digest. Another possible reason could be the differences in the enzyme kinetics between 
the static and the dynamic models. Removal of products from the hydrolytic reaction in 
the dynamic model may have allowed the cleavage of the retained larger peptides 
further into small peptides with sequences different than that obtained from the static 
model.  
 
Release of antioxidant peptides by oilseed proteins such as soy (Chen et al., 1995, 1998; 
Park et al., 2010), peanut (Chen et al., 2007) and rapeseed (Xue et al., 2009) have been 
reported. Moreover, recent studies have reported antioxidative activity of flaxseed 
protein hydrolysates (Marambe et al., 2008; Udenigwe et al., 2009; Udenigwe et al., 
2010). None of these are simulated GI digestion studies. Besides that, the proteins have 
been hydrolyzed using commercial proteases of microbial origin or by using a single 
digestive enzyme in these studies. There are in vitro studies reporting the ability of fish 
proteins to generate antioxidant peptides upon digestion with digestive enzymes found 
in the GI tract (Kim et al., 2007; Nakajima et al., 2009). These simulated in vitro GI 
digestion studies are based on the static digestion models without simulating absorption 
process. The results of the present study indicate that the peptides generated using the 
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static model will be different than when absorption is simulated, thereby influencing the 
bioactivity of the resulting hydrolysis product. Since the dynamic model closely mimics 
the human GI digestion, results obtained from the dynamic model were considered 
closer to the in vivo condition than the static model. The ability to scavenge OH• was 
shown only by the gastric + intestinal digest obtained from the static model but not from 
the dynamic model. Therefore, it could be hypothesized that bioactive peptides with 
OH• scavenging activity are not generated during GI digestion of flaxseed proteins. 
Considering the inability to scavenge OH•, the digests obtained using the dynamic 
model were not further studied for antioxidant activity. However, the findings from the 
static model exhibited that in vitro digestion of isolated flaxseed protein with two step 
hydrolysis using pepsin followed by pancreatin can generate a hydrolysate with OH• 
scavenging activity. This information will be important in developing functional food 
ingredients such as antioxidant flaxseed protein hydrolysate with peptides resistant to 
further hydrolysis by digestive enzymes. 
 
4.1.5.3 Flaxseed protein degradation pattern during simulated gastrointestinal 
digestion and its relationship with bioactivities of the digests 
The degradation pattern of polypeptides in the isolated protein during simulated GI 
digestion (static and dynamic models) was assessed using SDS-PAGE profile. Figure 
4.8 and 4.9 show the electrophoretic profile of the unhydrolyzed protein and the 
remaining residues of flaxseed protein upon simulated GI digestion using the static and 
dynamic models.  
 
A clear difference in polypeptide degradation pattern was not observed between the 
SDS- PAGE profile of the remaining residues (NR) for the static and dynamic models. 
When separated proteins were analyzed for molecular weights, five major polypeptide 
bands (~ 48, 41, 29, 20 and 13 kDa) were visible in the isolated flaxseed protein under 
NR conditions (Figures 4.8a, b and 4.9b). At the end of gastric phase digestion of both 
models, the polypeptide bands within the molecular mass range of ~ 20 to 48 kDa 
disappeared completely leaving the low molecular mass bands that also showed a 
reduction in the intensity (Figure 4.9c and Table 4.16).  
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Figure 4.8 SDS PAGE profile of the unhydrolyzed protein and remaining residue 
of flaxseed protein obtained from (a) static model and (b) dynamic model (R: 
reducing, NR: non reducing). Gels used were gradient mini gels (resolving 8-25% 
T and 2% C, stacking zone 4.5 %T and 3 %C, 43×50×0.45 mm, polyacrylamide 
gels cast on GelBond® plastic backing, buffer 0.112 M acetate, 0.112 M Tris, pH 
6.4). Each well was loaded with 5 µg protein 
 
 
At the end of subsequent intestinal phase digestion, the LMW band (~13 kDa) showed a 
further reduction of intensity, which was greater in the static model compared to that of 
the dynamic model as shown in Figure 4.9d. Due to the significantly higher DH value 
shown, a higher percentage loss of pixel intensity was expected in the remaining residue 
from gastric + intestinal digestion of the dynamic model compared to the static model. 
Moreover, there was appearance of a new band below 13 kDa at the end of gastric + 
intestinal digestion and this was mainly visible in the static model. These results 
revealed that there is a difference in protein hydrolysis when intestinal phase was 
simulated with simultaneous absorption compared with no absorption. This is due to the 
influence of absorption of digested products on the enzyme kinetics as described by 
Savoie (1994). 
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                      Static model                                             Dynamic model 
Figure 4.9 Electropherogram images (X axis: Pixel position; Y axis: Pixel intensity) 
of polypeptide bands in the unhydrolyzed protein and the remaining flaxseed 
protein residue (non-reducing) at the end of each digestion phase using the static 
and the dynamic models of digestion. (a) Molecular weight markers (kDa), (b) 
Initiation of digestion, (c) at the end of gastric phase (2 h), (d)At the end of gastric 
+ intestinal phase (6 h)  
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Table 4.16 Difference (%) in polypeptide band intensity in the remaining flaxseed 
protein residues at the end of digestion phases compared to the initiation of 
digestion 
Model Digestion phase Percentage difference in pixel intensity1 of 
polypeptide bands 
 
48 kDa 41 kDa 29 kDa 20 kDa 13 kDa 
Static Gastric (2 h) -100 -100 -100 -100 +14.8 
 Gastric + intestinal (6 h) -100 -100 -100 -100 -80.6 
Dynamic Gastric (2 h) -100 -100 -100 -100 +20.5 
 Gastric + intestinal (6 h) -100 -100 -100 -100 -41.8 
 
1Negative values indicate reduction of pixel intensity and positive values indicate gaining of pixel 
intensity of polypeptide bands compared to the intiation of digestion 
 
Accumulation of insoluble degradation products of the LMW polypeptide band during 
gastric + intestinal digestion could be suggested as the reason for the appearance of a 
new polypeptide band <13 kDa in the residue obtained at the end of gastric + intestinal 
digestion. However, the LMW band was not completely hydrolyzed at the end of 
intestinal phase digestion of both models. The degradation pattern of flaxseed protein 
(static model) at each phase of digestion is discussed in detail in section 4.2.3 of the 
results and discussion chapter of this thesis. 
 
The results showed that digestion with pepsin was able to hydrolyze all the major 
protein bands in the isolated flaxseed protein. The HMW bands were extensively 
hydrolyzed by pepsin. The LMW polypeptide bands remaining upon pepsin catalyzed 
digestion were further hydrolyzed by pancreatin. Based on the SDS- PAGE profiles of 
undigested residues of flaxseed protein, it could be hypothesized that degradation of 
polypeptides above 13 kDa may be mainly responsible in generating peptides with high 
ACEI activity. The hydrolysis of polypeptide of ~13 kDa could be responsible for 
generation of OH• scavenging peptides in the intestinal phase of the static model. 
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4.1.5.4 Peptide fractionation using size exclusion chromatography 
Size exclusion chromatography was used to estimate the molecular mass distribution 
profile and to fractionate the bioactive flaxseed protein digests into peptides based on 
their molecular masses. It is widely used as the first step to separate complex mixtures 
of peptides where the peptides are separated based on the molecular size. Figure 4.10 
indicates the size exclusion chromatograph of the standard peptides (Insulin chain A, 
angiotensin II and Hip- His- Leu) used.  
 
 
 
Figure 4.10 Elution profiles of molecular weight standards. Superdex peptide 10/30 
was used with the AKTA explorer system. The column was equilibrated and eluted 
with 20 % (v/v) acetonitrile with 0.05 % (v/v) TFA, at a flow rate of 0.5 mL/min 
 
The absorbance at 214 nm is specific for peptide bonds. Therefore, presence of peptides 
in the observed peaks (Figure 4.10) was confirmed. The aromatic amino acids, their 
derivatives, peptides as well as proteins containing aromatic amino acids absorb at 280 
nm (Amarowicz & Shahidi, 1997). Therefore, the presence of peptides with Trp, Phe or 
Tyr was confirmed when higher absorbance was seen at 280 nm. The flaxseed protein 
digests were injected to the size exclusion column (SEC) and subjected to FPLC under 
similar conditions to that used for peptides of known molecular weights. The molecular 
mass distribution profile of peptides in the digests was determined based on the 
retention times shown by these standard peptides. 
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4.1.5.4.1 Molecular mass distribution profile of the gastric digest of flaxseed 
protein 
Figure 4.11 shows the molecular mass distribution profile of flaxseed protein digested 
by pepsin in the simulated gastric phase. The gastric digest was comprised of peptides 
larger than 0.5 kDa. The presence of high molecular mass peptides (>1.05 kDa) as the 
majority in the gastric digest further confirmed the observed low DH (7.96 ± 0.2 %) and 
long average PCL (12.5) values (Table 4.17). It further indicated that pepsin digestion 
resulted in generation of long chain peptides from flaxseed protein.  
 
 
Figure 4.11 Molecular mass distribution profile of peptides in the gastric digests of 
flaxseed protein  
 
Peptide fractions of the gastric digest were collected based on the elution time of 
standard peptides, insulin chain A (2.5 kDa), angiotensin II (1.04 kDa) and Hip-His-Leu 
(0.5 kDa). The obtained fractions were pooled into three fractions; namely, GF-I 
(>2.5kDa), GF-II (1.05-2.5 kDa) and GF-III (0.5-1.05 kDa) (Figure 4.11). GF-II and 
GF-III yielded very low absorbance at 280 nm. Therefore, the peptides in these 
fractions may contain aromatic amino acids at very low levels. Absence of any peak at 
280 nm indicated the lack of aromatic amino acids in GF-I. 
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 (a) Angiotensin I-converting enzyme inhibitory activity of peptide fractions in the 
gastric digest 
As the unfractionated gastric digest did not show any OH• scavenging activity, the 
peptide fractions were not analyzed for OH• scavenging activity. Only the ACEI activity 
of these fractions was determined. The peptides in GF-I (>2.5 kDa) had no ACEI 
activity whereas both GF-II (1.05-2.5 kDa) and GF-III (0.5-1.05 kDa) exhibited ACEI 
activity (Table 4.17). Of the peptides possessing ACEI activity, those between 0.5 to 
1.05 kDa had significantly higher (P<0.05) ACEI activity than those between 1.05 to 
2.5 kDa (Table 4.17). This indicates that the ACEI activity of peptides in the gastric 
digest increases with the decrease in the size of the peptides. The results further suggest 
that the ACEI activity of the unfractionated gastric digest was due to peptides with 
molecular masses between 1.05 to 0.5 kDa. The GF-III fraction had the highest ACEI 
activity and the IC50 value was 0.07 ± 0.0 mg/mL (Table 4.17). This value was lower 
than that of unfractionated gastric digest, which was 0.25 ± 0.0 mg/mL (Table 4.10) 
indicating that separation of small and large peptides from the gastric digest resulted in 
segregation of ACEI molecules from the complex mixture. 
 
Table 4.17 Angiotensin I-converting enzyme inhibitory activity of gastric digested 
flaxseed protein fractions in relation to their molecular masses 
1Values are means ± standard deviations of duplicate analyses 
abMeans in the same column followed by the same letter are not significantly different (P<0.05) 
ACEI: Angiotensin 1-converting enzyme inhibitory, GF: Gastric digest fraction 
N.D.: Not determined 
 
In a recent study by Udenigwe et al. (2009), an IC50 value between 0.04 and 0.06 
mg/mL for LMW fraction (<1 kDa) of pepsin digested flaxseed protein was identified. 
Fraction Molecular mass of 
peptide fraction 
ACEI (%)1 IC50 
( mg of solids /mL)1 
GF-I >2.5kDa - - 
GF-II 1.05-2.5 kDa 82.92 ± 2.8b N.D. 
GF-III 0.5-1.05 kDa 99.44 ± 0.1a 0.07 ± 0.0 
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These values are lower than that found in the present study (0.07 ± 0.0 mg/mL, Table 
4.17). Udenigwe et al (2009) utilized an E/S of 1/100 and digestion time of 4 h with 
pepsin, which provided greater enzyme level and longer digestion time compared to that 
employed in the present study (E/S: 1/250 w/w, digestion time 2 h). Therefore, the size 
/length of peptides generated by the action of pepsin on flaxseed protein would be 
different in these studies causing the differences in ACEI activities. Moreover, the 
specific enzyme activity of pepsin was not specified by Udengwe et al. (2009), which 
made the comparison between the findings of their study with that of ours more 
difficult. 
 
4.1.5.4.2 Molecular mass distribution profile of the gastric + intestinal digest of 
flaxseed protein and bioactivities of the peptide fractions-Static model 
The gastric + intestinal digest of flaxseed protein contained a negligible amount of 
peptides >2.5 kDa (Figure 4.12, peptides eluting at a retention time of 22 min or less). 
The majority of the peptides in the digest had molecular masses ranging from 2.5 kDa 
to <0.5 kDa. This was also in accordance with Lo and Chan (2005), who reported that 
digestion of soy protein isolate with pepsin followed by pancreatin released peptides <3 
kDa molecular mass. Simulated GI digestion of chickpea (Kabuli and Desi) and yellow 
pea protein resulted in peptides with molecular weight <4 kDa (Barbana & Boye, 2010). 
The peptides eluting with a retention time less than 40 min was found to be < 0.5 kDa 
based on the molecular weight distribution profile of standards (Figure 4.10).  
 
The gastric + intestinal digest obtained using the static model was fractionated into two 
major fractions of >1 kDa (sGIF-I) and <1kDa (sGIF-II) molecular mass as shown in 
Figure 4.12 for assessment of bioactivities. Of these, sGIF-II was considered more 
important than sGIF-I as the smaller peptides (<1 kDa) have a greater potential to be 
absorbed through the small intestine than peptides with more than three amino acid 
residues. The majority of peptides in the digest was of <1 kDa molecular mass (Figure 
4.12). This was in contrast to the gastric digest in which the majority of peptides were 
>1 kDa molecular mass. 
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Figure 4.12 Molecular mass distribution profile of peptides in the gastric + 
intestinal digest of flaxseed protein (static model) 
The peptides of low molecular mass eluting around 60 min were present in the gastric + 
intestinal digest but were not observed in the gastric digest. The results revealed that 
pancreatic enzymes in the presence of bile salts had broken down the pepsin digested 
flaxseed protein further into much smaller peptides. The peaks observed at 280 nm in 
sGIF-II could be due to aromatic amino acid containing peptides (Figure 4.12). 
 
The peptide fractions obtained from simulated gastric + intestinal digestion of flaxseed 
proteins were considered more important than the gastric digest alone as the small 
intestinal digestion hydrolyzed the gastric digest further and generated shorter peptides 
that may be bioavailable. The peptide fractions were further evaluated for both 
bioactivities because the gastric + intestinal digest before fractionation exhibited ACEI 
and OH• scavenging activities.  
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(a) Angiotensin I-converting enzyme inhibitory activity  
According to the results of Table 4.18, the ACEI activity of peptide fractions (sGIF-I 
and sGIF-II) of the gastric + intestinal digest (static model) was found to be greater than 
that of unfractionated digest (Table 4.10). The IC50 of both fractions were smaller than 
that of the unfractionated digest indicating the greater ACEI potency of the peptide 
fractions than the unfractionated digest. Lo and Chan (2005) also reported that 
fractionation of soy protein digests resulted in a higher ACEI active peptide fraction 
than crude unfractionated digest. 
 
Table 4.18 Angiotensin I-converting enzyme inhibitory activity of peptide fractions 
in the gastric + intestinal digest obtained using the static model 
1Values are means ± standard deviations of duplicate analyses 
abMeans in the same column followed by the same letter are not significantly different (P<0.05)  
ACEI: Angiotensin 1-converting enzyme inhibitory, sGIF: Static model gastric + intestinal digest fraction 
 
The sGIF-I (<1 kDa) had significantly higher (P<0.05) ACEI activity than that of sGIF-
II (>1 kDa) at the concentration 0.67 mg/mL. However, the IC50 of sGIF-I and sGIF-II 
was not significantly different (P<0.05) (Table 4.18). This showed that both fractions 
had similar potency for ACE inhibition. Of these, sGIF-II was the most important 
fraction as it consisted of short chain peptides, which could have greater potential for 
absorption than large peptides.  
 
The <1 kDa fraction obtained from the hydrolysis of flaxseed protein with pancreatin 
(E/S: 1/100, time 4 h) and then by ultrafiltration exhibited an IC50 of 0.14 to 0.16 
mg/mL for ACE inhibition (Udenigwe et al., 2009). This value was smaller than the 
IC50 for <1 kDa fraction observed in the present study (0.55 ± 0.01 mg/mL). Pepsin 
hydrolyzed flaxseed protein digest was subjected to subsequent digestion with 
pancreatin to simulate intestinal digestion after the gastric phase, instead of subjecting 
Fraction Molecular mass of 
peptide fraction 
ACEI (%)1 IC50 
(mg of solids/mL)1 
sGIF-I 
 
sGIF-II 
>1 kDa 
 
<1 kDa 
61.0 ± 0.2a 
 
54.1 ± 1.7b 
0.50 ± 0.0a
 
0.55 ± 0.0a 
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undigested protein for pancreatin digestion as Udenigwe et al. (2009) reported. A 
comparison between the results of present study (Table 4.18) and Udenigwe et al. 
(2009) lead to the hypothesis that ACEI potential of flaxseed protein digest could be 
improved if gastric phase digestion was blocked and flaxseed protein is directed to 
digestion by the intestinal phase enzymes only. However, we observed a reduction in 
ACEI activity for the unfractionated digests when flaxseed protein was treated with 
intestinal phase enzymes without using a gastric phase break down (Table 4.11). The 
variability in the E/S, which influences the kinetics of enzyme catalyzed hydrolysis, and 
fractionation of peptides could be the factors that caused the differences in ACEI 
activities of peptides generated during flaxseed protein digestion by pepsin and 
pancreatin in these two studies. Also in contrast to the study of Udenigwe et al. (2009), 
bile acids along with pancreatin were used in the intestinal phase of the current study. 
The bile acids assist in lipid absorption and affect the digestion and assimilation of 
dietary proteins by accelerating the hydrolysis by pancreatic proteases. Bile acids could 
bind to hydrophobic pocket(s) of the protein substrates and may destabilize its structure, 
making additional interior domains of the dietary protein available for luminal 
endoprotease action (Gasset al., 2007). This further explains the differences found in 
the peptides of flaxseed protein digest obtained in our study compared to that of 
Udenigwe et al. (2009). 
 
Figure 4.13 shows the ACEI activity of the unfractionated gastric + intestinal digest 
(static model) and its peptide fractions in relation to the concentration in the assay 
mixture. At low concentrations, sGIF-I and sGIF-II had similar ACEI activity. When 
the concentration exceeded 0.3 mg/mL the ACEI activity of sGIF-I (> 1 kDa) exceeded 
that of sGIF-II (<1 kDa) and was closer to that of sGIF-II at 1.3 mg/mL. The 
unfractionated digest showed an ACEI activity lower than that of peptide fractions 
except at 0.7 mg/mL where it had an ACEI activity similar to sGIF-II (Figure 4.13). 
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Figure 4.13 Angiotensin I-converting enzyme inhibitory activity of unfractionated 
gastric + intestinal digest of flaxseed protein (static model) and its peptide fractions 
in relation to concentration in the assay mixture 
 
(b) Hydroxyl radical scavenging activity  
Table 4.19 shows the OH• scavenging activity of sGIF-I and sGIF-II. The sGIF-II (<1 
kDa), which had LMW peptides exhibited significantly higher (P<0.05) OH• 
scavenging activity (70.62 ± 0.4 %) than sGIF-I (>1kDa; 55.32 ± 0.0 %) at the 
concentration used (Table 4.19). However, there was no significant difference between 
the IC50 values of sGIF-I (0.46 ± 0.1 mg/mL) and sGIF-II (0.44 ± 0.0 mg/mL). Similar 
to ACEI activity, both fractions showed improved OH• scavenging activity than that of 
the unfractionated digest (IC50:0.70 ± 0.1 mg/mL; Table 4.12).  
 
Figure 4.14 shows the OH• scavenging activity of the unfractionated and fractionated 
gastric + intestinal digests in relation to the concentrations used in the assay mixture. 
According to Figure 4.14, the OH• scavenging activity of the fractionated gastric + 
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intestinal digests apparently deviated from that of the unfractionated digest at high 
concentrations. The differences were minimal at low concentrations. 
 
Table 4.19 Hydroxyl radical scavenging activity of peptide fractions in the gastric 
+ intestinal digest-Static model 
 
 
 
 
 
1Values are means ± standard deviations of duplicate analyses 
abMeans in the same column followed by the same letter are not significantly different (P<0.05) 
OH•: Hydroxyl radical, sGIF: Static model gastric + intestinal digest fraction 
 
 
 
 
Figure 4.14 Hydroxyl radical scavenging activity of the unfractionated gastric + 
intestinal digest of flaxseed protein and its peptide fractions in relation to the 
concentration in assay mixture 
Fraction Molecular mass of 
peptide fraction 
OH• scavenging 
activity(%)1 
IC50 
(mg /mL)1 
sGIF-I 
sGIF-II 
>1 kDa 
<1 kDa 
55.32 ± 0.0b
70.62 ± 0.4a 
0.46 ± 0.1a 
0.44 ± 0.0a 
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Recent reports also have shown that flaxseed protein hydrolysates <1 kDa have OH• 
scavenging activity (Udenigwe et al., 2009). However, in those studies flaxseed protein 
was subjected to hydrolysis by pepsin and pancreatin separately, which is different from 
the sequential digestion by pepsin and pancreatin employed in the current study. The 
lack of OH• scavenging activity of unfractionated dialysate obtained using the dynamic 
model of the current study indicated that the bioavailability of OH• scavenging peptides 
in sGIF-II is unlikely. Therefore, the OH• scavenging activity of the fractions of gastric 
+ intestinal digest obtained using the static model was not studied further. 
 
4.1.5.4.3 Molecular mass distribution profile of the gastric + intestinal digest of 
flaxseed protein and bioactivities of the peptide fractions of dialysate-Dynamic 
model 
Figure 4.15 shows the FPLC chromatograms of retentate (a) and dialysate (b) of gastric 
+ intestinal digest of flaxseed protein obtained using the dynamic model. There was a 
noticeable difference in the molecular mass distribution profile of both retentate and 
dialysate as expected. The retentate consisted of both large (>1 kDa) and small (<1kDa) 
peptides. This shows that although the MWCO of the dialysis membrane was 1 kDa 
there were notable amount of peptides from flaxseed protein digestion < 1 kDa retained 
in the dialysis bag without diffusing out during the 4 h of intestinal phase digestion.  
 
The dialysate was expected to have peptides <1 kDa. However, in addition to the <1 
kDa peptides, it also had smaller amount of peptides of >1 kDa (Figure 4.15). Although 
there is no clear explanation for this observation, the > 1 kDa fraction in the dialysate 
may be a result of aggregation of small peptides during the concentration (freeze 
drying) step. 
 
 Both dialysate and retentate had peptides containing aromatic amino acids (Figure 4.15, 
Absorbance at 280 nm). In the retentate, aromatic amino acids were found in both 
peptides greater than and less than 1 kDa of size. However, in the dialysate, aromatic 
amino acids were mainly confined to peptides of <1 kDa. 
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Figure 4.15 Molecular mass distribution profile of peptides in the (a) retentate and 
(b) dialysate of the gastric + intestinal digest of flaxseed protein obtained using 
dynamic model 
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Since the dialysate represents the bioavailable digestion products of flaxseed protein, 
only the dialysate was fractionated into peptides of different molecular masses (Figure 
4.15 b) for further detection of bioactivities. Three fractions were collected from the 
dialysate. dGIF-I had peptides >1 kDa whereas dGIF-II and dGIF-III had peptides 
<1kDa (Figure 4.15). 
 
(a) Angiotensin I-converting enzyme inhibitory activity  
The percent ACEI activity (at 6.66 mg of solids/mL) and IC50 values for ACE inhibition 
determined for the peptide fractions of dialysate of gastric + intestinal digest (dynamic 
model) are shown in Table 4.20. The high molecular mass peptide fraction in the 
dialysate (dGIF-I) showed the highest ACEI activity (94.96 ±0.9 %), whereas the 
fraction with the lowest molecular mass (dGIF-III) had the lowest ACEI activity (1.36 
±1.4 %) (Table 4.20) .However, the fraction dGIF-II which had <1 kDa peptides had 
considerably high ACEI activity (73.19 ± 0.8 %) about 20 % lower than dGIF-I and 70 
% higher than dGIF-III. The IC50 for ACEI activity was determined only for dGIF-I and 
dGIF-II and was not determined for dGIF-III due to negligible ACEI activity shown by 
that fraction. The IC50 value of dGIF-II (3.71 ± 0.0mg/mL) was significantly higher 
(P<0.05) than that of dGIF-I indicating significantly higher (P<0.05) ACEI activity than 
that of dGIF-II (Table 4.20).  
 
Table 4.20 Angiotensin I-converting enzyme inhibitory activity of peptide fractions 
in the dialysate of gastric + intestinal digest-dynamic model 
 1Values are means ± standard deviations 
abcMeans in the same column followed by the same letter are not significantly different (P<0.05)  
ACEI: Angiotensin1-converting enzyme inhibitory’ dGIF: Dynamic model gastric + intestinal digest 
fraction 
N.D.: Not determined 
 
Fraction Molecular mass of peptide 
fraction 
ACEI activity 
(%)1 
IC50 
(mg of solids/mL)1 
 
dGIF-I >1 kDa 94.96 ± 0.9a 0.61 ± 0.0 b 
dGIF-II 0.5-1 kDa 73.19 ± 0.8b 3.71 ± 0.0 a 
dGIF-III <0.5 kDa 1.36 ± 1.4c N.D. 
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Figure 4.16 presents the ACEI activity of the unfractionated dialysate and the dialysate 
fractions plotted against the concentration in assay mixture (mg of solids/mL).  
 
Figure 4.16 Angiotensin I-converting enzyme inhibitory activity of unfractionated 
dialysate obtained using the dynamic model and its peptide fractions in relation to 
concentration in assay mixture 
 
The percent ACEI activity of dGIF-I was greater than that of unfractionated dialysate 
and dGIF-II throughout the range of concentrations studied. However, dGIF-II was 
selected for further purification and for peptide sequencing as it included molecules <1 
kDa, which had absorption potential via the small intestine. 
 
4.1.5.5 Sequence of peptides in the most Angiotensin I-converting enzyme 
inhibitory fraction of digests 
The amino acid sequence of peptides in the most ACEI-FPLC fractions of flaxseed 
protein digests (GF-III and dGIF-II) obtained using the dynamic model were analyzed. 
The bioactive FPLC fractions of the gastric + intestinal digest obtained from the static 
model was not used for sequencing because of the differences in bioactivities observed 
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between the static and the dynamic model. The peptide content in the FPLC fractions 
with ACEI activity were first analyzed by ESI-MS connected to a UPLC. The most 
abundant ions in total ion current chromatograms of each FPLC fraction (results not 
shown) were selected and subjected to de novo sequencing using UPLC-MS/MS. The 
amino acid sequence and MS/MS spectra of those peptides identified with high 
certainty (> 50 %) are given in Table 4.21 and Appendix II, respectively.  
 
The amino acid sequence of four peptides in GF-III and six peptides in dGIF-II were 
identified with high certainty (>50 % probability). The PCL of the sequenced peptides 
in GF-III and dGIF-II ranged from 6-8 and 5-7, respectively. The molecular mass of 
peptides in GF-III ranged from 715 to 855.377 Da. Peptides in dGIF-II were in the 
range of 602 to 874 Da. At present there is no published study reporting the sequence of 
ACEI peptides released from GI digested flaxseed protein. A search carried out in 
databases such as Biopep (http://www.uwm.edu.pl/biochemias), EROP-Moscow 
(http://eropinbi.ras.ru), SwePep (http://www.swepep.org) and PepBank 
(http://pepbank.mgh.harvard.edu), which consist of potentially bioactive peptide 
sequences, showed that there is no previously reported ACEI peptides possessing the 
similar sequences of flaxseed protein derived ACEI peptides identified in the present 
study. However, some of the previously reported ACEI sequences were located within 
the peptides sequenced in the present study. For example, based on an in silico 
approach, Iwaniak and Dziuba (2009) reported the antihypertensive peptide sequences, 
Val-Leu-Pro and Val-Phe in soy 7S globulin. The sequence Val-Leu-Pro was also found 
in chicken connectin and β casein (Iwaniak & Dziuba, 2009). This sequence was found 
within the peptide Phe-Val-Leu-Pro-Gln-Phe present in GF-III, whereas the sequence 
Val-Phe was within the peptide Val-Phe-Leu-Pro-Gln in dGIF-II. Wu et al. (2008) 
isolated the ACEI peptide Phe-Leu, a sequence located in napin and cruciferin (two 
major canola protein components) from Alcalase hydrolyzed canola meal. This peptide 
sequence was located in the peptide Val-Phe-Leu-Pro-Gln of dGIF-II derived from 
flaxseed protein.  
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Table 4.21 Amino acid sequence of the peptides in the most angiotensin I-
converting enzyme inhibitory-FPLC fractions of flaxseed protein digests obtained 
using the dynamic model 
1Obtained using the MassLynx software 
 FPLC: Fast Protein Liquid Chromatography 
The single letter coding for amino acids are given within paranthesis 
 
 
 
 
 
Sample FPLC 
fraction 
Amino acid sequence1 Calculated 
molecular 
mass1 
Probability1 
Gastric digest GF-III Phe-Asn-Leu-Pro-Leu-Leu 
(FNLPLL) 
 
715.37 
 
100 
  Phe-Leu-Thr-Pro-Val-Phe 
(FLTPVF) 
 
722.34 100 
  Phe-Val-Leu-Pro-Gln-Phe 
(FVLPQF) 
 
749.35 98.31 
  Leu-Pro-Ala-Gly-Val-Val-Asp-
Trp (LPAGVVDW) 
855.38 
 
99.97 
 
Gastric + intestinal 
digest-dialysate 
 
dGIF-II 
 
Val-Phe-Leu-Pro-Gln 
(VFLPQ) 
 
 
602.34 
 
50.35 
  Thr-Pro-Pro-Ala-Ala-Arg 
(TPPAAR) 
 
611.34 59.05 
  Trp-Asn-Leu-Asn-Ala 
(WNLNA) 
616.30 
 
91.31 
   
Leu-Leu-Val-His-Val-Val 
(LLVHVV) 
 
 
678.44 
 
83.58 
  Asn-Leu-Asp-Thr-Asp-Leu 
(NLDTDL) 
689.32 100 
     
  Gln-Asn-Glu-Gly-Leu-Glu-Trp 
(QNEGLEW) 
 
 
874.38 50.12 
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The amino acid sequence of SSPs in flaxseed protein is not known except for conlinin 
(2S; 19.06 kDa) (Truksa et al., 2003). None of the bioactive peptide sequences 
identified in the current study was found within the primary sequence of conlinin. This 
indicated that conlinin may not be the precursor protein of these peptides.  
 
Pepsin was the digestive enzyme used in the gastric phase for digestion of flaxseed 
proteins. All the peptide sequences of GF-III was in agreement with Nelson and Cox 
(2000) who reported that protein digestion by pepsin generates peptides with aromatic 
and hydrophobic amino acids in their C-terminal position. One peptide (Phe-Asn-Leu-
Pro-Leu-Leu) had a hydrophobic amino acid in the C-terminal (Table 4.20). Three 
peptides (Phe-Leu-Thr-Pro-Val-Phe, Phe-Val-Leu-Pro-Gln-Phe, Leu-Pro-Ala-Gly-Val-
Val-Asp-Trp) sequenced in GF-III, had aromatic amino acids in the C-terminal position. 
 
The dialysate of gastric + intestinal digestion included absorbable peptides generated 
upon sequential digestion of flaxseed protein by pepsin followed by pancreatin. None of 
the peptides detected in dGIF-II were found to be derived from peptides in GF-III. Of 
the fractions of gastric digest, GF-III represented the most ACEI fraction. Therefore, the 
peptides in dGIF-II are probably derived from those in GF-I and GF-II or less abundant 
peptides in GF-III. Although not in the same order, two peptides in GF-III (Phe-Leu-
Thr-Pro-Val-Phe and Phe-Val-Leu-Pro-Gln-Phe) shared four amino acids (Val, Phe, 
Leu and Pro) in common with the peptide Val-Phe-Leu-Pro-Gln in dGIF-II. The 
presence of Trp and Leu in the C-terminus of peptides Gln-Asn-Glu-Gly-Leu-Glu-Trp-
Arg and Asn-Leu-Asp-Thr-Asp-Leu was according to the cleavage specificity of 
chymotrypsin, whereas the presence of C-terminal Arg in the peptide Thr-Pro-Pro-Ala-
Ala-Arg was in accordance to the cleavage specificity of trypsin as reported by Nelson 
and Cox (2000). The C-terminal position of the other peptides in dGIF-II had amino 
acids such as Ala (Trp-Asn-Leu-Asn-Ala), Gln (Val-Phe-Leu-Pro-Gln) and Val (Leu-
leu-Val-His-Val-Val). Unlike pepsin, pancreatin used in the present study was a mixture 
of endopeptidases (trypsin, chymotrypsin and elastase) and exopeptidases 
(carboxypeptidases A and B). Of these, elastase cleaves bonds at aliphatic amino acid 
residues, whereas carboxypeptidases A and B cleave respectively aromatic amino acids 
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and Arg or Lys from C-terminal end of peptides or protein (Klen et al., 2005). 
Therefore, peptides with diverse range of amino acids in the C-terminal position were 
expected in dGIF-II due to the simultaneous action of different proteases in pancreatin.  
 
Cheung et al. (1980) highlighted the importance of the first three amino acid residues of 
the C-terminal part of ACEI peptide sequence in binding with ACE. It was suggested 
that peptide sequences containing aromatic (Trp, Tyr and Phe) or hydrophobic amino 
acid residues or Pro at the C-terminus or amino acids with positively charged functional 
groups at N-terminus are potent inhibitors of ACE (Cheung et al., 1980). ACE has little 
affinity for substrates or competitive inhibitors with C-terminal dicarboxylic amino 
acids or with penultimate (next to last) Pro residues. An antepenultimate (third from 
last) aromatic amino acid residue enhances binding of the peptide with ACE (Cheung et 
al., 1980). The superiority of Pro as the C-terminal residue is suggested to be due to the 
rigid ring structure of this amino acid that may lock the carboxyl group into a 
conformation favorable for interaction with the positively charged residue at the active 
site of the enzyme (Cushman et al., 1987). Moreover, the presence of Pro residues in 
peptides increases their resistance to intestinal brush border enzymes and protect their 
degradation in vivo (Kim et al. 1972). All the identified peptides in GF-III and two 
peptides in dGIF-II had Pro residues within their sequences. Two of the peptides 
identified from GF-III (Phe-Asn-Leu-Pro-Leu-Leu and Phe-Val-Leu-Pro-Gln-Phe) had 
Pro in the antepenultimate position. The peptide Val-Phe-Leu-Pro-Gln identified in 
dGIF-II had Gln, which is the acid amide of dicarboxylic glutamic acid at the ultimate 
C-terminus and Pro at the penultimate position and this was in contrast with the 
structure activity data reported by Cheung et al. (1980). However, it is possible that Glu 
residues when present with an amino acid such as Gly, Val, Ala, Ile or Pro does not 
have a negative effect on the active site of ACE and can therefore be accommodated by 
the enzyme (Suetsuna & Chen, 2001). In agreement with Cheung (1980), C-terminal 
aromatic amino acids were present in three of the identified peptides in GF-III (Phe-
Leu-Thr-Pro-Val-Phe, Phe-Val-Leu-Pro-Gln-Phe and Leu-Pro-Ala-Gly-Val-Val-Asp-
Trp) and one peptide found in dGIF-II (Gln-Asn-Glu-Gly-Leu-Glu-Trp). Also one 
peptide in GF-III (Phe-Asn-Leu-Pro-Leu-Leu) and three peptides in dGIF-II (Trp-Asn-
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Leu-Asn-Ala, Leu-leu-Val-His-Val-Val and Asn-Leu-Asp-Thr-Asp-Leu) had 
hydrophobic amino acids (Ala, Val and Leu) at the C-terminus.  
 
Gomez-Ruiz et al. (2007) recently suggested that a C-terminal Leu residue may 
contribute significantly to ACEI potential. This is in agreement with the presence of C-
terminal Leu in Phe-Asn-Leu-Pro-Leu-Leu (GF-III) and Asn-Leu-Thr-Asp-Leu (dGIF-
II). The peptide Thr-Pro-Pro-Ala-Ala-Arg, present in dGIF-III had positively charged 
Arg residue at C-terminus. Presence of positively charged Lys or Arg at the C-terminus 
was previously reported in ACEI peptides such as casokinins (casein derived), 
bradykinin and in some synthetic inhibitors (Cheung et al., 1980), which does not fit 
with the ACE active site model proposed by Ondetti and Cushman (1982). However, 
structure activity data suggest that the positive charge on the guanidine or ɛ amino 
group of the C-terminal Arg and Lys side chains, respectively contributes substantially 
to ACEI potency. For example removal of Arg from C-terminus of bradykinin results in 
an essentially inactive analogue (Meisel, 1993). In such peptides the mechanism of 
ACE inhibition includes inhibitor interaction with an anionic binding site, which is 
different from the catalytic site of ACE (FitzGerald & Meisel, 2000). 
 
It is important to note that the structure activity relationship of ACEI peptides are 
predicted mostly based on studies of di- and tri-peptides and they may not always be 
extrapolated to peptides with long PCL. Wu et al. (2006) proposed models for food 
protein derived ACEI peptides of varying length based on the sequence of previously 
published ACEI peptides suggesting that in peptides with 4-10 amino acid residues the 
C-terminal tetrapeptide but not the tripeptide modulates or regulates the ACEI potency. 
The most preferred amino acids starting from C-terminus were Tyr, Cys for the first 
position, His, Trp, Met for the second position, Ile, Leu, Val, Met for the third position 
and Trp for the fourth position (Wu et al., 2006). In agreement with Wu et al. (2006) 
peptides Leu-Pro-Ala-Gly-Val-Val-Asp-Trp (GF-III) had Val, whereas peptides Trp-
Asn-Leu-Asn-Ala, Gln-Asn-Glu-Gly-Leu-Glu-Trp, and Val-Phe-Leu-Pro-Gln (dGIF-II) 
had Leu in the 3rd position from the C terminus. Wu et al. (2006) also reported that the 
fourth amino acid residue from C-terminus is more important in determining ACEI 
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potency than the second and third amino acid residues in pentapeptides and 
hexapeptides. None of the peptides detected in the flaxseed protein digests had Trp as 
the 4th residue. Based on QSAR modeling, Pripp et al. (2004) reported that when the 
PCL becomes longer the importance of C-terminal structure of peptides on ACEI 
potency is reduced and other steric effects, not related to C-terminal composition, begin 
to interfere with the ACEI potency. This may be also applicable to peptides identified in 
the present study as they contained relatively high PCL. Moreover, the confirmation of 
peptides in a specific environment is also expected to contribute to its ACEI potency 
(Vermeirssen et al., 2004). For example the trans form of C-terminal Pro showed 
significant improvement in the enzyme substrate affinity rather than its cis form. 
(Gomez-Ruiz et al., 2004). However, the structure activity relationship of ACEI 
peptides has not been completely elucidated.  
 
The most important sequenced peptides are those in dGIF-II as these represent the 
ACEI peptides that have the potential for absorption through intestinal membrane. 
Vermeirssen et al. (2004) highlighted the importance of ACEI peptides to reach the 
cardiovascular system in the active form. Therefore, investigation of bioavailability of 
ACEI peptides derived from flaxseed protein digestion is important. The peptides 
detected in dGIF-II and reported in this study were more than 2-3 amino acid residues 
long. Several studies report the absorption of small ACEI peptides through intestine. 
For example, consumption of sour milk containing the ACEI tri peptides Val-Pro-Pro 
and Ile-Pro-Pro have been shown to lower blood pressure modestly in hypertensive 
subjects (Tuomilehto et al., 2004). Another study showed the presence of Val-Pro-Pro 
in abdominal aorta of SHR suggesting that these ACEI tripeptides are absorbed in the 
intestine and resistant to intestinal peptidases (Masuda et al., 1996). The major 
mechanism for absorption of Val-Pro-Pro through intestinal epithelium was found to be 
by paracellular diffusion (Satake et al., 2002). In addition to these short chain peptides, 
research show the bioavailability of long chain ACEI peptides. For instance, the long 
chain ACEI peptides such as His-Leu-Pro-Leu-Pro generated by simulated GI digestion 
of human milk (Quiros et al., 2008) and Ala-Leu-Pro-Met-His-Ile-Arg (lactokinin) 
(Vermeirssen et al., 2002), are transported through the intestinal epithelium intact. In a 
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recent study, Platerink et al. (2006) reported the presence of ACEI peptides, Ile-Pro-
Pro-Leu and His-Leu-Pro-Leu-Pro in human plasma upon ingestion of a drink 
containing them. Previous studies conducted using Caco-2 cell monolayers showed the 
bioavailability of antihypertensive octapeptide Gly-Ala-Hyp-Gly-Leu-Hyp-Gly-Pro 
obtained from chicken collagen hydrolysate (Shimizu et al., 2010) and hexapeptide 
Lys-Val-Leu-Pro-Val-Pro (Sun et al., 2009). The potential mechanism by which these 
peptides are absorbed was found to be paracellular diffusion. Similarly, in the current 
study, peptides that passed through the dialysis bag in the intestinal phase of the 
dynamic model, may represent the molecules available via passive diffusion. Due to the 
absence of brush border peptidases in the intestinal phase of the present study, it is 
difficult to conclude whether these peptides could be absorbed intact via transcellular 
pathway. The bioavailability of the peptide Leu-Leu-Val-His-Val-Val (dGIF-II) through 
transcellular pathway is questionable as peptides containing an N-terminal Leu are 
highly susceptible to cellular peptidase hydrolysis (Satake et al., 2002). 
 
To date, no published amino acid sequences of ACEI peptides released upon GI 
digestion of flaxseed protein are available, although the possibility of releasing such 
peptides upon enzymatic hydrolysis has been reported. The information on ACEI 
peptide sequences obtained in the current study will be useful in predicting the 
precursor SSPs of flaxseed for bioavailable ACEI peptides. Of the SSPs with known 
sequences, glycinin in soy, glutelin in rice, α-zein in maize, vicilin and albumin PA2 in 
pea, napin and cruciferin in canola have been already identified as precursor proteins 
generating ACEI peptides (Guang & Phillips, 2009; Hong et al., 2008).  Such prediction 
for flaxseed protein with certainty requires sequence information on the complete 
flaxseed proteome, which is not available at present.  
 
4.1.6 Summary of the findings of study I 
The findings of the present study fill an existing gap on the information of flaxseed, 
whether the GI digestion can release bioactive peptides in relation to CVD health. The 
ability of flaxseed protein to release ACEI and OH• scavenging peptides was proved 
using a static and a dynamic model of in vitro digestion. The dynamic model was 
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considered more physiologically relevant to the in vivo conditions as it included 
simultaneous absorption in the intestinal phase.  
 
The DH and bioactivities of flaxseed protein digests obtained using the dynamic model 
and the static model of digestion are summarized in Table 4.22. The gastric + intestinal 
digest obtained using the dynamic model showed a significantly higher (P<0.05 ) DH 
than that of the static model. Moreover, differences in amino acid compositions in the 
gastric + intestinal digests obtained using the two models indicated that the enzyme 
kinetics are favored towards hydrolysis of flaxseed protein in the dynamic model than 
the static model to release aromatic amino acids. 
 
Table 4.22 The degree of hydrolysis and bioactivities of flaxseed protein digests 
1Values are means ± standard deviations of duplicate analyses 
DH: Degree of hydrolysis; ACEI: Angiotensin 1-converting enzyme inhibitory, OH•: Hydroxyl radical 
N.D.: Not determined (due to inactivity shown at 0.67 mg/mL) 
 
The bioactivities of gastric + intestinal digest of flaxseed protein varied with the type of 
digestion model used. For example, the gastric and gastric + intestinal digests of 
flaxseed proteins obtained using both models possessed ACEI activity. However, the 
ACEI activity of the gastric + intestinal digest obtained using the dynamic model was 
significantly higher than that from the static model. 
 
Sample DH (%)1 IC50: ACEI activity 
(mg of N/mL)1 
IC50: OH• scavenging 
activity (mg of N/mL)1 
 
Initiation of digestion 3.31 ± 0.03 N.D. N. D. 
 
Gastric digest 
 
7.96 ± 0.16 
 
0.16 ± 0.00 
 
N. D. 
Gastric + intestinal digest 
Static model 
 
43.95 ± 0.8 
 
 
 
 
0.40 ± 0.0 
Dynamic model 46.78 ± 0.3   
Dialysate  0.04 ± 0.0 N. D. 
Retentate  0.05 ± 0.0 N.D 
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The OH• scavenging activity was only shown by the gastric + intestinal digest obtained 
using the static model. This shows that the static model, commonly used in simulated 
GI digestion studies, may not correctly estimate the potential of food protein to generate 
bioactive peptides during GI digestion. 
 
The flaxseed protein derived ACEI peptides possessed the potential for absorption 
through the small intestine by paracellular diffusion. Peptides in the molecular mass 
range of 0.5-1 kDa contributed mostly to the ACEI activity of the absorbable GI digest 
of flaxseed protein. Of the ACEI peptides generated during GI digestion of flaxseed 
protein, Val-Phe-Leu-Pro-Gln, Thr-Pro-Pro-Ala-Ala-Arg, Trp-Asn-Leu-Asn-Ala, Leu-
Leu-Val-His-Val-Val, Asn-Leu-Asp-Thr-Asp-Leu, and Gln-Asn-Glu-Gly-Leu-Glu-Trp 
were found to be in the most ACEI bioavailable fraction of the GI digest. 
 
4.1.7 Linkage to study II 
As shown in study I, flaxseed protein has ACEI and OH• scavenging peptide sequences 
that can be released during digestion. Moreover, flaxseed protein has the potential of 
generating absorbable ACEI peptides during GI digestion. Study I was carried out using 
protein isolated from flaxseed.  
 
 Currently, the use of isolated flaxseed protein in food formulation is rare whereas 
whole flaxseed, ground flaxseed and partially defatted meal are the commonly available 
sources of flaxseed protein in food stores. Of these, whole and ground flaxseed are most 
popularly used in breads, muffins, waffles, pancakes, biscuit, crackers, bagels, tortillas, 
smoothies etc. Defatted flaxseed meal is also available in the market as a fiber rich 
source that can be used in cereals, salads, blender drinks etc. In these flaxseed protein 
sources, the protein component is associated with other seed matrix components, 
especially, mucilage and lipids. The complex seed matrix (cell walls, linked with 
sugars, carbohydrates and/or lipids) can influence the flaxseed protein digestibility, 
nature of hydrolysis products generated during GI digestion and thereby the 
bioactivities of the digested products. For example, the flaxseed protein source/s, which 
show protein digestibility similar to that of isolated flaxseed protein will indicate high 
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potency to generate ACEI peptides during GI digestion. Therefore, the findings of the 
study I cannot be used to predict the ability of the commonly available flaxseed protein 
sources to generate ACEI peptides upon GI digestion. Determination of any impact of 
seed matrix components on the digestibility of flaxseed proteins is important to identify 
the most suitable form of flaxseed to deliver protein derived ACEI peptides. 
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4.2 Study II:  Effect of seed components on the digestibility of flaxseed protein 
In this study, the effect of lipids and soluble polysaccharides (mucilage) of flaxseed on 
the digestibility of seed protein was studied using the static digestion model. The milled 
flaxseed products (whole, demucilaged , , demucilaged and defatted) used in the study 
represented mucilage, oil and protein retained in the seed matrix as they are naturally 
present. Comparison of protein digestibility in these materials to that of isolated flaxseed 
protein allowed us to understand the digestibility properties of flaxseed protein without 
interference of other seed components. Presence of mucilage and oil in the flaxseed 
protein sources could adhere to the dialysis membrane in the dynamic model interfering 
and underestimating the dialysis process. Therefore, the dynamic model was not used to 
simulate GI digestion in the present study. 
 
4.2.1 Proximate composition of the flaxseed protein sources used for the study 
The proximate composition of the different sources of laboratory prepared flaxseed 
protein used in the present study is given in Table 4.23. The proximate composition of 
milled whole flaxseed was within the range of the average composition of flaxseed 
reported by Bhatty (1997), except for the protein content. The protein component of the 
milled whole flaxseed (18.5 ± 0.3 %) was in agreement with the value (18.29 %) 
reported by the US Department of Agriculture, (2009) but lower than the average values 
(20-25 %) reported by Bhatty (1997). The composition of flaxseed varies with genetics, 
growing environment, seed processing and method of analysis (Pradhan et al., 2010), 
which could be the possible reason for the observed difference. According to Hall et al. 
(2006), the protein content of flaxseed can vary between 10 % and 30 % depending on 
the variety and provenance of the plant. Specifically, the protein content of the seeds 
decrease when the oil content increases (Carter, 1993; Cunnane et al., 1993). 
 
The milled whole flaxseed had a TDF content of 27.19 ± 0.3 % comprised mostly of 
IDF (22.32 ± 0.7 %), whereas SDF was 4.88 ± 0.4 %. According to Madhusudhan 
(2009), two thirds of the TDF in flaxseed is IDF consisting of cellulose and lignin. The 
SDF in flaxseed is mainly comprised of mucilage (Carter, 1993). 
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Table 4.23 Composition of flaxseed materials (fresh weight basis) used for the simulated gastrointestinal digestion study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1Values are means ± standard deviations 
2% N x 6.25 
SDF: Soluble dietary fibre; IDF: Insoluble dietary fibre; TDF: Total dietary fibre 
Sample Moisture 
(%)1 
Ash
 (%)1 
Lipids
(%)1 
Protein 
(%)1,2 
Dietary fiber
(%)1 
           SDF                IDF      TDF
Milled whole 
flaxseed 
5.74 ± 0.1 4.04 ± 0.0 40.62 ± 0.5 18.5 ± 0.3 4.88 ± 0.4 22.32 ± 0.7 27.19 ± 0.3
 
Milled and 
demucilaged 
flaxseed 
 
 
0.81 ± 0.1 
 
4.52 ± 0.1 
 
43.93 ± 1.2 
 
21.08 ± 0.2 
 
3.17 ± 0.2 
 
22.45 ± 1.7 
 
25.63 ± 1.9 
Milled, 
demucilaged and 
defatted flaxseed   
4.89± 0.0 8.84 ± 0.1 0.23 ± 0.0 40.81± 0.4 2.98 ± 1.1 32.50 ± 2.4 35.06 ± 1.2
 
Isolated flaxseed  
protein 
 
 
5.98 ± 0.9 
 
4.13 ± 0.3 
 
0.55 ± 0.1 
 
86.01 ± 0.2 
 
5.41 ± 0.8 
 
2.59 ± 1.4 
 
8.01 ± 0.6 
143 
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The SDF in milled whole flaxseed was in agreement with previously reported values for 
flaxseed (5-8 %) (Cui et al., 1996). 
 
In the present study, demucilaging helped to lower SDF by 35 % and TDF by 5.7 % 
compared to milled whole flaxseed. Demucilaging was done with whole flaxseed; 
therefore soluble polysaccharides in the seed coat were removed. There are no reports 
on the amount of soluble polysaccharides found in the seed cotyledons and endosperm 
of flaxseed. Therefore, it was assumed that the seed coat mucilage was mostly removed 
by the method of demucilaging (using 0.5 M NaHCO3) employed in the current study. 
According to Mazza and Biliaderis (1989), extraction using water at 25 °C and boiling 
water extracted only 3.5-5.5 % and 9 % mucilage, respectively, lower than that obtained 
in the current study (35 %). Removal of mucilage led to a higher percentage of protein 
(21.08 ± 0.2 %) and lipid (43.93 ± 1.2 %) in milled and demucilaged flaxseed compared 
to milled whole flaxseed (18.5 ± 0.3 % of protein and 40.62 ± 0.5 % lipid). Similar 
findings were reported by Alzueta et al. (2002). 
 
Screw pressing of demucilaged flaxseed followed by hexane extraction dramatically 
decreased the oil content in the resulting milled, demucilaged and defatted flaxseed to 
0.23 ± 0.0 %, and increased the protein level up to 40.81 ± 0.4 % (Table 4.23) compared 
to the oil (40.62 ± 0.5 %) and protein (18.5 ± 0.3 %) content in milled whole flaxseed. 
Oomah and Mazza (1998) also reported a 1.7 times increase in protein content of a 
laboratory defatted flaxseed meal compared to the original flaxseed and this 
corresponded to the decrease in lipid content due to defatting. The SDF % of milled, 
demucilaged and defatted flaxseed (2.98 ± 1.1 %) was lower than that of milled whole 
flaxseed (4.88 ± 0.4 %) and milled and demucilaged flaxseed (3.17 ± 0.2 %), which was 
expected due to the removal of oil.  
 
The protein isolated from the milled, demucilaged and defatted flaxseed had 86.01 ± 0.2 
% protein content and very low lipid content (0.55 ± 0.1%). Although the TDF content 
was lower in isolated flaxseed protein, it had higher SDF content compared to the other 
samples (Table 4.23). The flaxseed protein used in this study was extracted by stirring 
 
 
145 
 
the milled, demucilaged and defatted flaxseed at an alkaline pH (8.5) followed by acid 
precipitation at pH 3.8. It is reported that the hemicelluloses and polysaccharides that 
are present as complexes with protein and polyphenol are solubilized under alkaline 
conditions (Selvendran, 1984). During centrifugation of the alkaline slurry of flaxseed 
protein extraction, any viscous mucilage remaining in the milled, demucliaged and 
defatted flaxseed settles between the insoluble fibrous residue and less viscous 
supernatant and is decanted along with the supernatant protein extract. During the 
acidification step the mucilage forms complexes with protein and is precipitated (Dev & 
Quensel, 1988). Therefore, it is hypothesized that residual mucilage remaining in the 
milled, demucilaged and defatted flaxseed can become soluble at alkaline extraction and 
co-precipitate with protein during acid precipitation leading to a relatively high SDF 
level in the protein isolate. 
 
4.2.2 In vitro digestibility of flaxseed protein and the effects of seed components on 
digestibility 
The effect of mucilage and flaxseed oil on the digestibility of seed protein was 
determined by analyzing the TCA soluble N upon digestion of flaxseed protein sources 
in the presence and absence of these components. As shown in Table 4.24, all flaxseed 
protein sources had appreciable amounts of TCA soluble N before digestion. Therefore, 
the net value of TCA soluble N at the end of each digestion phase was determined by 
deducting the % TCA soluble N at zero time from that determined at the end of each 
digestion phase. The net % TCA soluble N released at the gastric phase and gastric + 
intestinal phase during the static model of digestion were compared between different 
samples to investigate the effect of flaxseed matrix components on protein digestibility.  
 
All flaxseed protein sources had limited digestibility during gastric phase (pepsin 
catalyzed) digestion. Milled whole flaxseed, which contained a high level of mucilage, 
and lipids had no or limited in vitro digestibility of protein (net % TCA soluble N was 
0.55 ±1.4%) at the end of the gastric phase (Table 4.24). It showed a significantly lower 
(P<0.05) protein digestibility at the end of the gastric phase compared to the other 
flaxseed protein sources. 
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Table 4.24 Digestibility of flaxseed protein in the presence of matrix components as 
determined using % TCA soluble N  
1Values are means ± standard deviations of duplicate analyses 
abcMeans in the same column followed by the same letter are not significantly different (P<0.05) 
2gastric phase: 2 h 
3Gastric + intestinal phase: 6 h 
For each sample a sample weight containing 1g of protein was used for the simulated GI digestion 
TCA: Trichloroacetic acid 
 
There was no significant difference (P<0.05) between milled and demucilaged flaxseed 
and milled, demucilaged and defatted flaxseed for protein digestibility during the gastric 
phase. This suggests that mucilage is the main seed matrix component that limits 
flaxseed protein digestion by pepsin. The isolated form of flaxseed protein had the 
highest digestibility during the gastric phase and this was significantly higher (P<0.05) 
than the other sources.  
 
Oomah and Mazza (1998) showed that the in vitro protein digestibility of flaxseed was 
influenced by commercial processing. The digestibility of protein in milled whole 
flaxseed (0.55 ± 1.4%) at the end of the gastric phase of the current simulated GI 
digestion study was lower than that reported by Oomah and Mazza (1998) (milled 
whole flaxseed: 36.1 %) upon digestion with pepsin alone. It is important to note that 
Flaxseed 
protein  
source 
TCA soluble N (%)1 Net TCA soluble N (%)1
Initiation 
of digestion 
Gastric  
phase2 
Gastric 
+ 
intestinal 
phase3 
Gastric 
phase2 
Gastric 
+ 
intestinal 
phase3 
Milled whole 
flaxseed 
19.62 ± 0.0 20.17 ± 1.4 32.23 ± 0.5 0.55 ± 1.4 c 12.61 ± 0.5c 
 
Milled and 
demucilaged 
flaxseed 
 
 
9.68 ± 1.2 
 
28.07 ± 1.4 
 
60.68 ± 1.6 
 
18.39 ± 1.4 b 
 
51.00 ± 1.6b 
Milled, 
demucilaged 
and defatted 
flaxseed  
 
16.06 ± 2.7 37.63 ± 2.2 82.85 ± 6.4 21.57 ± 2.2 b 66.79 ± 0.6a 
Isolated 
flaxseed 
protein 
12.16 ± 0.1 40.41 ± 0.4 80.16 ± 1.8 28.25 ± 0.4a 68.00 ± 1.8a 
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these authors used 16 h of pepsin digestion, which is longer than the physiological 
gastric phase digestion. The in vitro protein digestibility of defatted flaxseed meal 
investigated by Oomah and Mazza (1998) upon pepsin digestion was 28.9 % whereas it 
was 21.57 ± 2.2 % in the present study. Unlike the milled, demucilaged and defatted 
flaxseed used in the present study, the flaxseed meal used by Oomah and Mazza (1998) 
was not demucilaged. Moreover, the meal was exposed to various heat treatments (e.g. 
hexane extraction of residual oil followed by further heat processing at 75 °C and 105 
°C). The denaturation temperature of flaxseed protein is between 66 and 117 °C, 
depending on the cultivars and processing conditions (Oomah et al., 2006). Therefore, 
in the study conducted by Oomah and Mazza (1998), the heat treatment used may have 
caused denaturation of flaxseed protein and facilitated enzyme accessibility, improving 
digestibility. This exposure of enzyme accessible sites may have overcome any negative 
effect caused by the residual mucilage present in the flaxseed meal on the protein 
digestibility.  
 
It is also important to consider the differences in the methods used to express protein 
digestibility by different studies, which make comparisons difficult. For example, 
Oomah and Mazza (1998) determined the in vitro digestibility of flaxseed protein by 
determining the protein content in pepsin indigestible residues, whereas in the current 
study, the in vitro digestibility of flaxseed protein was calculated by expressing the 
TCA soluble N in the digest. Trichloroacetic acid, when used at the concentrations 
between 5-40 % (w/v), precipitates proteins by unfolding them and inducing a “sticky” 
state responsible for protein association (Sivaraman et al., 1997). Therefore, the use of 
TCA as a precipitating agent allows separation of oligopeptides and amino acids from 
the undigested protein that is in soluble form. This could be another reason for the 
higher digestibility values reported by Oomah and Mazza (1998) compared to those 
obtained in the current study. Trichloroacetic acid also inactivates enzymes.  
 
The digestibility of flaxseed protein (as shown by the net TCA soluble N %) with all 
seed components (milled whole flaxseed; 0.55 ± 1.4%) and in isolated form (isolated 
flaxseed protein; 28.25 ± 0.4 %) at the end of the gastric phase was much lower 
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compared to the values reported for soy flour and isolated soy protein. Clatterbuck et al. 
(1980) have reported 75.3 to 84.5 % digestibility for heat treated soy flour digested with 
pepsin in vitro. Ou et al. (2004) and Wang et al. (2008) reported 86.4 % and 63.6 % 
digestibility for isolated soy protein after 2 h digestion with pepsin, respectively. 
Although the amino acid composition in flaxseed protein is comparable to that of soy 
(Oomah, 2001), structural features of protein and the seed matrix components 
associated with protein may influence digestibility. The differences in pepsin digestion 
pattern between flaxseed protein and soy protein could be attributed to the differences 
in the availability of the scissile sites of protein substrate to pepsin (Wang et al., 2008). 
Poor solubility and presence of insoluble aggregates might result in a decrease in the 
availability of scissile peptide bonds (Wang et al., 2008), leading to poor in vitro 
digestibility. The soluble polysaccharide (mucilage) content of soybean is negligible. 
Soluble polysaccharides can increase viscosity of the digesting mixture and reduce the 
accessibility of enzyme to the substrate protein therefore reducing protein breakdown. 
Moreover, the E/S ratios (1/143 w/w in Ou et al., 2004 and 1/100 w/w in Wang et al., 
2008) used in these studies were much greater than that used in the gastric phase of the 
current study (1/250 w/w), which may have led to the low protein digestibility values 
observed in the current study.  
 
The milled whole flaxseed (containing mucilage and lipid) had the lowest digestibility 
of protein (12.61 ± 0. 5 %) at the end of the simulated intestinal phase and this was 
significantly lower (P<0.05) than the other samples (Table 4.24). In spite of the limited 
digestibility in the gastric phase, protein digestibility was improved in milled whole 
flaxseed at the end of gastric + intestinal phase (12.61 ± 0. 5 %), which may be due to 
lipid breakdown by pancreatic lipases in the presence of bile salts. This may have 
facilitated protein digestibility. Honig and Rackis (1979) reported 68.2 % digestibility 
for whole soy bean after gastric + intestinal digestion, a much higher value than the 
digestibility of milled whole flaxseed (12.61 ± 0.5 %) found in the current study. 
However, Honig and Rackis (1979) used digestion of soybeans for 18 h with pepsin and 
1 h with pancreatin, which is not relevant to the physiological condition.  
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At the end of the gastric + intestinal phase, the protein in milled, demucilaged and 
defatted flaxseed showed significantly higher (P<0.05) digestibility (66.79 ± 0.6 %) 
than milled whole flaxseed (12.61 ± 0.5 %). Previously, pepsin-pancreatin digestion of 
defatted flaxseed meal had shown 61 % in vitro digestibility (Madhusudhan & Singh, 
1985). In contrast to the simulated gastric phase, the protein digestibility of milled, 
demucilaged and defatted flaxseed was significantly higher (P<0.05) than that of milled 
and demucilaged flaxseed (51.00 ± 1. 6 %) at the end of the gastric + intestinal phase. 
This showed that digestion of flaxseed protein by pancreatin was significantly improved 
when both mucilage and oil were removed than with removal of mucilage alone. In a 
study using soy, Honig and Rackis (1979) also showed an increased protein digestibility 
in dehulled defatted soy flour (81 %) compared to whole soybean (68. 2 %). Of the 
flaxseed protein sources used, the highest in vitro GI digestibility was shown by isolated 
flaxseed protein (68.00 ± 1.8 %). Wang et al. (2008) determined the in vitro protein 
digestibility of flaxseed protein extract obtained from extruded flaxseed (extrusion 
temperature: 84-180 °C), which was in the range of 69-77 %. The high protein 
digestibility reported by Wang et al. (2008) could be possibly due to denaturation of 
protein during extrusion (El-Hady & Habiba, 2003).  
 
There was no significant difference (P<0.05) between the protein digestibility of milled, 
demucilaged and defatted flaxseed and isolated flaxseed protein at the end of the 
intestinal phase (Table 4.24). The residual oil content in these two products was not 
different. Isolated flaxseed protein had slightly higher SDF content than milled, 
demucilaged and defatted flaxseed (Table 4.23). The remaining SDF in the isolated 
flaxseed protein had negligible or minimal effect on its protein digestibility (Table 
4.24). The in vitro GI digestibility exhibited by isolated flaxseed protein (68.00 ± 1.8 
%) was lower than for isolated soy protein (88.5 to 89. 8 % by Clatterbuck et al., 1980 
and 71.04 % by Wang et al., 2008). In the isolated form, the digestibility of flaxseed 
protein increased ~ 40 % at the end of the gastric + intestinal digestion compared to the 
gastric digestion. According to Wang et al. (2008), for soy protein, only ~7 % increase 
in digestion was found. Presence of trypsin inhibitors in soy protein (28-32 mg/g in soy 
flour and 1.2-30 mg/g in soy protein isolate; Anderson & Wolf, 1995) could be greatly 
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responsible for this difference. Content of trypsin inhibitors in flaxseed is very low 
compared to legumes (Wanasundara et al., 1999).  
 
In the current study (Study II), the digestibility of flaxseed protein was determined 
using the static model of digestion instead of the dynamic model. The static model and 
the dynamic model of GI digestion did not show notable difference in the amount of 
polypeptide degradation in isolated flaxseed protein in spite of the differences in 
bioactivities of the released peptides (Section 4.1.5.3). The findings of this study 
indicate that presence of both mucilage and oil in flaxseed causes low GI digestibility of 
flaxseed protein. To the best of my knowledge, there is no published in vitro study 
reporting the digestibility of flaxseed protein under simulated GI digestion conditions. 
The in vitro protein digestibility in extruded flaxseed reported by Wang et al. (2008) 
was upon digesting flaxseed protein extract using the multienzyme technique proposed 
by Hsu et al. (1977), which involved a multienzyme solution containing trypsin, 
chymotrypsin and peptidase. Although these enzymes represent those in the intestinal 
phase, the gastric phase digestion of protein by pepsin was omitted in their method, 
deviating from the actual physiological process of digestion.  
 
Several reports indicate a reduction in protein digestibility due to the presence of lipid 
and fiber along with protein as shown in the present study. In a review, Wickham et al. 
(2009) highlighted the importance of incorporating surface active lipids originating 
from ingested food or from gut secretions in the determination of protein digestibility. 
These surface active lipids form complex lipid structures such as emulsions or 
liposomes in the gastric environment and liposomes and micellar phases in the duodenal 
environment, which influences protein digestibility (Wickham et al., 2009). Proteins 
can be absorbed in the model stomach emulsion interface and can be desorbed under the 
duodenal conditions. Therefore, adsorption to emulsion interface makes proteins more 
resistant to pepsin digestion (Dufour et al., 1998). Moreover, fluorescence and FTIR 
spectroscopy analysis has shown that proteins adsorbed to oil/water interfaces can be 
partly denatured. Therefore, at least part of the protein can be considered removed from 
the aqueous environment and therefore unavailable for digestion (Husband et al., 2001). 
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The absorption of proteins into the emulsion created by oil of milled whole flaxseed 
could be responsible for the resistance shown by protein in milled whole flaxseed for 
gastric phase digestibility (Table 4.24). The lack of emulsion formation could be the 
reason for higher gastric phase protein digestibility in protein isolate compared to other 
protein sources. Similarly, the defatting of demucilaged flaxseed also resulted in an 
improvement in protein digestibility although it was not significantly different (P<0.05) 
than that of milled and demucilaged flaxseed.  
 
In addition to oil, consumption of food with high fibre content, mainly in soluble form 
decrease the digestibility and availability of food nutrients including proteins. The 
susceptibility of β lactoglobulin to proteolysis by trypsin and chymotrypsin was 
retarded by soluble polysaccharides such as pectin, gum arabic and xylan (Mouecoucou 
et al., 2004a). A significant reduction in the in vitro GI digestibility of peanut protein 
isolate was also reported in the presence of gum arabic and xylan (Mouecoucou et al., 
2004b). The authors hypothesized that this effect was due to existence of nonspecific 
interactions between molecular species in protein-polysaccharide mixtures. Some fibre 
types are reported to reduce the activity of enzymes involved in protein digestion while 
others have no effect. For example, Schneeman (1978) showed a decrease in 
chymotrypsin activity with the incorporation of xylan, whereas pectin improved the 
activity of trypsin and chymotrypsin. Schneeman (1978) reported that some enzymes in 
the in vitro system may be absorbed into the fibre matrix and thereby lose activity due 
to reduced availability. Under in vivo conditions, increased viscosity of digesta in the 
small intestine caused by soluble fibres will reduce the gut transit time due to 
suppressed intestinal contractions, which lead to less mixing of dietary components with 
digestive enzymes (Degen et al., 2007). In a study carried out using broiler chicks, 
Rebole et al. (2002) identified that when mucilaginous material extracted from flaxseed 
was added to maize /soybean meal based diets, the mucilage had a negative effect on 
lipid digestibility and had no effect on protein digestibility. In contrast, Alzueta et al. 
(2001) found a decrease in amino acid digestibility of broiler chicks fed with flaxseed. 
The increase in viscosity of digesta due to the presence of mucilage in flaxseeds has 
been highlighted as the reason for reduced amino acid digestibility. The conditions used 
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in the present in vitro study closely resemble the human digestive system and therefore 
a similar effect of flaxseed mucilage could be expected when consumed by humans. 
 
The digestibility of flaxseed protein was compared with that of casein under the static 
model of digestion. Protein in milled whole flaxseed and milled and demucilaged 
flaxseed had lower digestibility than casein (65.46 ± 1.7 %; Section 4.1.5.1). Under the 
simulated GI digestion conditions used, the digestibility of milled, demucilaged and 
defatted flaxseed as well as isolated flaxseed protein were similar to that of casein. 
Casein, due to its low disulfide bond content and high Pro content, has the configuration 
of a non-rigid protein molecule. Action of pepsin can destabilize the micellar structure 
of casein and open more sites for enzymatic action. Plant proteins such as soybean has 
lower digestibility than casein due to the more complex and chemically stable structure 
of soy protein (Baglieri et al., 1995). Two major storage proteins have been identified in 
flaxseeds; a predominant salt soluble fraction with high MW (11-12S), and a water 
soluble basic component with low MW (1.6-2S) (Chung et al., 2005; Madhusudhan & 
Singh, 1983, 1985). Similarities between the properties of the major storage protein of 
flaxseeds and those of other important oilseeds have been suggested (Oomah & Mazza, 
1993). However, Chung et al. (2005) reported that flaxseed protein has low sulfhydryl 
(S-H) content and high disulfide (S-S) content. The values for S-S and S-H content of 
11-12S flaxseed protein are lower than that of soy 11S protein. There is a possibility 
that digestibility of flaxseed protein can be greater than that of soy protein. However, 
most of the properties of flaxseed protein are still awaiting investigation. Therefore, the 
exact reason why flaxseed protein show similar digestibility to casein is under 
explained. 
 
4.2.3 Degradation of flaxseed proteins during gastrointestinal digestion: Effect of 
matrix components 
Figure 4.17 shows the polypeptide bands remained in the undigested residue following 
digestion of flaxseed protein sources at the gastric phase and the gastric + intestinal 
phase compared to the samples taken at the initiation of digestion (zero time).  
 
 
153 
 
 
Figure 4.17 Degradation pattern of flaxseed protein in the presence and absence of matrix components (0=undigested protein; 
G= gastric digested; G+I= gastric + intestinal digested; NR=non reducing; R=reducing; MWM: Molecular weight markers). 
Gels used were gradient mini gels (resolving 8-25% T and 2% C, stacking zone 4.5 %T and 3 %C, 43×50×0.45 mm, 
polyacrylamide gels cast on GelBond® plastic backing, buffer 0.112 M acetate, 0.112 M Tris, pH 6.4). Each well was loaded 
with 5 µg protein 
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Figure 4.17 further shows the degradation pattern of flaxseed protein from different 
sources during GI digestion in vitro. A clear difference was observed in the protein 
digestion pattern between different samples. Under the NR condition, five major 
polypeptide bands (~48, 41, 29, 20 and 13 kDa) were visible in all forms of undigested 
flaxseed protein along with a few minor bands. The band intensities varied depending 
on the type of protein source used. The polypeptide bands of 48 kDa and 41 kDa were 
the most intensely stained. Similar results were reported by Chung et al. (2005) for the 
major fraction of flaxseed protein.  
                                                                                                                                                                     
Under reducing conditions, the 48 kDa and 41 kDa disappeared and several intense 
bands having molecular weight of 34-26 kDa, 26-17 kDa and ~ 10 kDa were observed 
in the undigested samples (Figure 4.17) indicating the presence of S-S bonded 41 and 
48 kDa peptide oligomers. Most of the 12S protein that have S-S bonded subunits are 
reported to dissociate into constituting acidic and basic polypeptides with molecular 
weights in the range of 30-39 kDa and 20-27 kDa, respectively (Marcone et al., 1998). 
There were no bands appearing below ~13 kDa under reducing conditions, which 
indicated that the ~13 kDa polypeptide was free from S-S bonds. The presence of S-S 
bonded oligomers in flaxseed protein was previously reported (Chung et al., 2005; 
Sammour, 1988). The major fraction of flaxseed protein was reported to contain 61.4 
μmols of S-S bonds per gram of protein (Chung, 2001). According to Sammour (1988) 
the flaxseed protein extracted with Tris/HCl buffer exhibited five S-S bonded bands 
(56, 52, 51, 49 and 48 kDa) under NR conditions, which on reduction gave acidic sub 
units (~35 kDa) and basic subunits (21-15 kDa). 
Krause et al. (2002) showed that the four major bands (55, 50, 46 and 36 kDa) detected 
in flaxseed protein extracted with NaCl corresponded to 11S globulin and the faintly 
stained polypeptide bands (54, 36 and 21 kDa from 7S globulins and 7-10 kDa) were 
free from interchain S-S bonds. Sammour (1999) extracted protein from flaxseed flour 
with water, buffer, urea and SDS and observed that all the extracts contained six major 
bands with MWs of 55 kDa, 50 kDa, 47 kDa, 45 kDa, 43 kDa and 41 kDa under NR 
conditions. The intensely stained protein bands in milled whole flaxseed observed in 
our study were within this MW range. Chung et al. (2005) identified that the major 
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fraction of flaxseed protein had two prominent polypeptide bands (40 and 48 kDa), 
which resulted in three predominant bands (20, 23 and 31 kDa) under reducing 
conditions. Oomah and Mazza (1998) subjected flaxseed protein extracted with NaCl to 
SDS-PAGE under reducing conditions and observed four polypeptide bands with 
approximate molecular weight of 14, 24, 25 and 34 kDa. The observed differences in 
molecular mass of polypeptide bands resulted in the present study compared to other 
studies could be due to the differences in protein extraction medium and the cultivar 
used. A previous study has shown that the molecular weight of polypeptide bands 
observed in SDS-PAGE can vary with the type of reagent used for protein extraction 
(Marfo & Oke, 1989). 
 
The degradation pattern of flaxseed protein bands during each phase of digestion was 
determined when unhydrolyzed protein and the remaining residues upon GI digestion 
were separated in SDS-PAGE (Figure 4.18; Table 4.25). Initially, seven protein bands 
were detected in the milled whole flaxseed (Figures 4.17 and 4.18 (I) b). Following the 
simulated gastric + intestinal digestion of milled whole flaxseed, all these bands lost 
their intensity compared to the sample at the initiation of digestion (Figures 4.17 and 
4.18 (I) d; Table 4.25). Gastric digestion contributed to higher level of degradation of 
protein bands in milled whole flaxseed flour compared to the intestinal digestion. The 
protein bands of ~29 kDa and ~18 kDa which appeared as minor bands were the ones 
that were completely digested during simulated GI digestion (Table 4.25). However, no 
complete disappearance of any of the major polypeptide bands was observed. Of these, 
the bands at ~20 and ~13 kDa were found to be the most resistant to digestion with only 
20 % loss in intensity (Table 4.25).  
 
A notable decrease in the intensity of protein bands was detected in milled whole 
flaxseed at the end of digestion phases (Figure 4.18(I); Table 4.25), which was in 
contrast to the digestibility values determined as % TCA soluble N (Table 4.24). 
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Figure 4.18 Electropherogram images (X axis: Pixel position; Y axis: Pixel intensity) of polypeptide bands in the undigested 
protein residue of flaxseed protein sources (non-reducing) at the end of each digestion phase. (a) Molecular weight markers 
(kDa), (b) Initiation of digestion, (c) at the end of gastric phase (2 h), (d) at the end of gastric + intestinal phase (6 h). Peaks 
designated with arrows were followed for intensity analysis
(I) Milled whole flaxseed (II) Milled and demucilaged 
flaxseed  
(III)   Milled, demucilaged  
and defatted  flaxseed 
(IV) Flaxseed protein  
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Table 4.25 Difference (%) in polypeptide band intensity in flaxseed protein residues at the end of digestion phases 
Source Digestion phase Percentage difference of pixel intensity1 of polypeptide bands 
48 kDa 41 kDa 29 kDa 23 kDa 20 kDa 18 kDa 16 kDa 13 kDa 
Milled whole 
flaxseed 
Gastric (2 h) -71 -67 -63 -100 -18 -42 N.D. -34 
Gastric + intestinal (6 h) 
 
-86 -70 -72 -100 -20 -100 N.D. -19 
Milled and 
demucilaged flaxseed 
Gastric (2 h) -89 -79 -54 N.D. -100 -35 N.D. +58 
Gastric + intestinal (6 h) 
 
-100 -100 -100 N.D. -100 -100 N.D. -12 
Milled, demucilaged 
and defatted flaxseed 
Gastric (2 h) -100 -100 -100 N.D. -100 -100 -100 +3 
Gastric + intestinal (6 h) 
 
-100 -100 -100 N.D. -100 -100 -100 -51 
  Isolated flaxseed 
protein 
Gastric (2 h) -100 -100 -100 N.D. -100 N.D. N.D. +15 
Gastric + intestinal (6 h) -100 -100 -100 N.D. -100 N.D. N.D. -81 
1Negative and positive values indicate reduction and gain, respectively of pixel intensity of polypeptide bands compared to the initiation of digestion (e.g. -100 
indicates a complete loss of a polypeptide band) 
N.D.: Not detected 
Band molecular masses refer to those in Figure 4.18
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After each phase of digestion, the pH of the digest was reduced to 3.8 (pH at which 
flaxseed protein is minimally solubilized) prior to the recovery of the undigested residue 
used for SDS-PAGE. Our previous studies indicated that at least 10 % of flaxseed 
proteins are soluble at this pH (Section 4.1.2). Therefore, even though there was limited 
protein digestibility in milled whole flaxseed during the gastric phase, the solubility of 
proteins at pH 3.8 could be the reason for the significant reduction of intensity of 
polypeptide bands.  
 
The protein degradation pattern of milled and demucilaged flaxseed showed a notable 
difference with greater polypeptide band degradation when compared to that of milled 
whole flaxseed (Figures 4.17 and 4.18; Table 4.25). In contrast to the seven protein 
bands detected in the milled whole flaxseed, only six bands were detected in the milled 
and demucilaged flaxseed at the initiation of digestion (Figure 4.18(II) b). The minor 
protein band, which was around 23 kDa, was not visible in the electophoregram of the 
milled and demucilaged flaxseed (Figure 4.18(II) b). However, similar to milled whole 
flaxseed, five major polypeptide bands were detected in the milled and demucilaged 
flaxseed. At the end of the gastric phase digestion, there was an increase in the intensity 
of the protein band at ~13 kDa (Table 4.25). This could be a result of generation of new 
oligopeptides around 13 kDa, which are insoluble at pH 3.8, during gastric digestion. 
After the simulated intestinal digestion phase, the majority of the polypeptides in the 
milled and demucilaged flaxseed were completely hydrolyzed except for the 
polypeptide ~13 kDa, which resisted digestion showing only 12 % reduction of the 
pixel intensity (Figure 4.18(II) d; Table 4.25). 
 
In milled, demucilaged and defatted flaxseed, seven polypeptide bands were detected at 
the initiation of digestion (Figure 4.18(III) b). Instead of the polypeptide band around 
23 kDa, which was observed in the milled whole flaxseed, there was the appearance of 
a new minor band of ~16 kDa (Figure 4.18(III) b). It was not certain whether these 
minor bands are true new proteins or indicate contamination. The loss of intensity of 
polypeptides bands at the end of gastric phase and small intestinal phase was greater in 
milled, demucilaged and defatted flaxseed than that of oil containing but mucilage free 
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protein source (milled and demucilaged flaxseed). A complete loss of intensity of the 
polypeptide bands including the intensely stained bands of 48 and 41 kDa at the end of 
gastric phase was observed for the oil and mucilage free flaxseed protein source. 
Similar to milled and demucilaged flaxseed, the existence of a LMW polypeptide band 
(~13 kDa) was visible at the end of gastric + intestinal phase (NR). The intensity of this 
band was 2 % greater at the end of gastric phase digestion than that detected at the 
initiation of digestion indicating the generation of a digestion resistant oligopeptide of 
~13 kDa during gastric digestion. This band still existed at the end of gastric + intestinal 
digestion, at 51 % lower intensity than that of initiation of digestion showing its 
digestion resistance (Figure 4.14(III) d; Table 4.25). 
 
The isolated flaxseed protein showed five polypeptide bands (Figures 4.17d and 
4.18(IV) b). The minor bands of ~23 kDa, 18 kDa and 16 kDa that were present in other 
flaxseed protein sources were not detected with appropriate intensity in the isolated 
protein. Certain minor protein bands may have been solubilized at pH 3.8 and removed 
following centrifugation, which was used for the initial isolation of flaxseed protein and 
this could be the reason for not detecting them. Similar to milled, demucilaged and 
defatted flaxseed (free of oil and mucilage), in the isolated protein (free of cell wall 
components, oil and mucilage), the majority of the protein bands including ~48 and 41 
kDa were completely absent at the end of both digestion phases indicating high 
susceptibility of these bands for digestion by pepsin and pancreatin. Also, the residue of 
gastric digestion of isolated protein showed increased pixel intensity of the ~13 kDa 
band (Figure 4.18(IV) c; Table 4.25), probably due to the generation of new 
undigestible oligopeptides during gastric phase digestion.  
 
The residue of gastric + intestinal digestion of isolated protein also had the ~13 kDa 
band that was stained with lower intensity (81 % compared to initiation of digestion) 
than that of milled, demucilaged and defatted flaxseed (51 %; Table 4.25). Moreover, at 
the end of gastric + intestinal phase a new band appeared below 13 kDa, which can be 
considered as a degraded product of the ~13 kDa band. (Figure 4.18(IV) d). 
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The polypeptide degradation pattern of milled and demucilaged flaxseed, milled, 
demucilaged and defatted flaxseed and isolated protein were in agreement with the 
digestibility values obtained for these samples at different digestion phases (Table 
4.25). The results showed that the hydrolysis of all the polypeptides in flaxseed protein 
was limited in the presence of mucilage and oil. They were susceptible to hydrolysis by 
the digestive enzymes when oil and/or mucilage were removed. All the forms of 
flaxseed protein used for the digestion study had a low molecular weight band (~13 
kDa) that resisted digestion by both pepsin and pancreatin. 
 
4.2.4 Summary of the findings of study II 
The in vitro GI digestibility of protein in different flaxseed protein sources when 
arranged according to the descending order was as follows; isolated flaxseed protein 
and milled, demucilaged and defatted flaxseed > milled and demucilaged flaxseed > 
milled whole flaxseed. Presence of both mucilage and oil limits protein digestibility of 
flaxseed protein. According to the results, the most suitable form of flaxseed that can be 
consumed to obtain the benefit of flaxseed protein derived bioactive peptides will be the 
isolated protein or the milled, demucilaged and defatted flaxseed. 
 
At present no in vitro simulated GI digestion studies have been published on the effect 
of flaxseed mucilage and oil on flaxseed protein digestibility. Knowledge of the 
influence of these matrix components provides information on the most suitable form of 
flaxseed consumption. The physical form in which foods are consumed is an important 
factor to be considered in determining the bioavailability of nutrients (Bjorck et. al. 
1994). The measure of peptides and amino acids released during proteolysis indicates 
how proteins can be broken down into small molecules that are more easily absorbed 
and utilized (Restani et al., 1992). Therefore, the digestibility of flaxseed protein is an 
indication of its efficacy to generate bioactive peptides during GI digestion. The in vitro 
study discussed under study I  indicated that flaxseed protein digestion can generate 
potentially bioavailable ACEI peptides. Consumption of flaxseed in the form of whole 
seed or milled whole flaxseed may limit the generation of such bioactive peptides due to 
limited digestibility. Therefore, mucilage and oil removed ground flaxseed or protein 
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free of oil, mucilage and cell wall components would be ideal sources to release ACEI 
peptides during GI digestion. 
 
4.2.5. Linkage to study III 
Findings of study II showed that the removal of mucilage and oil, which are the two 
biopolymers available in large amounts in flaxseed, is necessary to enhance protein 
digestibility. Therefore, removal of mucilage and oil in flaxseed could improve the 
ability of flaxseed protein to release ACEI peptides of interest. These findings can be 
utilized to generate flaxseed protein products as a source of bioactive peptides, as well 
as to extend flaxseed value chain through protein product development. Flaxseed, which 
is gaining popularity as a functional food is mainly consumed as whole seed either as it 
is or in milled form. The low digestibility of milled whole flaxseed indicated the limited 
ability of obtaining the advantage of flaxseed protein derived ACEI peptide if 
consumed. Use of isolated protein or ground form of oil and mucilage-free flaxseed in 
bioproducts as well as generation of flaxseed protein derived bioactive peptide rich 
products will be important choices to deliver the flaxseed protein derived ACEI 
peptides to consumers. Since flaxseed protein has limited food applications, conversion 
of flaxseed protein into a hydrolysate containing bioactive peptides will be ideal in this 
regard. The limited hydrolysis of flaxseed proteins using commercially available food 
grade proteolytic enzymes will produce hydrolysates possessing a range of bioactivities 
as well as enhanced functionalities that will find application in wide variety of 
functional food products. Therefore, the potential for obtaining bioactive peptides from 
flaxseed protein using enzymatic means other than GI enzymes will be investigated in 
the next study and in order to explore ways to develop flaxseed protein bioproducts.
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4.3 Study III: Generation and characterization of bioactive peptides by exogenous 
hydrolysis of flaxseed proteins with a commercial fungal protease 
This study was aimed at identifying the potential of generating bioactive protein 
hydrolysates for functional food applications via hydrolysis of flaxseed protein with 
Flavourzyme which is a commercially available food grade protease. The resulting 
flaxseed protein hydrolysates (FPHs) were screened for several cardioprotective 
bioactivities namely ACEI activity, bile acid binding ability, antioxidant activities (OH• 
and O2•- scavenging activities, ability to inhibit linoleic acid oxidation, metal chelating 
activity) and antithrombotic activity. The effect of E/S (Leucine aminopeptidase units/g 
protein) and hydrolysis time (h) on the DH and bioactivities of FPHs were also 
determined. Of the bioactivities screened, ACEI and OH• scavenging activities 
investigated in study I, were selected for further analysis of bioactive peptides in the 
FPHs. 
 
4.3.1 Hydrolysis of flaxseed protein by Flavourzyme 
The isolated flaxseed protein was hydrolyzed by Flavourzyme at different E/S and time 
of hydrolysis. The enzymatic hydrolysis of flaxseed protein was carried out at the 
optimum temperature (50 °C) for the activity of Flavourzyme. Since Flavourzyme has 
its optimum activity in a range of pH (5-9), the pH of the reaction mixture was adjusted 
to pH 7 prior to hydrolysis in order to provide optimal conditions for enzyme action. 
During hydrolysis pH of the mixture decreased from 7 to 5 (approximately). However, 
the pH value remained within the optimum range throughout the hydrolysis.  
 
Flavourzyme is a commercially available fungal protease, extracted from Aspergillus 
oryzae. It is also known as leucyl aminopeptidase consisting of exopeptidase and 
endoprotease complex, which can be used for extensive hydrolysis of food proteins 
(Hamada, 2000; Novozyme, 2010). Protein hydrolysates with bioactive peptides are 
important ingredients in functional food applications. However, the free amino acids and 
small peptides in protein hydrolysates also act as taste compounds themselves or serve 
as reactants for the Maillard reaction. Therefore, such hydrolysates contribute to taste 
and flavor of the end product (Lin et al., 2008). Hydrolysis of proteins by proteases can 
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cause undesirable bitter flavors due to the formation of polypeptides of a certain length 
with hydrophobic peptides at the end of the polypeptide chain (Hamada, 2000). This 
bitterness can limit the application of the resulting hydrolysate as an ingredient in food 
applications. Flavourzyme can cleave off the hydrophobic residues in proteins and avoid 
bitter flavors in resulting hydrolysates (Hamada, 2000). Moreover, Flavourzyme 
generates short peptides upon protein hydrolysis, which are less resistant to further 
hydrolysis by proteolytic enzymes. Therefore, Flavourzyme was preferred in this study 
over the other commercially available fungal proteases, which are mainly 
endoproteases. 
 
The lyophilized FPHs had a N content ranging from 11.18 % to 12.51 %. Table 4.26 
shows the DH and average PCL of the resulting FPHs. Flavourzyme caused extensive 
hydrolysis (>50 % DH) of flaxseed protein under a majority of the E/S and hydrolysis 
time combinations used (Table 4.26). The DH, which is a measure of the number of 
peptide bonds cleaved as a percentage of total peptide bonds in the protein (Adler-
Nissen, 1986), ranged from 11.94 ± 4.1 % to 70.62 ± 5.9 % (Table 4.26) for flaxseed 
protein and increased with the increasing E/S and time of hydrolysis. The maximum DH 
(70.62 ± 5.9 %; PCL: 1.4) was achieved when the protein was hydrolyzed at an E/S of 
80 (LAPU/g of protein) for 20 h. The lowest DH (11.94 ± 4.1 %; PCL: 9.2) was when 
protein was hydrolyzed at an E/S of 1.5 (LAPU/g of protein) for 12 h. The average PCL 
of the FPHs ranged from 1.4 to 9.2 and decreased with increasing DH (Table 4.26). 
Average PCL of most hydrolysates was <4 indicating extensive hydrolysis of flaxseed 
protein have occurred. Therefore, the majority of the FPHs were expected to contain 
predominantly short chain peptides. Results showed that both the time of hydrolysis and 
E/S had significant effects (P<0.01) on DH values, whereas only the E/S had a 
significant effect (P<0.01) on PCL.  
 
The high DH observed in the current study was as expected due to the exopeptidase and 
endoprotease activity of Flavourzyme. However, Pedroche et al. (2002) highlighted the 
necessity of using more than one protease to obtain extensive DH (>50 %) stating that 
one enzyme cannot achieve such a high DH within a reasonable time. However, in the 
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current study, flaxseed protein isolate was identified as a potential substrate protein for 
Flavourzyme to generate hydrolysates with over 50 % DH. 
 
Table 4.26 Hydrolysis conditions employed and degree of hydrolysis and peptide 
chain length resulted in for the flaxseed protein hydrolysates  
1 Experimental points obtained using a Central Composite Rotatable Design; Temperature:  50°C 
2Values are means ± standard deviations of duplicate analyses 
abcMeans  in the same column followed by same letters are not significantly different (P<0.05) 
 E/S: Enzyme to substrate ratio; LAPU: Leucine amino peptidase unit; DH: Degree of hydrolysis; PCL: 
Peptide chain length 
 
Hydrolysis for 12 h and 23.3 h at an E/S of 47.5 LAPU/ g protein, 4 h and 20 h at an E/S 
of 80 LAPU/ g protein and 12 h at 93.5 LAPU/ g protein generated hydrolysates with 
DH above 50 % (Table 4.26). A hydrolysate with high DH is expected to be enriched 
with short chain peptides and amino acids released from the parent protein. Studies have 
shown the rapid absorption of short chain peptides such as di and tri peptides by the 
E/S  
(LAPU/g protein)1 
Time of 
hydrolysis (h)1 
DH  
 (%)2 
Average PCL2 
1.5 12.0 11.94 ± 4.1c 9.16 ± 3.2 
 
15.0 4.0 25.13 ± 1.6c 3.99 ± 0.3 
 
15.0 20.0 47.30  ±3.5b 2.12 ± 0.2 
 
47.5 0.7 24.63 ± 2.9c 4.11 ± 0.5 
 
47.5 12.0 64.24 ± 0.7a 1.56 ± 0.02 
 
47.5 23.3 65.42 ± 5.1a 1.54 ± 0.1 
 
80.0 4.0 57.15 ± 4.1ab 1.76 ± 0.1 
 
80.0 20.0 70.62 ± 5.9a 1.42 ± 0.1 
 
93.5 12.0 64.86 ± 4.7a 1.55 ± 0.1 
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human intestine (Adibi & Morse, 1971). Therefore, protein hydrolysates with short 
peptides and bioactive properties will be beneficially desirable ingredients in the 
development of physiologically functional foods.  
 
The maximum DH exhibited by flaxseed protein in the current study (70.62 ± 5.9 %) 
was greater than the DH values reported for Flavourzyme hydrolyzed proteins from 
other oilseeds such as soy, which had DH of 39.5 % upon 8 h of hydrolysis (Hrckova et 
al., 2002) and DH of 5.46 to 17.86 % upon 1 to 8 h of hydrolysis (Tsou et al., 2010) and 
sunflower that had DH of 42.2 % upon 3 h of hydrolysis (Villanueva et al., 1999). The 
maximum DH value (70.62 ± 5.9 %) of FPHs obtained by Flavourzyme hydrolysis alone 
was also greater than the recently reported values for Alcalase-Flavourzyme 
hydrolysates of yellow pea protein hydrolysate (DH: 58.89 %) but lower than the Kabuli 
(DH: 77.58 %) and Desi (DH: 77.53 %) chickpea protein hydrolysates prepared by the 
same enzymes (Barbana & Boye, 2010). Alcalase, unlike Flavourzyme, is an 
endoprotease with very high substrate specificity and it can hydrolyze most of the 
peptide bonds within a protein molecule (Zhang et al., 1998). Generally, alkaline 
proteases, including Alcalase, exhibit higher activities than do acid or neutral proteases 
such as Flavourzyme (Rebeca et al., 1991).  
 
Pre-digestion with Alcalase, exposes a number of N terminal sites, facilitating 
hydrolysis by Flavourzyme (Pedroche et al., 2002). Therefore, a hydrolysate prepared 
by sequential hydrolysis of Alcalase and Flavourzyme tend to have higher DH than 
when Flavourzyme was used alone. However, the variations in DH could be due to the 
differences in the protein composition, time of hydrolysis and E/S levels employed and 
differences in sensitivity of the methods used for determining DH.  
 
4.3.2 Bioactivities of flaxseed protein hydrolysates  
The freeze-dried, FPHs were screened for several in vitro bioactivities and the results 
are shown in Table 4.27. 
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Table 4.27 Angiotensin I-converting enzyme inhibitory, antioxidant and antithrombotic activities of flaxseed protein 
hydrolysates  
 
 
 
 
 
 
 
 
 
 
 
 
  
1Experimental points obtained using a Centre Composite Rotatable Design; Temperature was maintained at 50°C  ; 2Values are means ± standard 
deviations of duplicate analyses; abcde Means in the same column followed by the same letter are not significantly different (P<0.05); 3Concentration: 
0.67 mg/mL; 4Concentration:  0.5 mg/mL; E/S: Enzyme to substrate ratio; LAPU: Leucine amino peptidase units; ACEI: Angiotensin 1-converting 
enzyme inhibitory; OH•: Hydroxyl radical; O2•-: Superoxide radical; Unhydrolyzed protein was not included in statistical analysis 
E/S 
(LAPU/g 
protein)1 
Time of 
hydrolysis 
(h)1 
 
 
ACEI 
activity 
(%)2,3 
Antioxidant activities (%)1  
 
Antithrombotic 
activity (%)2,3 
OH• 
scavenging 
activity2,4 
O2•- 
scavenging 
activity2,3 
Inhibition of 
linoleic acid 
oxidation2,3 
Metal chelating 
activity 2,3 
1.5 12.0 88.29 ± 1.1a 21.63 ± 0.6a 37.32 ± 1.1a 94.33 ± 4.5a 15.95 ± 0. 7cd 8.39 ± 1.9 
15.0 4.0 87.83 ± 1.3a 21.46 ± 0.5a 29.39 ± 1.9de 71.48 ± 3.9b 24.91 ± 3.1ab 0 
15.0 20.0 78.96 ± 0.1b 19.68 ± 1.3ab 35.84 ± 2.6ab 49.23 ± 0.3cd  20.22 ± 1.12bc 0 
47.5 0.7 86.45 ± 0.4a 22.08 ± 0.3a 26.33 ± 2.5e 66.81 ± 8.9b 16.57 ± 0.4cd 19.83 ± 2.1 
47.5 12.0 76.06 ± 0.8c 17.44 ± 1.3abc 36.59 ± 2.1ab 69.80 ± 3.3b 17.62 ± 2.7cd 0 
47.5 23.3 73.19 ± 0.5d 16.53 ± 3.5abc 36.31 ± 0.7ab 62.14 ± 7.9bc 14.40 ± 1.2d 10.65 ± 3.2 
80.0 4.0 76.76 ± 0.2bc 18.33 ± 2.3abc 33.37 ± 1.0bcd 35.28 ± 5.5d 21.22 ± 1.4abc 0 
80.0 20.0 71.59 ± 0.4d 12.48 ± 2.7c 29. 80 ± 1.2cde 0.71 ± 4.7e 26.08 ± 2.1a 0 
93.5 12.0 72.65 ± 0.8d 14.60 ± 0.8c 39.41 ± 1.9a 88.17 ± 1.4a 23.46 ± 0.7ab 11.34 ± 0.3 
Unhydrolyzed protein 0 0 0 19.62 ± 1.6 29.57 ± 0.7 0 
Bioactivity of 
standards 
Captopril Carnosine Ascorbic acid Ascorbic acid Carnosine Antithrombin 
100 ± 0.0 63.50 ± 4.0 62.24 ± 1.1 63.87 ± 0.5 84.99 ± 0.4 100.00 ± 0.0 
166
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4.3.2.1 Angiotensin I-converting enzyme inhibitory activity 
The  ACEI activity of the FPHs (0.67 mg hydrolysate/mL in the assay mix) ranged from 
71.5 9 ± 0.4 % to 88.29 ± 1.1 % (Table 4.27) indicating that all the FPHs had ACEI 
activity over 70 %. Maximum ACEI activity (88.29 ± 1.1 %) was observed when the 
protein was hydrolyzed for 12 h at E/S of 1.5 LAPU/g protein. The two hydrolysates 
prepared using E/S (LAPU/ g protein) of 15 and 47. 5 for 4 h and 0.7 h, respectively 
also had ACEI activities above 85 % at the concentrations used. The ACEI activity of 
these three FPHs were significantly greater (P<0.05) compared to the others.  
 
Hydrolysis of proteins with heat, alkali and acids also can generate bioactive peptides. 
Therefore, the ACEI activity was also determined for the unhydrolyzed protein and for 
the protein treated with exact time and temperature combinations as used in the 
experiment with no added Flavourzyme. These test samples including unhydrolyzed 
protein showed no ACE inhibition. This confirms that the ACEI activity of the FPHs is 
due to the peptides released as a result of Flavourzyme catalyzed hydrolysis. Captopril, 
which was used as the standard ACE inhibitor showed 100 % inhibition of ACE at 0.67 
mg/mL (Table 4.27).  
 
The ACEI activities of the FPHs showed a significant decrease (P<0.05) when DH was 
beyond 25 % (Figure 4.19), indicating that extensive hydrolysis resulted in low PCL and 
reduced ACEI activity. According to the results, high molecular weight (HMW) 
peptides in the FPHs were better ACE inhibitors than the low molecular weight (LMW) 
peptides. Contrasting results were shown for Flavourzyme hydrolysates of tilapia fish 
protein (Raghavan & Kristinsson, 2009) and soy protein (Chiang et al., 2006), with 
these studies reporting an increased ACEI activity with increase in DH. However, the 
hydrolysates in these studies, which had been tested for ACEI activity, had lower ranges 
of DH values. The maximum DH values in both studies (25 % or less) were lower 
compared to the current study (70.62 %). Since unhydrolyzed flaxseed protein did not 
show any ACEI activity, with the increase in DH, the ACEI value would reach a 
maximum and then start to decrease thereafter. For example, for Alcalase hydrolyzed 
chickpea protein, Pedroche et al. (2002) observed an increase in ACEI activity up to 30 
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% DH and reported a decrease in ACEI activity thereafter. The lowest DH observed in 
our study was 11.94 ± 4.1 % (Table 4.26). Hence the response of ACEI activity in 
relation to DH below 11.94 % could not be detected. 
 
Figure 4.19 Angiotensin I-converting enzyme inhibitory activity of flaxseed protein 
hydrolysates in relation to degree of hydrolysis (r2=0.98). A concentration of 0.67 
mg hydrolysate/mL was used for the assays 
 
Wu et al. (2006) reported that in long chain peptides (4-10 amino acid residues), the 
tetra peptide residue at the C-terminal end determines their structural requirement for 
effective inhibition of ACE activity. Therefore, it could be hypothesized that with the 
increase of DH, the exoproteases in Flavourzyme may be involved in removing amino 
acids from the C-terminal position of the ACEI peptides in FPHs making them less 
active resulting in a decrease in ACEI activity with further increase in DH. 
 
The IC50 values for ACEI activity were calculated for three selected FPHs (DH: 11.94 
%, 24.63 % and 25.13 %) possessing ACEI values above 85 % and are presented in 
Table 4.28. The ACEI values of these FPHs were significantly higher (P<0.05) than that 
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of all the other hydrolysates (Table 4.28). These FPHs had IC50 values ranging between 
0.07 and 0.09 mg/mL (Table 4.28) suggesting their ability to inhibit 50 % of ACE 
activity at a low concentration. 
 
Table 4.28 The IC50 for angiotensin I-converting enzyme inhibitory activity in 
flaxseed protein hydrolysates 
1Values are means ± standard deviations of duplicate analyses 
E/S: Enzyme to substrate ratio; LAPU: Leucine amino peptidase units; DH: Degree of hydrolysis 
ACEI: Angiotensin I-converting enzyme inhibitory 
 
 
The IC50 values for ACEI activity observed in the present study were greater than those 
reported for defatted flaxseed meal hydrolyzed with Alcalase and Thermolysin (Wu et 
al., 2004). According to the process of Wu et al. (2004), Alcalase produced a 
hydrolysate with an IC50 of 64.3 g/mL, whereas the hydrolysate produced by 
Thermolysin had an IC50 of 37.1 g/mL for ACEI activity. The hydrolysate resulting 
from sequential hydrolysis of Thermolysin and Alcalase had an ACEI IC50 of 34.2 
g/mL. However, these reported values were for hydrolyzed defatted flaxseed meal and 
not for the purified protein.  When the meal is subjected to hydrolysis the resulting 
hydrolysate may contain various soluble, non-protein matrix components. For example, 
strong ACEI activities have been reported from plant derived flavanoids and 
proanthocyanidins (Hansen et al., 1996; Wagner et al., 1991) and guanosine derivatives 
(Kim et al., 2003). Therefore, it is not certain whether the observed ACEI activity of the 
hydrolyzed flaxseed meal is solely due to peptides resulting from protein hydrolysis or 
any other component released from the complex chemical constituents of meal. 
E/S ( LAPU/g 
protein) 
Time of 
hydrolysis (h) 
DH  
(%)1 
ACEI activity 
(%)1 
IC50 
(mg of hydrolysate 
/mL)1 
1.5 
 
12.0 11.94 ± 4.1 88.29 ± 1.1  0.07 ± 0.0  
47.5 0.7 24.63 ± 2.9 86.45 ± 0.4 0.09 ± 0.0  
 
15.0 
 
4.0 
 
25.13 ± 1.6 
 
87.83 ± 1.3 
 
0.07 ± 0.0  
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The ACEI IC50 values  of FPHs reported in the present study were much lower 
compared to the crude hydrolysates of soy protein hydrolyzed with Alcalase (IC50 0.34 
mg/mL) (Wu & Ding, 2002), rapeseed protein hydrolyzed with Thermolysin (IC50 0.32 
mg/mL) (Marczak et al., 2003), Alcalase-Flavourzyme hydrolyzed Kabuli and Desi 
chickpea proteins (0.316 and 0.228 mg/mL, respectively) and yellow pea protein (0.412 
mg/mL) (Barbana & Boye, 2010), which indicated the high ACEI potential of FPHs 
generated in the present study. These differences in ACEI potency could be due to a 
various factors including differences in proteolytic enzymatic activity generating 
different peptide compositions in the hydrolysate, differences in parent protein structure, 
hydrolytic conditions (E/S, time, pH and temperature).  
 
In a recent study, Nakahara et al. (2010) showed that a peptide enriched soy sauce like 
seasoning with an ACEI-IC50 value of 0.45 mg/mL demonstrated antihypertensive 
effects in SHR. Moreover, oral ingestion of a tryptic casein hydrolysate having an IC50 
value of 0.166 mg/mL (Karaki et al.,1990)  and milk fermented with Lactobacillus 
heleveticus (ACEI-IC50: 0.16-0.26 mg/mL; Fuglsang et al., 2002) showed significant 
blood pressure reduction in SHR. The IC50 value for the FPHs reported herein is 
therefore within the concentration range likely to mediate an antihypertensive effect. 
 
The ACEI activity of the three FPHs with high activity (above 85 %) showed dose 
dependent relationships when plotted against the hydrolysate concentration. Figure 4.20 
shows the relationship between ACEI activity and hydrolysate concentration for the 
hydrolysate having maximum ACE inhibition (IC50: 0.07 mg/mL; DH: 11.94 %). There 
was an increase in the ACEI activity with the increasing hydrolysate concentration. 
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Figure 4.20 The Angiotensin I-converting enzyme inhibitory activity and amount of 
hippuric acid released in the presence of the flaxseed protein hydrolysate having 
11.94 % degree of hydrolysis in the assay mixture 
 
4.3.2.1.1 Angiotensin I-converting enzyme inhibitory pattern  
The ACEI patterns of the three most potent ACEI- FPHs (DH: 11.94 %, 24.63 % and 
25. 13 %) were determined by the Lineweaver-Birk plots. The Lineweaver Birk plot for 
the hydrolysate with a DH of 11.94 % (ACEI IC50: 0.07 mg/mL) is shown in Figure 
4.21. The results indicated that these FPHs compete with Hip-His-Leu and prevents its 
binding with the active site of ACE causing ACE inhibition. Therefore, the FPHs were 
identified as competitive inhibitors of ACE with respect to Hip-His-Leu, which was 
used as the substrate for ACE in the assay.  
 
Most food derived ACE inhibitors generated by microbial protease hydrolysis were 
found to be competitive inhibitors. Such inhibitors include alkaline protease hydrolysate 
of sardine muscle (Matsufuji et al., 1994) and soy protein (Wu & Ding, 2002). 
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Figure 4.21 Lineweaver-Birk plots for angiotensin I-converting enzyme with or 
without flaxseed protein hydrolysate (Degree of hydrolysis: 11.9 %) having the 
highest angiotensin I-converting enzyme inhibitory activity. V: velocity of reaction 
measured as the amount of hippuric acid released per second, S: Substrate (Hip-
His-Leu) concentration in the assay mixture 
 
The non-competitive ACEI peptides also have been reported in some protein 
hydrolysates. The cationic peptide fraction of flaxseed protein hydrolysate generated by 
Alcalase hydrolysis and Thermolysin hydrolysate exhibited mixed type non-competitive 
ACE inhibition (Udenigwe et al., 2009). Similar results have been reported by 
Udenigwe and Aluko (2010) for flaxseed protein hydrolysate with a high Fischer ratio 
generated by Thermolysin followed by pronase catalyzed hydrolysis. The authors 
highlighted that peptides in the hydrolysate inhibited ACE activity by binding both to 
the enzyme active site and allosteric site and the peptides interacted with ACE in both 
its free and substrate bound forms. The enzymes Thermolysin, Pronase and Alcalase 
have different specificities compared to Flavourzyme used in the present study. For 
example, Thermolysin cleaves proteins at the N terminal region of hydrophobic amino 
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acids (Phe, Tyr, Leu, Ile, Val). Alcalase is an endopeptidase and pronase possess both 
exopeptidase and endopeptidase activity (Udenigwe & Aluko, 2010). Different 
specificities of these enzymes with that of Flavourzyme could have generated different 
peptides in the flaxseed protein hydrolysates with different modes of ACE inhibition. 
 
4.3.2.2 Antioxidant activities 
The unfractionated FPHs were also screened for several in vitro antioxidant activities 
(scavenging of OH•, O2•-, ability to inhibit linoleic acid oxidation and metal chelating 
activity) as given in Table 4.27. 
 
4.3.2.2.1 Hydroxyl radical scavenging activity  
The OH• scavenging activity of the FPHs (at 0.5 mg of hydrolysate /mL) ranged from 
12.48 % to 22.08 % (Table 4.27). The maximum OH• scavenging activity (22.08 ± 0.3 
%) was found in the FPH prepared with an E/S of 47.5 LAPU/g protein for 0.7 h (DH: 
24.63 %). The OH• scavenging activity of this hydrolysate was significantly greater 
(P<0.05) than that of hydrolysates prepared at 80 LAPU/ g protein for 20 h and 93.5 
LAPU/ g protein for 12 h. It was not significantly different (P<0.05) than the OH• 
scavenging activity of other FPHs. The hydrolysate prepared with an E/S of 80.0 
LAPU/g of protein for 20 h (DH: 70.62 %) had the lowest OH• scavenging activity 
(12.48 ± 2.7 %) (Table 4.27). Similar to ACEI activity, there was no OH• scavenging 
activity in the unhydrolyzed flaxseed protein. Carnosine (0.5 mg/mL), a dipeptide with 
proven antioxidant activity, showed 63.5 % activity under the defined reaction 
conditions (Table 4.27). 
 
Similar to ACEI activity, a plot of OH• scavenging activity of the FPHs against their DH 
values showed that increasing DH led to a decrease in the OH• scavenging ability 
(Figure 4.22). The OH• scavenging activity was greater in FPHs possessing lower DH 
and higher PCL compared to those with higher DH and lower PCL (Figure 4.22, Table 
4.27). This suggests that the relatively long chain peptides acted as potent OH• 
scavengers.  
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Figure 4.22 Hydroxyl radical scavenging activity of flaxseed protein hydrolysates in 
relation to degree of hydrolysis (r2=0.94). Concentration of 0.5 mg hydrolysate/mL 
was used for the assays. 
 
The long chain peptides in hydrolysates of lower DH may have been further hydrolyzed 
into short chain peptides thereby reducing the OH• scavenging activity. Previous studies 
on fish protein hydrolysates also have shown a decrease in OH• scavenging activity 
above a certain DH (You et al., 2009). Long chain antioxidant peptides (5-16 amino 
acid residues) also have been isolated from hydrolyzed soy protein (Chen et al., 1995). 
In contrast to the findings of the current study, Flavourzyme hydrolyzed soy 
concentrates had an increase in OH• scavenging activity with increased DH (Moure et 
al., 2006). The FPH that showed the highest OH• scavenging activity (22.08 %) was 
selected for further studies. 
 
Figure 4.23 shows the variation of OH• scavenging activity of the FPH possessing 
maximum activity (22.08 %; DH: 24.63 %) in relation to the hydrolysate concentration. 
Similar to ACEI activity, there was a dose dependent relationship between the OH• 
scavenging activity and FPH concentration.  
DH (%)
0 10 20 30 40 50 60 70 80
%
 H
yd
ro
xy
l r
ad
ic
al
 sc
av
en
gi
ng
 a
ct
iv
ity
0
5
10
15
20
25
Unhydrolyzed 
protein 
 
 
175 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.23 Hydroxyl radical scavenging activity of the flaxseed protein 
hydrolysate having 24.63 % degree of hydrolysis in relation to hydrolysate 
concentration 
 
The increase in activity per unit change in FPH concentration was greater at 
concentrations below 1.25 mg/mL and was lower at concentrations above that limit 
(Figure 4.23). 
 
The FPHs, which had above 85 % ACEI activity (DH: 11.94 %, 24.63 % and 25.13 %) 
were the ones showing the highest OH• scavenging activities (above 20 %). Therefore, 
the IC50 values of those FPHs were calculated for OH• scavenging activity and they 
ranged from 2.03 ± 0.5 to 3.06 ± 2.4 mg/mL (Table 4.29). The IC50 values shown by the 
FPHs were greater than that for ACEI activity (Table 4.28). This further indicated that 
the FPHs had a lower potential for OH• scavenging compared to ACE inhibition. 
 
Previous studies support the presence as well as absence of OH• scavenging activity of 
protein hydrolysates obtained by microbial protease catalyzed hydrolysis. Flavourzyme 
hydrolyzed soy concentrate upon passing through a 50 kDa membrane previously 
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showed an activity of 21.81 % (concentration used: 0.1 mg protein/mL) at a DH of 28.8 
% and this value was found to be similar to the OH• scavenging activity shown by FPH 
at similar DH (Moure et al., 2006). In a recent study, Pownall et al. (2010) reported the 
absence of OH• scavenging activity in pea protein hydrolyzed with Thermolysin.  
 
Table 4.29 The IC50 for hydroxyl radical scavenging activity of flaxseed protein 
hydrolysates 
1 Values are means ± standard deviations of duplicate analyses 
E/S: Enzyme to substrate ratio; LAPU: Leucine aminopeptidase units 
DH: Degree of hydrolysis; OH• Hydroxyl radical 
Rapeseed peptides generated by Alcalase hydrolysis had a weaker  
 
Rapeseed peptides generated by Alcalase hydrolysis had a weaker OH• scavenging 
activity (IC50 of 2.53 to 6.79 mg/mL) (Zhang et al., 2008) compared to the FPHs 
generated in current study. Egg yolk protein hydrolysate prepared by sequential 
hydrolysis by Orientase and Protease from Bacillus spp., had a greater OH• scavenging 
activity (91.7 %) than the maximum activity reported by us at 0.5 % concentration 
(Sakanaka & Tachibana, 2006). Udenigwe and group (Udenigwe et al., 2009; Udenigwe 
& Aluko, 2010) reported OH• scavenging activity of flaxseed protein hydrolysates. In 
one study (Udenigwe et al., 2009), LMW (< 1kDa) cationic peptide fractions obtained 
from Alcalase, ficin, pancreatin, papain, Thermolysin and trypsin, were evaluated for 
OH• scavenging ability. The least cationic peptide fraction of Alcalase hydrolysis (IC50: 
0.08 mg protein/mL), ficin (0.26 mg  protein/mL), trypsin (IC50: 0.01 mg protein/mL), 
papain (IC50: 0.51 mg protein/mL), Thermolysin (IC50: 0.05 mg protein/mL) and 
pancreatin (IC50: 0.07 mg protein/mL) exhibited high OH• scavenging activity.  
Sequential hydrolysis of flaxseed protein by Thermolysin followed by pronase, resulted 
E/S ( LAPU/g 
protein) 
Time of 
hydrolysis (h) 
DH ( %)1 OH•  
scavenging 
activity (%)1 
IC50 
(mg hydrolysate/mL)1 
1.5 12.0 11.94 ± 4.2 21.63 ± 0.6 3.06 ± 2.4 
 
47.5 0.7 24.63 ± 2.9 22.08 ± 0.3 1.56 ± 0.8 
 
15.0 4.0 25.13 ± 1.6 21.46 ± 0.5 2.03 ± 0.5 
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in maximum scavenging of 31.5 % (5 mg protein/mL), which is a moderate OH• 
scavenging activity (Udenigwe & Aluko, 2010). Very low levels of Phe residues in the 
peptide mixture, was considered a contributing factor for the moderate OH• scavenging 
activity in flaxseed protein hydrolysates (Udenigwe & Aluko, 2010). Formation of a 
stable o-, m- or p-Tyr by trapping a OH• and hydroxylation of aromatic ring have been 
reported as the reason for strong OH• scavenging ability of Phe (Sun et al., 1993). Figure 
4.23 showed a OH• scavenging activity of 31.5 % by the Flavourzyme catalyzed FPH at 
<1 mg/mL hydrolysate concentration.  
 
In previous studies, OH• scavenging activity of hydrolyzed flaxseed protein have been 
determined upon further modification of the hydrolysates. These modifications include 
removal of HMW peptides and enrichment of the hydrolysates with cationic peptides 
(Udenigwe et al., 2009), removal of aromatic amino acid containing peptides and 
recovering BCAA containing peptides by passing the hydrolysate through activated 
carbon column (Udenigwe & Aluko, 2010). In contrast, the hydrolysate that we used 
was crude in nature without concentrating specific peptides.    
 
 4.3.2.2.2 Superoxide radical scavenging activity 
The O2•- scavenging activity of the FPHs (0.67 mg of hydrolysate/mL) ranged from 
26.33 ± 2.5 to 39.41 ± 1.9 % (Table 4.27). The highest O2•- scavenging activity was 
observed when the protein was hydrolyzed at E/S of 93.5 LAPU/g for 12 h (DH: 64.86 
%). This was significantly higher (P<0.05) than the activities shown by the FPHs 
prepared by treating flaxseed protein with 15 LAPU/g for 4 h, 47.5 LAPU/g for 0.7 h 
and with 80 LAPU/g for 4 h and 20 h (Table 4.27). The unhydrolyzed protein did not 
show any O2•- scavenging activity. Therefore, it could be hypothesized that O2•-
scavenging peptides are released during hydrolysis of flaxseed protein by Flavourzyme, 
which increased the O2•- scavenging activity of FPHs. However, all hydrolysates had 
lower O2•- scavenging activity than ascorbic acid (62.24 ± 1.1 %), which was used as the 
standard (Table 4.27).  
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According to published research, both the size and structure of the peptides are 
determinants of antioxidant activity.  Chen et al. (1995) found that the presence of His, 
Pro and Tyr in the sequence as well as the hydrophobic amino acids, Val or Leu at the N 
terminal are the main structural features of antioxidant peptides obtained from soy bean 
protein digests. However, unlike the OH• scavenging activity, the O2•-scavenging 
activity of FPHs did not show any correlation with the DH (Figure 4.24).  
Figure 4.24 Superoxide radical scavenging activity of flaxseed protein hydrolysates 
in relation to degree of hydrolysis. A concentration of 0.67 mg hydrolysate/mL was 
used for the assays 
It is possible that the structure of peptides play a role in determining the O2•-scavenging 
activity of the FPHs and not the PCL. The hydrolysate that showed the highest O2•- 
scavenging activity (39.41 %) was selected for further studies. 
 
The FPH with the highest O2•- scavenging activity (39.41 %; DH of 64.86 %) was 
further investigated to determine the IC50 for O2•- scavenging activity. The FPH had an 
IC50 of 1.2 mg of hydrolysate /mL. It showed an increasing O2•- scavenging activity with 
the increase in concentration (Figure 4.25).  
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Figure 4.25 Superoxide radical scavenging activity of the flaxseed protein 
hydrolysate having 64.86 % degree of hydrolysis in relation to hydrolysate 
concentration 
 
There are many biological reactions generating O2•-, which is highly toxic. Superoxide 
radical ·itself is a poorly reactive radical. However, it causes indirect cell damages by 
generating highly reactive oxygen species such as singlet oxygen and OH• (Benzie, 
2000). Therefore, study of the scavenging ability of O2•- is important. The flaxseed 
protein hydrolysate with high Fischer ratio prepared by Thermolysin-pronase hydrolysis 
(Udenigwe & Aluko 2010) also exhibited O2•- scavenging activity with a reported IC50 
value of 1.67 ± 0.19 mg protein/mL. 
 
The unfractionated FPH with highest O2•- scavenging activity resulted in an IC50 of 1.2 
mg of hydrolysate /mL and hence had a greater activity than the hydrolysate prepared by 
Udenigwe and Aluko (2010). Also the highest O2•- scavenging activity shown by the 
FPH was greater than the cationic peptide rich fraction of flaxseed protein hydrolysates 
generated by hydrolyzing flaxseed protein with seven different proteases as described by 
Udenigwe et al. (2009). As reported by these authors, the flaxseed protein hydrolysates 
prepared by pepsin, trypsin, Thermolysin and pancreatin as well as the least cationic 
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fraction generated by Alcalase hydrolysis had no O2•-scavenging activity. The IC50 for 
O2•- scavenging activity for hydrolysates prepared from Alcalase, ficin and papain 
ranged from 1.66 to 3.98 mg protein/mL, which was greater than that observed in 
current study (1.2 mg of hydrolysate/mL). Our results indicate that it is possible to 
generate FPHs with higher O2•- scavenging ability using Flavourzyme compared to the 
above mentioned proteolytic enzymes.  
 
The O2•- scavenging activity of FPHs was weaker than that of  hydrolysates of wheat 
germ prepared with Alcalase (IC50: 0.4 mg/mL) (Zhu et al., 2006), egg yolk protein 
prepared with proteinase from Bacillus sp. (90 % O2•-  scavenging activity at 0.5 % 
concentration; Sakanaka & Tachibana, 2006) and Alcalase hydrolysates of alfalfa leaf 
protein (67 % at 0.9 mg/mL) (Xie et al., 2008) and rapeseed protein (IC50: 1.05 mg/mL) 
(Pan et al., 2009). 
 
4.3.2.2.3 Ability to inhibit linoleic acid oxidation 
All the FPHs showed the ability to inhibit linoleic acid oxidation (Table 4.27). In some 
FPHs it was greater than that of the standard (ascorbic acid) used (63.87 ± 0.5 %). The 
highest activity (94.33 ± 4.5 %) was found in the FPH prepared under the conditions; 
1.5 LAPU/ g protein for 12 h. This FPH had the lowest DH (11.94 %; PCL: 9.1). There 
was no significant difference between this FPH and that prepared using 93.5 LAPU/g 
protein for 12 h for inhibition of linoleic acid oxidation (88.17 ± 1.4 %). The lowest 
activity (0.71 ± 4.7 %) was in the FPH with the highest DH (70.6 %; PCL: 1.4) (Table 
4.27). Unlike other bioactivities tested, the unhydrolyzed flaxseed protein also inhibited 
linoleic acid oxidation (19.62 ± 1.6 %; Table 4.27). Hydrolysis by Flavourzyme 
increased the inhibition of linoleic acid oxidation in all the FPHs except the FPH 
prepared using E/S of 80 LAPU/ g protein for 20 h (Table 4.27). The results further 
indicated that the FPHs with long chain peptides (PCL~9) were potent inhibitors of 
linoleic acid oxidation (Table 4.27). However, when plotted in a graph (Figure 4.26) the 
activity of FPHs did not show any correlation with the DH similar to the O2•- scavenging 
activity (Figure 4.25).  
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Figure 4.26 Inhibition of linoleic acid oxidation of flaxseed protein hydrolysates in 
relation to degree of hydrolysis. Concentration of 0.67 mg hydrolysate/mLwas used 
for the assays 
 
As stated previously, the lack of a direct relationship between antioxidant activity and 
DH suggested that the specific composition (e.g., type of peptides, ratio of different free 
amino acids) was an important factor in determining the ability of FPHs to inhibit 
linoleic acid oxidation. The hydrophobic amino acids such as Phe and Gly in peptides 
were reported to contribute to inhibition of lipid peroxidation as they make the peptides 
soluble in lipid and thereby facilitate better interaction with radical species. Moreover, 
the activity of His containing peptides has also been reported to act against lipid 
peroxidation (Chen et al., 1998). This activity may be due to presence of an imidazole 
ring in His structure, which may be involved in hydrogen donation and lipid radical 
trapping ability (Chen et al., 1998). 
 
The FPH that possessed the maximum ability to inhibit linoleic acid oxidation (94.33 %, 
DH: 11.94 % was selected for further studies. The IC50 of this FPH was 0.4 mg/mL. As 
shown in Figure 4.27, there was a dose dependent relationship between the hydrolysate 
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and the percent inhibition of linoleic acid oxidation. However, at concentrations below 
~<0.3 mg/mL, the FPH did not show any activity.In the present study, the ferric 
thiocyanate assay was first used with a control sample (with no hydrolysate) to 
determine the time taken to form maximum level of peroxides of linoleic acid oxidation. 
In this assay the increase in absorbance at 507 nm was used as an indication of the 
increase in concentration of peroxides formed. 
 
 
 
 
 
 
 
 
 
Figure 4.27 The inhibition of linoelic acid oxidation of the flaxseed protein 
hydrolysate having 11.94 % degree of hydrolysis in relation to hydrolysate 
concentration 
 
The maximum peroxide formation was observed at 48 h (results not shown) and 
decreased thereafter. As peroxides are unstable, they gradually decompose into 
secondary oxidation products (Chen et al., 1996). This led to a decrease in absorbance 
(at 507 nm) after the second day of incubation in the current study. As oxidation 
proceeds, peroxides are gradually decomposed into LMW compounds that can be 
measured using the TBA reagent (Chen et al., 2007). As shown by Chen et al., (2007), 
peanut protein hydrolyzed with Alcalase inhibits oxidation of linoleic acid by 79 % at 20 
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mg/mL. This concentration was much higher than that used in the present study (0.67 
mg/mL). Therefore, the Flavourzyme hydrolyzed flaxseed protein (especially that 
having DH of 11.94 %) had a greater ability to inhibit linoleic acid oxidation compared 
to the peanut protein hydrolysate reported by Chen et al. (2007). A marked inhibition of 
linoleic acid oxidation also has been shown by a gelatin hydrolysate of Alaska pollack 
skin prepared with Alcalase followed by Pronase E (58 % inhibition; Kim et al., 2001). 
According to Dong et al. (2008), Alcalase catalyzed silver carp protein hydrolysate 
showed higher inhibition of linoleic acid oxidation than when Flavourzyme was used. 
The ability to inhibit linoleic acid oxidation by unhydrolyzed flaxseed protein and FPH 
has not been previously reported. 
 
4.3.2.2.4 Metal chelating activity 
In the present study, the ability of FPHs to chelate ferrous ions was investigated. Similar 
to inhibition of linoleic acid oxidation, the unhydrolyzed flaxseed protein had 29.57 ± 
0.7 % metal chelating activity. Interestingly, the metal chelating activities of all the 
FPHs were lower than that of the unhydrolyzed protein (Table 4.27). Therefore, the 
hydrolysis of flaxseed protein by Flavourzyme reduced its metal chelating activity. This 
indicated that hydrolysis of flaxseed protein by Flavourzyme may not release metal 
chelating peptides or that the activity was lost due to hydrolysis.  
 
Transitional metal ions such as Fe2+ act as prooxidants, and can catalyze the generation 
of reactive oxygen species such as OH• which, in turn, oxidize unsaturated lipids 
(Burkitt, 2001; Stohs & Bagchi, 1995). Therefore, chelation of metal ions will prevent 
oxidative damage leading to cardioprotection. Metal chelating activity was previously 
shown by various protein hydrolysates including Alcalase hydrolyzed wheat germ 
protein (Zhu et al., 2006), Thermolysin hydrolyzed pea protein (Pownall et al., 2010), 
porcine collagen hydrolyzed by a mixture of bovine pancreas, protease of Streptomyces 
and protease of Bacillus spp (Li et al., 2007), porcine hemoglobin (Chang et al., 2007) 
and silver carp protein (Dong et al., 2008) prepared with Alcalase and Flavourzyme. 
The optimal metal chelating activity involves aliphatic compounds, where a five-
member ring is formed, composed of the metal ion and two chelating ligands (Miller et 
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al., 1990). Hydrophobic amino acids as well as His were rich in hydrolysates with metal 
chelating activity (Megias et al., 2008; Pownall et al., 2010). It was suggested that the 
imidazole ring is responsible for the strong metal chelating activity of the amino acid, 
His (Megias et al., 2008). In addition, the importance of N-terminal peptide sequence of 
peptides (Chen et al., 1998), presence of amino acids such as Tyr, Met and Trp 
(Amarowicz, 2008) as well as acidic and/or basic amino acids (Suetsuna et al., 2000), in 
the metal chelating activity has been reported.  
 
According to the results, it is possible that the amino acid compositions of peptides in 
FPHs prepared in the current study were not favoring their ability to chelate metals. The 
flaxseed protein used for this study had a relatively high amount of acidic amino acids 
such as Asp and Glu as well as the basic amino acid Arg (See Table 4.6 shown in the 
results and discussion chapter of this thesis), which could be the reason for its high 
metal chelating activity. It could be hypothesized that Flavourzyme had hydrolyzed the 
flaxseed protein leaving acidic amino acid containing peptide chains intact in the 
unhydrolyzed residue, resulting in FPHs with low metal chelating activity. 
 
The chelation of metal ions can decrease the amount of free iron available to participate 
in the Fenton reaction used for determination of OH• scavenging activity and ultimately 
decrease the formation of the OH• (Halliwell & Gutteridge, 1990). Therefore, if a 
hydrolysate shows both OH• scavenging activity and metal chelating activity it is 
important to clarify that the OH• scavenging activity observed was not due to chelation 
of iron. The absence of metal chelating activity of FPHs further confirmed that the 
results obtained in deoxy ribose assay was due to their ability to scavenge OH• 
generated by the Fenton reaction.  
 
The metal chelating activity of the hydrolysates was not studied further and the IC50 was 
not determined. 
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4.3.2.2.5 Antithrombotic activity 
The antithrombotic activity of FPHs, unhydrolyzed protein and the standard 
antithrombin, are shown in Table 4.27. Most hydrolysates showed minimal or no 
antithrombotic activity. The unhydrolyzed proteins and blanks also did not exhibit 
antithrombotic activity indicating that the activity shown was due to products generated 
by Flavourzyme catalyzed hydrolysis of flaxseed protein. The FPHs possessing 
antithrombotic activity showed comparatively lower activity at the concentration used, 
which ranged from 8.39 ± 1.9 (E/S: 1.5 LAPU/ g protein; Time: 12 h; DH: 11.94 %) to 
19.83 ± 2.1 % (E/S: 47.5LAPU/ g protein; Time: 0.7 h; DH: 24.6 %). The hydrolysates 
below and above 24.63 % DH had low or no antithrombotic activity.  
 
In the current study, the inhibition of thrombin catalyzed coagulation of fibrinogen was 
measured and expressed as antithrombotic activity (Table 4.27). Antithrombotic 
peptides, derived from food proteins, which show nearly no toxic effect, have broad 
application in cardiovascular disease prevention and treatment. Antithrombotic activity 
was previously observed in a few studies on hydrolyzed food proteins. They included 
fermented soy foods such as pronase digest of mature natto (IC50: 36.2 to 162.1 µM) and 
kidney membrane protease digests of matured tempeh (IC50: 9.8 to 148.2 µM) (Gibbs et 
al., 2004). An antithrombotic peptide in the kidney membrane protease digest of tempeh 
had Arg–Pro sequence and had 63 % homology to a previously reported thrombin 
inhibitor, hirutonin (DiMiao et al., 1992). Rapeseed peptides derived from Alcalase 
hydrolysis showed marked inhibitory activities on the thrombin-catalyzed coagulation of 
fibrinogen at certain concentrations (e.g. 90 % inhibition at 30 and 40 mg/mL) although 
their inhibitory effects were not dose-dependent. The antithrombotic activity of rapeseed 
peptides were lower than heparin (standard used) and was higher than that of egg white 
hydrolysate (Yang et al., 2007), when used at the same concentration. 
 
Due to the weaker antithrombotic activity shown by the hydrolysates compared to that 
of the standard, antithrombin (100 % at the used concentration of 0.67 mg/mL), further 
analysis of this bioactivity was not carried out. 
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4.3.2.2.6 Bile acid binding ability 
The bile acid binding ability of FPHs and unhydrolyzed protein was determined in vitro 
using five individual bile acids (SCDC, SC, STC, SGC and SDC). In contrast to other 
bioactivities assayed, all the hydrolyzed flaxseed proteins (0.67 mg/mL) demonstrated 
no or very low bile acid binding ability (results not shown). Therefore, the IC50 value 
was not determined for bile acid binding. Interestingly, the unhydrolyzed flaxseed 
protein (0.67 mg/mL) bound all five bile acids; 15.39 ± 4.8 %, 17.30 ± 0.6  %, 59.76 ± 
2.8 %, 37.95 ± 1.31 % and 32.20 ± 3.1 % of SCDC, SC, STC, SGC and SDC, 
respectively (Figure 4.28). The sample blanks (flaxseed protein isolate maintained at 50 
C without adding Flavourzyme, no hydrolysis occurred, DH: 0 %) possessed bile acid 
binding abilities, which were similar or greater than that of the hydrolyzed protein 
(results not shown). Therefore, the bile acid binding ability observed in the FPHs, even 
in very minute amounts, could not be attributed to Flavourzyme catalyzed hydrolysis.  
 
Figure 4.28 Bile acid binding ability of unhydrolyzed flaxseed protein and cholestyramine 
(SC=Sodium Cholate, SCDC=Sodium Chenodeoxycholate, SDC=Sodium Deoxycholate, 
SGC=Sodium Glycocholate, STC=Sodium Taurocholate; Flaxseed protein hydrolysates 
showed no binding effect) 
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The ability of cholestyramine, the bile acid binding and cholesterol-lowering drug, to 
bind the individual bile acids was also tested. Cholestyramine (0.67 mg/mL) bound 
71.44 ± 7.1 % SCDC, 27.07 ± 1.4 % SC, 58.59 ± 7.8 % STC, 56.94 ± 1.87 % SGC and 
79.33 ± 0.43 % of SDC. The ability to bind STC was greater, but not significantly 
different in unhydrolyzed flaxseed protein than cholestyramine (Figure 4.28). In this 
study, the majority of FPHs possessed short PCL due to extensive hydrolysis of 
flaxseed protein by Flavourzyme. The inability of peptides with short PCL to bind bile 
acids may be the reason for reduction of the bile acid binding ability upon hydrolysis. It 
has been demonstrated that the bile acid binding capacity of a peptide was closely 
related to its hydrophobic nature. Such peptides tend to bind with bile acids by 
hydrophobic interactions and get excreted into feces with bile acids (Higaki et al., 
2006). Therefore, the bile acid binding ability of unhydrolyzed flaxseed protein also 
could be due to its hydrophobic nature. 
 
The values for bile acid binding ability of cholestyramine observed in the present study 
deviated from the previously reported values (Yoshi-Starke & Wasche, 2004) and this 
could be attributed to the concentration of cholestyramine and the differences in the 
assay kit used. Only a few studies have reported bile acid binding of proteins and their 
hydrolysates in vitro, including soy protein and wheat gluten (Kahlon & Woodruf, 
2002), lupin protein and hydrolysates generated by pepsin as well as pepsin-pancreatin 
hydrolysis (Yoshi-Starke & Wasche, 2004), rapeseed protein (Yoshie-Stark et al. 2006) 
buckwheat protein and its pepsin-pancreatin digests (Ma & Xiong, 2009). 
 
Higaki et al. (2006) showed that the HMW fraction of soy protein digested with pepsin 
followed by pancreatin was capable of binding bile acids in vivo. In a previous study, 
lupin protein isolate (1 mg/mL, protein content 91.44 %) was able to bind 55.8 % 
SCDC, 54.4 % SC, 40.9 % STC, 63.9 % SGC and 58.4 % SDC. The bile acid binding 
ability of flaxseed protein was lower than that of lupin protein isolate except for STC 
binding (Yoshi-Starke & Wasche, 2004). Similar to present findings, Yoshi-Starke and 
Wasche (2004) also reported greater bile acid binding of lupin protein compared to 
cholestyramine. Yoshie-Stark et al. (2008) reported that rapeseed protein isolate (1 
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mg/mL, protein content 70.8 %) had a 5.77 % SC binding and 10 % SDC binding 
activity, which was much lower than the values shown by flaxseed protein in the present 
study.  
 
However, the simulated GI digestion carried out in  the study I of this thesis using 
dynamic model indicated that flaxseed protein when hydrolyzed sequentially by GI 
proteases (pepsin and pancreatin), generates a digest with a DH of 46.78 % (See section 
4.5.6.2 under the results and discussion chapter of this thesis). Hence, it is possible that 
the ability of intact flaxseed protein to bind bile acids is modified upon GI digestion. 
This would be the same for other proteins such as wheat gluten (Kahlon & Woodruf, 
2002) and rapeseed protein (Yoshie-Stark et al., 2006) whose bile acid binding ability in 
the digested form has not been reported.  
 
Since none of the FPHs showed considerable bile acid binding activity except the 
unhydrolyzed protein, this bioactivity was not studied further. 
 
4.3.3 Identification of precursor proteins of bioactive peptides based on 
degradation pattern of proteins  
Figure 4.29 shows the SDS-PAGE patterns (NR) of the protein isolate residues that 
remained upon Flavourzyme catalyzed hydrolysis. Of the major protein bands observed 
in the isolated flaxseed protein, the band with a molecular mass of around 48 kDa was 
highly susceptible for Flavourzyme catalyzed hydrolysis. At the DH of 11.94 %, this 
polypeptide band lost 90 % of its pixel intensity and was completely degraded when the 
DH was above 11.94 % (Table 4.30). The polypeptide band of ~41 kDa was visible in 
all the residues indicating its resistance to Flavourzyme hydrolysis. This was in contrast 
to protein band degradation observed in study I where simulated GI digestion caused 
complete degradation of the two HMW protein bands (48 and 41 kDa). At all the DH 
values the ~41 kDa band showed greater pixel intensity than that of the unhydrolyzed 
residue (Table 4.30). Therefore, in contrast to unhydrolyzed protein, the ~ 41 kDa band 
of samples at different DH may contain the degraded products of other polypeptides 
especially those of 48 kDa.  
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Figure 4.29 Electrophoretic separation of flaxseed protein isolate and residues 
remaining after hydrolysis under non reducing conditions. Lanes are labelled with 
degree of hydrolysis %; 0 degree of hydrolysis indicates unhydrolyzed flaxseed 
protein isolated at pH 3.8; MWM: molecular weight markers. Gels used were 
gradient mini gels (resolving 8-25% T and 2% C, stacking zone 4.5 %T and 3 %C, 
43×50×0.45 mm, polyacrylamide gels cast on GelBond® plastic backing, buffer 
0.112 M acetate, 0.112 M Tris, pH 6.4, Tris-Tricine running buffer). Each well was 
loaded with 5 µg protein 
 
The electrophoregrams of the unhydrolyzed residue at different DH are shown in 
Figures 4.30 and 4.31. Above the DH of 11.94 %,  there were new polypeptide bands 
that appeared with apparent mass below 10  kDa, most likely the hydrolytic products of 
the parent protein of the isolate (Figures 4.30 and 4.31). The polypeptide bands of 13 
and 12 kDa were completely degraded above 25.13 % DH leaving the insoluble LMW 
hydrolytic products (Figures 4.29, 4.30 and Table 4.30). 
 
Results indicated that flaxseed proteins of 43 kDa and lower  molecular masses were 
less susceptible to Flavourzyme catalyzed hydrolysis when compared to the protein 
band of 41 kDa. The indigestible residues corresponding to DH between 57.15 % and 
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70.6 2 % (Figures 4.29, and 4.30) showed identical electrophoretic patterns with ~ 41 
kDa protein band as the major remaining protein. 
 
Table 4.30 Difference (%) in polypeptide band intensity of the remaining flaxseed 
protein residues at the end of Flavourzyme catalyzed hydrolysis compared to the 
unhydrolyzed protein. 
DH: Degree of hydrolysis 
1Negative and positive values indicate respectively a reduction and gain of pixel intensity of polypeptide 
bands compared to the initiation of digestion (e.g. -100 indicates a complete loss of a polypeptide band). 
Band molecular masses refer to the Figure 4.30. 
 
The degradation of protein bands at different DH levels were compared with the 
bioactivities shown by the hydrolysates at those DH levels. As shown by SDS-PAGE 
(Figures 4.29 and 4.30), a significant reduction in the intensity of protein band of ~ 48 
kDa occurred when the DH achieved 11.94 %. The highest ACEI activity and highest 
inhibition of linoleic acid oxidation were shown by the hydrolysate with DH of 11.94 % 
(Table 4.27). Therefore, this suggests that peptides generated by hydrolysis of 48 kDa 
protein band may have contributed to ACEI activity and inhibition of linoleic acid 
oxidation shown by the hydrolysates. The protein band of 48 kDa could be acting as the 
precursor protein for generation of bioactive peptides with ACEI activity and inhibition 
of linoleic acid oxidation.  
 
DH (%) 
Percentage difference in pixel intensity1 of polypeptide bands  
48 kDa 41 kDa 29 kDa 20 kDa 13 kDa 12 kDa 
11.94 -90.6 +160.2 -43.81 -73.2 -3.5 -64.5 
24.63 -100 +125.3 -13.0 -38.9 -44.1 -84.4 
25.13 -100 +194.8 +1.9 -39.8 -39.2 -77.9 
47.30 -100 +232.7 +44.27 -100 -100 -100 
57.15 -100 +142.2 +105.7 +103.2 -100 -100 
64.24 -100 +161.7 +39.8 -40.9 -100 -100 
64.86 -100 +120.9 +52.4 +31.0 -100 -100 
65.42 -100 +82.7 +17.8 -21.5 -100 -100 
70.62 -100 +127.5 +10.1 -15.8 -100 -100 
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Figure 4.30 Electropherogram images (X axis: Pixel position; Y axis: Pixel 
intensity) of flaxseed protein isolate and residues remaining after hydrolysis with 
Flavourzyme (MWM: Molecular weight markers; DH: Degree of hydrolysis) 
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The precursor proteins responsible for generating peptides with the highest OH• 
scavenging activity as well as antithrombotic activity could be the protein around 48 
kDa and the protein around 12 and 13 kDa, as the intensity of these bands were reduced 
at 24.63 % DH (Figures 4.29 and 4.30). There was complete hydrolysis of polypeptide 
bands around 48 kDa and 12 kDa at DH of 64.86 % (Figures 4.29 and 4.30; Table 4.30) 
suggesting that these peptides could be the precursors for generation of O2•- scavenging 
peptides. 
 
4.3.4 Optimization of degree of hydrolysis and bioactivities 
Analysis of data using response surface methodology (RSM) resulted in the 
identification of the optimum reaction conditions that produce maximum DH and  
bioactivities (ACEI, OH•   and  O2•- scavenging and inhibition of linoleic acid oxidation) 
in FPHs. Based on the results, the effect of E/S (variable: X1) and time of hydrolysis 
(variable: X2) as well as interactions [e.g. E/S* time of hydrolysis (X1*X2)] on the DH, 
ACEI, OH•  and  O2•- scavenging and inhibition of linoleic acid oxidation (dependent 
variables) (See Table 3.1 under Materials and Methodology chapter of this thesis) in the 
process of hydrolysis were investigated.  
 
Response surface methodology is a statistical technique for designing experiments, 
building models, evaluating the effects of several factors, and searching for optimum 
conditions for desirable responses and reducing the number of experiments (Draper & 
Lin, 1990). In RSM, fewer experimental points can be utilized to evaluate multiple 
parameters and their interactions, compared to full factor factorial designs thus making 
it less laborious and time consuming (Cheison et al., 2007). Therefore, the experimental 
design used in the present study enabled the estimation of the effect of E/S and time of 
hydrolysis on response variables (DH and bioactivities) and their optimization with 
minimum experimentation. A quadratic response surface function was estimated by 
least-squares regression. The predicted optimal values for each of the independent 
variable were from the estimated response surface. The predictive capabilities of 
response surface models were explained using the coefficient of determination (R2). The 
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canonical analysis, which predicts the shape of the response surface curve generated by 
the model, was also carried out. 
 
4.3.4.1 Optimization of degree of hydrolysis 
Figure 4.31 shows the response surface plot obtained for DH in FPHs with the change in 
time of hydrolysis and E/S. The regression equation (eq 4.1) for DH was obtained after 
the analysis of variance (ANOVA).  
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Figure 4.31 Response surface plot for degree of hydrolysis (Y1) as a function of 
enzyme to substrate ratio, LAPU/ g of protein (X1) and time of hydrolysis, h (X2) 
 
Y1 = -22.42 +1.58* X1 + 4.83*X2 -0.12* X22-0.01 X1*X2-0.01X1 2             (4.1) 
 
The positive coefficients for independent variables (eq 4.1) showed that the increase in 
both the E/S and time of hydrolysis resulted in an increase in DH. At higher enzyme 
concentrations, more enzyme catalytic sites are available to participate in the hydrolysis 
of the substrate, resulting in greater cleavage of peptide bonds (Kurozawa et al., 2008). 
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Increase in hydrolysis time facilitates the hydrolysis further by improving the contact 
between enzyme and substrate.  
 
According to the t –test and p values (results not shown) time, time*time and E/S*time 
had a significant effect (P<0.05) on DH. The regression coefficient (R2) for the 
suitability of the response surface model (fit of the model) was 0.92. This indicated that 
92 % of the variability for DH can be explained by the independent variables and their 
interaction components of the model eq 4.1. The high R2 value indicated that the model 
was well adapted to the responses. The three-dimensional response surface plot (Figure 
4.31) was obtained from the statistically significant (P<0.05) model to determine the 
optimum levels of E/S and time of hydrolysis that yields maximum DH. As shown in 
Figure 4.31, the DH increased until time of hydrolysis and E/S reached optimum points. 
The response surface plot had a convex shape indicating a maximum point of DH 
(Figure 4.31).  
 
The canonical analysis, which is a type of linear statistical analysis used to locate the 
stationary point (Montgomery, 1991), showed that DH becomes maximum (73.3 %) at 
the combination of uncoded levels of 69.3 LAPU/ g protein (E/S) and 16.9 h (time of 
hydrolysis) (Table 4.31). 
 
Table 4.31 Canonical analysis of the response surface for degree of hydrolysis 
E/S: Enzyme to substrate ratio; LAPU: leucine amino peptidase units 
DH: Degree of hydrolysis 
 
 
 
Response 
variable 
 
Critical values of hydrolysis factors Predicted value Stationary 
Point X1 
E/S ratio 
(LAPU/g protein) 
X2 
Time (h) 
DH (%) 69.3 16.9 73.3 Maximum 
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4.3.4.2 Optimization of bioactivities 
The optimization was carried out for bioactivities such as ACEI activity and antioxidant 
activities (OH• scavenging, O2•- scavenging, inhibition of linoleic acid oxidation). The 
response surface plots and their best explanatory equations for bioactivities are given in 
Figure 4.32. The R2 of the response surface models for ACEI activity, OH• scavenging, 
O2•- scavenging activities and inhibition of linoleic acid oxidation were 0.97, 0.83, 0.72 
and 0.41, respectively.  
  
The high R2 value (0.97) of ACEI activity indicated that the model fits well to the data. 
The response surface plot for ACE inhibition (Figure 4.32a) was generated based on this 
model. The equation for the model (Figure 4.32a) indicated a decrease in ACEI activity 
with the increase in E/S and time of hydrolysis in the experimental region and this effect 
was significant (P<0.05). The positive effect shown by E/S* time on the ACEI activity 
was found to be not significant (P<0.05). The results confirmed the relationship shown 
by Figure 4.19, which showed a decrease in ACEI activity with an increase in DH. The 
response surface had a shape of a valley (Figure 4.32a) and there was no maximum 
point detected. The stationary point of the surface plot was a minimum, which 
demonstrated a minimum ACE inhibition (71.2 %) when E/S was 83.7 LAPU/g proteins 
and time of hydrolysis was 19.9 h (Table 4.32). The optimum conditions (time and E/S) 
for maximum ACEI activity could not be located by using the model designed for the 
experiment. Therefore, it can be suggested that higher ACE inhibition could be obtained 
by minimal hydrolysis of flaxseed protein by Flavourzyme, which will generate lower 
levels of DH. 
 
The R2 of models obtained for antioxidant activities (OH• scavenging, O2•- scavenging, 
inhibition of linoleic acid oxidation) were lower (R2: 0.83 and 0.72, respectively) than 
that of the models obtained for % ACE inhibition (R2: 0.97). However, as shown by the 
R2 values, a considerable % of variability in OH• and O2•- scavenging activity (83 % and 
72 %, respectively) were explained by the model equations (Figures 4.32b and c). The 
regression coefficients for both E/S and time of hydrolysis shown by the model equation 
for OH• scavenging were negative and they were positive for O2•- scavenging activity.                              
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Figure 4.32 Response surface plots for (a) angiotensin I-converting enzyme inhibitory, (b) hydroxyl radical scavenging, (c) 
superoxide radical scavenging activities and (d) inhibition of linoleic acid oxidation (For X1 and X2 refer Tables 4.32 and 4.33)
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197 
 
Table 4.32 Canonical analysis of response surface for angiotensin I-converting 
enzyme inhibitory activity 
E/S: Enzyme to substrate ratio; LAPU: Leucine aminopeptidase units 
ACEI: Angiotensin 1-converting enzyme inhibitory 
 
Therefore, increase in both parameters had a decreasing effect on the ability to scavenge 
OH• but led to an increase in O2•- scavenging activity. The E/S* time had a negative 
effect on both antioxidant activities. For OH• activity, none of these parameters 
including their interactions had a significant effect (P<0.05). But for O2•- scavenging 
activity, time and the interaction between E/S and time had a significant effect 
(P<0.05).  
 
The model equation for inhibition of linoleic acid oxidation (Figure 4.32d) explained 
only 41 % of the variability. An increase in E/S had a negative effect whereas increase 
in time of hydrolysis had a positive effect on the ability to inhibit linoleic acid 
oxidation. Also the interaction between E/S and time of hydrolysis had a decreasing 
effect on the ability to inhibit linoleic acid oxidation (Figure 4.32d). However, none of 
these effects were  significant (P<0.05).   
 
Unlike for ACEI activity, the canonical analysis revealed that the predicted response 
surfaces for all screened antioxidant activities had saddle points as stationary point 
(Table 4.33). Hence the estimated surfaces (Figure 4.32) did not have a maximum or 
minimum point. This indicated that the predicted optimum was away from the region of 
experiment (Liu et al., 2000). Therefore, a ridge analysis was carried out to locate the 
critical levels of independent variables that can produce a maximum response (Table 
4.33). The ridge analysis indicated that maximum antioxidant activities could be 
obtained when flaxseed proteins were hydrolyzed for relatively low DH using a 
moderate level of E/S and time (Table 4.33). The maximum OH• scavenging activity 
Response variable 
 
Critical values of hydrolysis 
factors 
Predicted 
value 
Stationary 
Point 
X1 
E/S ratio (LAPU/g 
protein) 
X2 
Time (h) 
% ACEI activity 83.7 19.9 71.2 Minimum 
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(estimated value: 21.9 %) could be obtained when flaxseed protein was hydrolyzed for 
1.5 h at an E/S of 30.2 LAPU/g protein. The ridge analysis also indicated that a 
maximum O2•- scavenging (estimated value of 38.6 %) can be obtained when flaxseed 
protein is hydrolyzed by Flavourzyme at an E/S of 4.9 LAPU/g protein for 16.3 h. 
Maximum ability for inhibition of linoleic acid oxidation should result when flaxseed 
protein is hydrolyzed at low E/S (1.6 LAPU/g protein) for 12.6 h. 
 
Table 4.33 Ridge analysis of response surface for antioxidant activities 
E/S: Enzyme to substrate ratio; LAPU: Leucine aminopeptidase units 
OH•: Hydroxyl radical; O2•- : Superoxide radical 
 
4.3.5 Characterization of bioactive peptides in the most bioactive flaxseed protein 
hydrolysates 
Based on the results, two bioactivities were selected for further study of Flavourzyme 
hydrolyzed flaxseed protein. They were ACEI and OH• scavenging activities. These two 
bioactivities were also studied on the GI digests of flaxseed protein. The two FPHs that 
possessed maximum ACE inhibition (DH: 11.94 %) and OH• scavenging activity (DH: 
24.63 %) were selected for characterization of the bioactive peptides in the FPHs.  
 
4.3.5.1 Amino acid composition of the most bioactive flaxseed protein hydrolysates 
The results of amino acid analysis in the most bioactive hydrolysates are given in Table 
4.34. Except for Glu, Pro and Val all the other amino acids were greater in the 
hydrolysate with a DH of 24. 6 % (ACEI hydrolysate) compared to that having a DH of 
11.94 % (OH• scavenging hydrolysate). This was expected as with the increase in DH 
more peptides and amino acids are released from the protein.  
Response variable 
 
Critical values of hydrolysis 
factors 
Predicted 
value 
Stationary 
Point 
X1 
E/S ratio (LAPU/g 
rotein) 
X2 
Time (h) 
% OH• scavenging activity 30.2 1.5 21.9 Saddle 
 
% O2•- scavenging activity 4.9 16.3 38.6 Saddle 
 
% inhibition of linoleic acid 
oxidation 
1.6 12.6 90.1 Saddle 
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Table 4.34 Amino acid composition (g/100g protein) of the most bioactive 
hydrolysates  
1 Hydolysate with the highest ACE inhibition; 2 Hydrolysate with the highest OH• scavenging activity 
3 Branched chain amino acids; 4 Conditionally essential 
 
 
 
Amino acid   DH (%) 
                     11.941           24.62 
Essential    
His 1.59 1.67 
 
Ile3 3.58 3.78 
 
Leu3 4.91 5.03 
 
Lys 2.20 2.41 
 
Met 1.98 2.41 
 
Phe 4.63 4.84 
 
Thr 3.15 3.21 
 
Trp 0.89 1.01 
 
Val3 4.41 4.13 
 
Non-essential  
  
Ala 3.81 4.29 
 
Arg4 9.75 10.36 
 
Asp 10.03 10.32 
 
Cys 2.26 2.27 
 
Glu 21.13 21.03 
 
Gly 5.23 5.78 
 
Pro 2.69 2.64 
 
Ser 4.77 4.81 
 
Tyr 1.71 1.77 
Lys/Arg 0.22 0.23 
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As discussed previously, there were no significant differences (P<0.05) between both 
hydrolysates for ACEI activity and OH• scavenging activity. This could be a reason for 
the absence of any marked differences in amino acid composition between the two 
hydrolysates. The amino acid composition of these Flavourzyme hydrolyzed flaxseed 
protein was compared with the hydrolysates of flaxseed protein reported by Udenigwe 
and Aluko (2010). The authors had calculated Fischer ratios (the ratio between 
branched chain amino acids and aromatic amino acids) for the flaxseed protein 
hydrolysates. Protein hydrolysates with higher Fischer ratio are important in the 
treatment of liver diseases. BCAAs have therapeutic effect as they are reported to be 
preferentially taken up by muscles, inhibit the transport of aromatic amino acids across 
blood brain barrier and are available for peripheral metabolism in advanced liver 
diseases (Clementte, 2000). According to Udenigwe and Aluko (2010), the hydrolysates 
prepared by treating Thermolysin hydrolyzed flaxseed protein with papain, ficin, 
Alcalase and pronase had Fischer ratios of 1.84, 1.60, 1.67 and 1.72. The Thermolysin-
pronase hydrolysate with the highest Fischer ratio had the ability to be converted to a 
BCAA rich mixture with a Fischer ratio of 23.65 when mixed with activated carbon. 
 
Based on the findings of the current study, the Fischer ratios of the two hydrolysates 
with DH of 11.94 % and 24.6 % were 1.78 and 1.69, respectively (Table 4.34). The 
hydrolysate with 11.94 % DH had a Fischer ratio greater than the highest Fischer ratio 
(1.72) reported for Thermolysin-pronase hydrolysate of flaxseed protein (Udenigwe & 
Aluko, 2010). The ratio between Lys:Arg was found to be 0.22 and 0.23 in the 
hydrolysates with DH values of 11.94 and 24.6 %, respectively (Table 4.34). High Lys: 
Arg ratios in the diet are reported to be responsible for atherogenicity (Kritchevsky et 
al., 1982). The Lys:Arg ratios of both FPHs were much lower than that previously 
reported for cholesterol lowering fish protein hydrolysate (1.1) by Wergedahl et al. 
(2004). This further indicated the potential cardiprotective effect of the selected FPHs. 
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4.3.5.2 Purification of bioactive peptides 
4.3.5.2.1 Purification of angiotensin I-converting enzyme inhibitory peptides using 
angiotensin I-converting enzyme immobilized to glyoxyl agarose 
ACE was immobilized to glyoxyl-agarose and the immobilized ACE was incubated 
with the FPH possessing maximum ACE inhibition as discussed in the methodology 
section. Since Captopril (D-3-mercapto-2-methyl-propionyl-L-proline) is a strong 
competitive ACE inhibitor (Wei et al., 1992) it was hypothesized that Captopril can 
release any ACEI peptides bound to ACE. The stock solution of commercial ACE used 
for this study had an activity of 0.14 units/mL. The ACE activity of immobilized ACE 
was 0.08 units /mL. There was a 33.5 % loss in ACE activity when immobilized ACE 
was incubated with FPH showing the highest ACEI activity. This reduction in ACE 
activity was expected to be the result of binding ACEI peptides in the FPH with the 
active site of ACE. The FPH recovered after incubating with immobilized ACE was 
expected to have a size exclusion chromatogram different from the original FPH due to 
binding of peptides with ACE. Although a reduction or absence of a peptide peak in the 
FPH was expected, no clear difference was detected between the chromatograms of the 
FPH before and after incubation (Figure 4.33).  
 
Figure 4.33 The size exclusion chromatograph of flaxseed protein hydrolysate 
(Degree of hydrolysis=11.9 %) before and after incubation with immobilized 
angiotensin I-converting enzyme. The absorbance was monitored at 214 nm 
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ACE immobilized to glyoxyl-agarose have been successfully used to purify ACEI 
peptides in sunflower protein hydrolysates prepared by sequential hydrolysis using 
Alcalase and Flavourzyme (Megias et al., 2009) as well as Alcalase hydrolyzed 
rapeseed protein (Megias et al., 2006). As commercial ACE is expensive this method 
was also expected to produce immobilized ACE that can be reused in ACE assays. 
However, in our study this was not possible due to the inability to detect the binding of 
ACEI peptide with immobilized ACE. Therefore, an alternative method was explored 
for the purification of the ACEI peptides by peptide fractionation using size exclusion 
column (SEC) connected to AKTA FPLC system followed by further concentration of 
peptides with RP-C18 spin columns. The same purification was carried out for FPH 
with high OH• Scavenging activity. 
 
4.3.5.2.2 Peptide fractionation of flaxseed protein hydrolysates 
The fractionation of FPHs was carried out using SEC connected to an AKTA FPLC. 
Figure 4.34 shows the molecular mass distribution profile of the FPHs that showed the 
highest levels of the selected bioactivities. Five peptide fractions namely F-I (>2.5 
kDa), F-II (1.05-2.5 kDa), F-III (0.5-1.05 kDa), F-IV (<0.5 kDa) and F-V (<0.5 kDa), 
were collected from each FPH based on the molecular mass (Figure 4.32).  
 
As shown by the absorbance at 280 nm, F-I, F-III, F-IV and F-V of all the FPH had 
phenolic groups or aromatic amino acid containing peptides (Figure 4.34). The peptide 
fractions obtained from each FPH were screened for the respective bioactivities shown 
by the unfractionated FPH. The results are displayed in Table 4.35. Amongst the 
fractions collected from the FPH having the highest ACEI activity, (Fig.4.34 a), F-I 
(>2.5 kDa) had no ACEI activity. The F-III (0.5 to 1.05 kDa) fraction had significantly 
higher (P<0.05) ACEI activity (76.7 ± 1.2 %) compared to other fractions. Therefore F-
III was identified to contribute most to the ACEI activity of the FPH with DH of 11.94 
% followed by F-IV, F-II and F-V. The IC50 for ACEI activity was calculated only for 
F-III as it had the highest ACE inhibition. Also the peptides in F-III were expected to be 
mostly short chain peptides (<1 kDa).  
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Figure 4.34 Elution profiles of flaxseed protein hydrolysates [(a) Angiotensin I-
converting enzyme inhibitory activity: 88.29 %; Degree of hydrolysis: 11.94 %, (b) 
Hydroxyl radical scavenging activity: 22.08 %; Degree of hydrolysis: 24.63 %] 
separated by FPLC using a size exclusion column (Superdex 10/30). The column 
was equilibrated and eluted with 20 % (v/v) Acetonitrile having 0.05 % (v/v) TFA, 
at a flow rate of 0.5 mL/min 
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Table 4.35 Bioactivities of peptide fractions of flaxseed protein hydrolysates in 
relation to molecular mass distribution 
1Values are means ± standard deviations of duplicate analyses 
abcMeans in the same column followed by same letter are not significantly different (P<0.05) 
 2Concentration used:  0.3 mg/mL; 3Concentration used: 0.5 mg/mL 
DH: Degree of hydrolysis; ACEI: Angiotenisn 1-converting enzyme inhibitory; OH•: Hydroxyl radical 
N.D.: Not determined 
 
The interest in short chain peptides was due to reported evidence that they are able to 
withstand proteolytic degradation by the enzymes in GI tract when orally ingested by 
humans (Aluko, 2008) and the ability to be absorbed without further hydrolysis. The 
IC50 for F-III was 0.08 mg/mL (Table 4.35). This was higher than the ACEI IC50 shown 
by the unfractionated FPH (0.07 mg/mL). Therefore, F-III had a weaker ACEI potency 
than the unfractionated FPH. The possible reason could be the synergistic effect on 
ACEI activity by different peptides in the hydrolysate. Therefore, separation of peptides 
according to the size resulted in a loss of ACEI activity, which might be because of the 
separation of synergistically active peptides. However, this F-III had higher ACEI 
potency than the strongly cationic <1 kDa fraction of Alcalase hydrolyzed flaxseed 
protein (IC50: 0.12 mg/mL) reported by Udenigwe et al. (2009). The ACEI IC50 in F-III 
was greater than the <1 kDa fraction of Thermolysin hydrolyzed flaxseed protein (0.02 
mg/mL) and weakly cationic <1 kDa fraction of Alcalase hydrolyzed flaxseed protein 
(~0.03 mg/mL) reported by Udenigwe et al. (2009). However, it the values reported by 
Udenigwe et al. (2009) were for <1 kDa fraction. Hence, the IC50 reported by Udenigwe 
 
 
Fraction 
 
 
Molecular 
mass 
distribution of 
peptides in the 
fraction (kDa) 
Flaxseed protein hydrolysates  
DH: 11.94 %  DH: 24.63% 
ACEI activity 
(%)1,2 
IC50 
(mg/mL)1 
 OH• 
scavenging 
activity 
(%)1,3 
IC50 
(mg/mL)1 
F-I >2.5 0c N.D.  43.39 ± 0.0a N.D. 
F-II 1.05-2.5 27.5 ± 1.1b N.D.  24.39 ± 0.4b N.D. 
F-III 0.5-1.05 76.7 ± 1.2a 0.08 ± 0.0  43.45 ± 4.5a 0.51 ± 0.0 
F-IV <0.5 38.2 ± 0.5b N.D.  22.96 ± 1.1b N.D. 
F-V <0.5 1.6 0 ±1.3c N.D.  0c N.D. 
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et al. (2009) could be the result of synergistic effects of many LMW peptides, whereas 
in the current study the IC50 was analyzed only for the 0.5-1.05 kDa fraction. Therefore, 
the contribution by peptides less than 0.5 kDa were not included. The absorbance at 280 
nm suggested the presence of phenolic groups or aromatic amino acids of the peptides 
in F-III indicating that the ACEI peptides in this fraction could possess hydrophobic 
side chains. This is in accordance to Murray and FitzGerald (2007) and Cheung et al. 
(1980) who reported that Pro and aromatic amino acids play an important role in ACEI 
peptides for binding with ACE  
 
The FPH with 24.6 % DH had the highest OH• scavenging activity (22.1 %) (Table 
4.27). The F- I (>2.5 kDa) and F-III (0.5 to 1.05 kDa) of this FPH had superior OH• 
scavenging activity (43.39 ± 0.0 % and 43.45 ± 4.5 %, respectively) compared to that of 
the unfractionated FPH (Table 4.27) when used at the same concentration. The OH• 
scavenging activity shown by F-I and F-III of the hydrolysate (DH: 24.63 %) were 
significantly higher (P<0.05) than those of other fractions (Table 4.35). However, there 
was no significant difference between F-I and F-III of the hydrolysate (DH: 24.63 %) 
for OH• scavenging activity. In contrast, according to Udenigwe et al. (2009), the HMW 
fraction (>1 kDa) of Alcalase hydrolyzed flaxseed protein did not show OH• scavenging 
activity. In the current study, IC50 for OH• scavenging activity was only calculated for 
F-III as it had high activity with LMW peptides (0.5 to 1.05 kDa) that have potential for 
intestinal absorption. The IC50 (0.51 mg/mL) of this fraction was much lower and 
therefore its OH• scavenging potency was greater than that of the unfractionated FPH 
(1.56 mg/mL). The presence of both pro-oxidants and antioxidants, could be the reason 
for the lower OH• scavenging activity in the unfractionated FPH. Removal of the 
associated pro-oxidants during the fractionation process could have enhanced this 
activity in the fractions. The F-III fraction obtained from the hydrolysates with DH 
11.94 % and 24.63 % (showing high ACEI activity and OH• scavenging activity, 
respectively) were selected for further characterization of bioactive peptides. 
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4.3.5.3 Amino acid sequence of peptides in the most bioactive flaxseed protein 
hydrolysate fractions 
Table 4.36 shows the amino acid sequence of peptides identified in the most bioactive 
FPLC fraction of the hydrolysates, which had the highest ACEI and OH• scavenging 
activities.  
 
Table 4.36 Amino acid sequence of peptides in the most bioactive fractions of 
flaxseed protein hydrolysates deduced from de novo sequencing 
1Obtained using the MassLynx software 
 FPLC: Fast Protein Liquid Chromatography 
The single letter coding for amino acids are given within paranthesis 
 
The two proposed peptide sequences in the most ACEI fraction of the flaxseed protein 
hydrolysate had relatively lower probability compared to that of the other peptides. 
Both these peptides had 6 amino acid residues. Similar to peptides obtained from GI 
digestion, none of these two peptide sequences matched with the amino acid sequence 
with conlinnin, the LMW flaxseed storage protein with a known amino acid sequence. 
Therefore, it is likely that these ACEI peptides are not derived from the sequence 
DH 
(%) 
Bioactivity FPLC fraction Amino acid sequence of 
peptides 
Molecular 
mass 
Probability1 
11.94 ACEI 
activity 
F-III 
(0.5-1.05 kDa) 
Gly-Leu-Leu-Leu-Pro-
Phe (GLLLPF) 
 
658.41 37.29 
Val-Val-His-Val-Leu-
Leu (VVHVLL) 
 
678.44 21.14 
24.63 OH•  
scavenging 
activity 
F-III 
(0.5-1.05 kDa) 
Asp-Val-Ala-Leu-Leu-
Pro-Ala (DVALLPA) 
697.40 59.11 
   Phe-Thr-Pro-Met-Pro-
Glu (FTPMPE) 
 
720.19 74.23 
   Pro-Ser-Asp-Glu-Gln-
Phe (PSDEQF) 
 
721.19 88.17 
   Met-Pro-Leu-Asp-Val-
Leu-Ser(MPLDVLS) 
 
773.24 100.00 
   Trp-Pro-Leu-Asp-Glu 
(WPLDE) 
658.26 76.19 
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known protein of flaxseed. The role of different amino acids in the peptides for its 
ACEI activity was discussed in detail under section 4.1.5.5. of the results and discussion 
chapter in this thesis. The importance of C-terminal aromatic amino acids (Trp, Tyr, 
Phe) and Leu for ACE inhibition has been shown by previous studies (Cheung, 1980; 
Gomez-Ruiz et al., 2007). Presence of Phe and Leu in the C-terminus of identified 
peptides could contribute to the ACEI potency of the identified peptides. Interestingly, 
Pro was in the C-terminal penultimate position in the peptide, Gly-Leu-Leu-Leu-Pro-
Phe, which is reported to induce low affinity of the inhibitor towards ACE (Cheung et 
al., 1980). Since the chain length of the identified peptides include more than 2-3 amino 
acid residues, it is possible that the steric effects of the peptide may be masking any 
negative influence caused by Pro in binding with ACE. 
 
Amino acid sequence of five peptides were proposed for the hydrolysate fraction with 
the highest OH• scavenging activity. The chain lengths of the peptides ranged from 5-7 
amino acid residues. Similarly, to the peptides in the most ACEI fraction, none of these 
peptides matched with the sequence in conlinnin. Generally, the scavenging of free 
radicals was attributed to the donation of hydrogen/electron. Structural features of some 
amino acids are found to be important for the free radical scavenging activity of 
peptides.  
 
For example, the imidazole group in His (Chen et al., 1995), indolic group in Trp and 
phenolic group in Tyr (Hernandez-Ledesma et al., 2005; Guo et al., 2009) act as 
hydrogen donors. Aromatic amino acids are generally considered as effective radical 
scavengers. They donate protons easily to free radicals that are electron deficient while 
maintaining their stability via resonance structures (Rajapakse et al., 2005). Moreover, 
Pro is reported to be an effective radical scavenger and Met residues also have been 
reported to contribute to the antioxidant activities of soybean peptides (Chen et al., 
1996) and fermented milk peptides (Hernandez-Ledesma et al., 2005). Met is prone to 
oxidation into Met sulfoxide and Cys donates the sulphur hydrogen (Hernandez-
Ledesma et al., 2005). All the peptides identified in the most OH• scavenging FPH 
fraction had Pro residues. The peptides Phe-Thr-pro-Met-Pro-Glu, Pro-Ser-Asp-Glu-
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Gln-Phe and Trp-Pro-Leu-Asp-Glu had aromatic amino acids in their sequence whereas 
Met, was found in two of the identified peptides (Phe-Thr-Pro-Met-Pro-Glu and Met-
Pro-Leu-Asp-Val-Leu-Ser), which explained the reason for high antioxidant activity of 
the hydrolysate fraction.  
 
In addition to the amino acid composition, the role of the position of amino acids and 
specific amino acid sequences on antioxidant activity of peptides has been identified. 
Chen et al. (1998) reported that peptides containing His at the C-terminus could act as 
effective scavengers towards various radical species. Suetsuna et al. (2000) found that 
the radical scavenging activity of the peptide Tyr-Phe-Tyr-Pro-Glu-Leu was strongly 
dependent on the dipeptide Glu-Leu. In addition, the amino acid sequence of 
antioxidant peptides such as Pro-His-His in soybean peptide (Saito et al., 2003), Gly-
Pro-Hyp in peptides of bovine skin gelatin hydrolysate (Kim et al., 2001) and Gly-Pro 
in peptide of fish skin gelatin are responsible for radical scavenging. However, none of 
the above sequences were found in the OH• scavenging peptides identified in the present 
study. 
 
The OH• scavenging activity was found in the gastric + intestinal digest obtained from 
the static model of simulated GI digestion but not in the dynamic model (See results of 
study I). The results of study I suggested that although flaxseed protein contains OH• 
scavenging peptide sequences, GI digestion might not release these peptides from 
flaxseed protein. The present study showed that both ACEI and OH• scavenging 
peptides can be released by hydrolyzing flaxseed protein with Flavourzyme. The 
bioactive FPHs produced by Flavourzyme catalyzed hydrolysis of flaxseed protein 
could be used as potential functional food ingredients. However, it is important to 
consider that the bioactive peptides in the FPHs will be exposed to the attack of 
digestive enzymes in the GI system upon consumption, which will further cleave these 
peptides either improving or reducing their activity. Therefore, further research is 
necessary prior to drawing any conclusion regarding the ability of such peptides 
identified in the present study to exert any health effect.  
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4.3.5.4 Summary of the findings of study III 
The results of the present study indicated that extensive degree of hydrolysis of flaxseed 
protein (up to a DH of 70 %) could be achieved by Flavourzyme catalyzed hydrolysis. 
Hydrolysis of flaxseed protein by Flavourzyme resulted FPHs with ACEI and 
antioxidant activities (scavenging of OH• and O2•-, inhibition of linoleic acid oxidation). 
Flaxseed protein hydrolysate with maximum ACEI activity shows competitive 
inhibition of ACE. The ACEI and OH• scavenging activity was greater in FPHs with 
long average PCL than the short chain peptides. For example maximum ACEI and OH• 
scavenging activities were shown by FPHs having DH values of 11.94 % (IC50: 0.07 
mg/mL) and 24.63 % (IC50:1.56 mg/mL), respectively.  The peptides ranging between 
0.5 kDa to 1.05 kDa in the respective FPHs contributed most to its ACEI activity and 
OH• scavenging activity. 
 
The O2•- scavenging and the ability to inhibit linoleic acid oxidation did not show any 
relationship with the DH. The FPHs had poor metal chelating ability and bile acid 
binding ability. Only a few FPHs showed antithrombotic activity.  
 
The unhydrolyzed flaxseed protein did not possess ACEI activity, OH•, O2•- scavenging 
activities and antithrombotic activity, but had metal chelating activity and the potential 
to inhibit linoleic acid. Flavourzyme catalyzed hydrolysis reduced the metal chelating 
activity of FPHs and improved the ability to inhibit linoleic acid oxidation in most of 
the FPHs. The unhydrolyzed flaxseed protein had better ability to bind bile acids in 
vitro than the FPHs. As flaxseed protein undergoes further hydrolysis in the GI system 
the bioactivities shown by the protein will be altered during the digestion process and 
therefore, was considered as not important. 
 
Of the polypeptides in isolated flaxseed protein, the 48 kDa polypeptide was the 
potential precursor of generating peptides with ACEI activity and ability to inhibit 
linoleic acid oxidation. The precursor proteins for OH• and O2•- scavenging peptides 
were the polypeptides of 48 kDa and 12 kDa.  
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The optimization study revealed that a maximum DH can be obtained when flaxseed 
protein is hydrolyzed with Flavourzyme at an E/S of 69.3 LAPU/ g of protein for 16.9 
h. The optimal reaction condition for ACEI activity was the hydrolysis of flaxseed 
protein at an E/S of 83.7 LAPU/ g protein for 19.9 h. For the antioxidant activities, the 
optimum reaction conditions could not be located in the range of experimental 
conditions used (E/S and time of hydrolysis) in this study and therefore estimated using 
ridge analysis. These values were, hydrolysis of flaxseed protein at 30.2 LAPU/g 
protein for 1.5 h for OH• scavenging activity, 4.9 LAPU/g protein for 16.3 h for O2•- 
scavenging activity, and 1.6 LAPU/ g protein for 12.6 h for inhibition of linoleic acid 
oxidation. 
 
De novo sequencing was able to deduce two peptide sequences, Gly-Leu-Leu-Leu-Pro-
Phe and Val-Val-His-Val-His-Leu, from the most ACEI  fraction (0.5-1 kDa) of the 
FPH (DH: 11.94 %). Five peptides with amino acid sequences of Asp-Val-Ala-Leu-
Leu-Pro-Ala, Phe-Thr-Pro-Met-pro-Glu, Pro-Ser-Asp-Glu-Gln-Phe, Met-pro-Leu-Asp-
Val-Leu-Ser, and Trp-Pro-Leu-Asp-Glu were deduced from the most OH• scavenging 
peptide fraction (0.5-1 kDa) of the FPH (DH: 24.63 %). 
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5. CONCLUSIONS 
The findings of the current research provide supportive evidence for cardioprotective 
health claims for flaxseed and its products, encouraging researchers to switch their 
focus from ALA, lignan and mucilage towards the protein component in seed. The 
following major conclusions can be drawn from the studies presented in this thesis.  
 
 Flaxseed proteins consist of ACEI peptide sequences that are released during 
simulated GI digestion. Several of these peptides of less than 1 kDa molecular 
mass can pass through the intestinal epithelium via paracellular diffusion 
implying that flaxseed protein consumption can generate a blood pressure 
lowering effect via ACEI mechanism of the released bioactive peptides. The 
antihypertensive effect of flaxseed protein needs to be further confirmed by in 
vivo studies. The highest ACEI potency is found in the peptides of 0.5-1 kDa in 
the absorbable fraction of GI digested flaxseed protein. The peptides of 5-7 
amino acid residues, that are abunduntly found in this potent group require 
structure function confirmation of their ACEI activity. Lack of matching peptide 
fragments in conlinin (sequence available) to the found ACEI peptides indicates 
possible involvement of other seed storage proteins such as linin for the release 
of these peptides. The exact precursor protein in flaxseed that releases ACEI 
peptides can be fully ascertained once the complete sequence of flaxseed 
proteome becomes available. 
 
  Of the flaxseed polypeptides, those above 13 kDa (48, 41, 29 and 20 kDa) could 
be the sources releasing ACEI peptides during GI digestion.  
 
 Although flaxseed proteins contain OH• scavenging peptide sequences, release 
of absorbable peptides with such activity during GI digestion is unlikely. 
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 Generation of peptides with bioactivities from flaxseed proteins was different 
when intestinal digestion includes continuous removal of digestion products (<1 
kDa) in comparison with a system that did not remove such products. Careful 
selection of conditions and interpretation of results is needed when generation of 
bioactive peptides during in vitro GI digestion is reported.  
 
 Oil and mucilage in flaxseed reduces flaxseed protein digestibility. The limited 
digestibility of proteins may limit the potential by whole flaxseed or 
milled/ground flaxseed to generate ACEI peptides limiting any antihypertensive 
effect. Defatted meal, which is low in oil, would be a potential source of ACEI 
peptides upon removal of mucilage.  
 
 Limited hydrolysis of flaxseed proteins with the commercial food grade protease 
Flavourzyme, releases peptides with ACEI and antioxidant activities. Bile acid 
binding ability is limited to unhydrolyzed flaxseed protein. 
 
 The 48 kDa and 13 kDa polypeptide bands in flaxseed protein could be the 
precursors of ACEI and antioxidant peptides rleased during Flavourzyme 
catalyzed hydrolysis.  
 
 Hexa- and heptapeptides of 0.5-1.05 kDa, generated from Flavourzyme 
 hydrolysis, are the primary contributors for ACEI and OH• scavenging activites. 
The ability of these peptides to resist GI digestion and retain bioactivities 
warrant further studies. 
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APPENDICES 
APPENDIX I 
A.1 Simulated GI digestion of flaxseed protein: static model I (with no simulated 
absorption) 
In the static model I, GI digestion conditions to simulate the human digestion system 
were identified based on the published literature. According to Oomen et al. (2003), 
human digestive juices are secreted at the ratio of 1:1.5:3:1 (Saliva: gastric Juice: 
Pancreatic juice: Bile). However, simulated saliva with amylase was not used in the 
current study due to lack of starch in flaxseed. Therefore, the ratio between volumes of 
digestive juices to be used in the static model I were determined as gastric juice juice 18 
mL: Pancreatic juice 36 mL: Bile 12 mL. The most suitable conditions for simulated GI 
digestion of flaxseed protein were determined based on the digestibility of casein. 
 
A.1.1 Determination of digestion conditions 
A.1.1.1 Determination of amount of protein to be used in the simulated GI 
digestion study - static model I 
Recommended daily protein intake  =0.8 g/kg of body weight/day 
 (Food and Nutrition Board, 2005) 
Average weight of male (Canadian)  =83.2 kg (Gilmore, 1999) 
Average weight of female (Canadian) =65.8 kg (Gilmore, 1999) 
Recommended protein intake (adult male) =83.2 × 0.8 
                  =66.56  g/day 
Recommended protein intake (adult female) =65.8 × 0.8 
      =52.64 g/day 
Average protein intake by the population = (66.56 + 52.64)/2 g/day 
(To meet recommended intake values) =59.6 g/d   
Number of meals taken per day  =3 
 248 
 
Amount of protein taken per meal (g) =59.6/3 
=19.86 or ~20 g 
Due to limitations in the size of reaction flask 1 g of protein was used for the digestion 
study and the digestive juices were scaled down accordingly. 
 
A.1.1.2 Determination of enzyme to substrate ratios and amount of digestive juices  
(a) Pepsin: protein ratio 
Armand et al. (1995) reported the pepsin output of healthy adults upon receiving a low 
fat diet, at basal level as well as upon pentagastrin stimulation. The pentagstrin 
stimulated pepsin output recorded in the study by Armand et al. (1995) was used to 
determine the pepsin in gastric juice of our simulated GI digestion study.  
 
 The reported pepsin output    =128961 U/h.  
The amount of pepsin in collected gastric juice = 718000 U/L 
Approximate time food retain in stomach  =2 h 
Amount of pepsin secreted for 2 h   =128961× 2= 257922 U         
Pepsin: Protein ratio     =257922 U/20g protein 
       =12.89 U/mg protein 
Amount of pepsin used for 1g of flaxseed protein =12890 U  
Volume of gastric juice having 12890 U pepsin =(1000 mL/718000 U)*12890 U 
       =17.95 mL 
 
(b) Volume of Pancreatic juice and pancreatin: protein ratio 
Okefee et al. (2006) have reported the Trypsin output after oral diet as 429.5 NFU/h 
NFU (National Formularly units) =USP 
Time for intestinal digestion  =6 h 
Trypsin output for 6 h   =429.5 × 6 
=2577 USP 
Trypsin: Protein ratio   =2577/20000 
=0.13 USP/mg protein 
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Amount of trypsin for 1g of flaxseed protein= 130 USP  
 
Table A1 digestion conditions used in the static model I 
 
 
A.1.2 Determination of ratios between digestive fluids 
The volume of total digestive secretions in man is estimated to be 10 L/day, i.e., around 
3 L/meal. (Laurent et al., 2007). Ratio between gastric juice; pancreatic juice: bile is 
estimated to be 1:1.5:3:1. According to the digestive juice ratios volume of pancreatic 
juice used will be 35.9 mL. Protease activity of sigma porcine pancreatin according to 
manufacturer: 209 USP/mg solid for 1 g protein. 
  
Gastric juice 17.95 mL: Pancreatic juice 35.9 mL: Bile 11.96 mL 
 
A.1.3 Preparation of digestive fluids 
The gastric control solution and intestinal control solution was prepared according to 
US Pharmacopeia (1995) with modifications in the pH. The simulated gastric fluid 
(SGF) and simulated intestinal fluid (SIF) were prepared fresh by mixing pepsin and 
pancreatin with the respective control solutions. The bile solution was prepared fresh by 
mixing 6 g of porcine bile extract (Sigma) in 1L of intestinal control solution. The 
mixture was centrifuged at 9820 × g for 15 min and filtered using whatman number 1 
filter paper prior to use. 
Digestion 
phase 
pH Time Digestive 
juice 
Composition  Enzyme E/S 
Gastric 2 2 h Gastric 
juice 
718000 U of pepsin/L of 
gastric control solution. 
(Sigma pepsin:3660 units 
of pepsin/mg solid) 
Pepsin 12.89 
U/mg 
protein 
 
Intestinal 7.5 6 h Pancreatic 
juice 
3611.1 USP of pancreatic 
trypsin /L of small 
intestinal control solution 
Pancreatin 130 
USP/g 
protein 
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A.1.4 Gastric phase digestion 
One gram of casein was suspended in 12 mL deionized water and the pH of the 
suspension was adjusted to 2 ± 0.1 The mixture was incubated in a double jacketed 
glass container at 37 ºC under mild stirring for 5 minutes. The gastric phase of the 
digestion was initiated by adding 18 mL of SGF (100 mL of the gastric fluid contained 
0.2 g of NaCl + 71800 U pepsin and HCL was added to adjust the pH to 2) to have a 
pepsin: protein ratio of 13 U/mg . The digestion was carried out at 37 ºC for 2 h in a 
double jacketed glass container. The contents were stirred using a magnetic stirrer. The 
gastric phase digestion was terminated by raising the pH to 7.5 using 1 M NaOH. 
 
 
A.1.5 Intestinal phase digestion 
 The digest from gastric phase was mixed with 12 mL of bile solution                         
and 36 mL of SIF (E/S: 130 USP of pancreatic trypsin/g protein). The mixture (pH=7.5) 
was stirred at 37 ºC for 4 h.         
 
A.1.6 Collection of samples 
Samples were collected at zero time and both at the end of gastric digestion and 
intestinal digestion. At the end of all phases the digestion was stopped by heating at 98 
ºC for 15 minutes in a water bath.  
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APPENDIX II 
MS/MS spectra of the most abundant peptides identified in the fraction of gastric digest with the highest ACEI activity 
 
 
 
Figure A1. MS/MS spectra of the peptide Phe-Asn-Leu-Pro-Leu-Leu 
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     Figure A2. MS/MS spectra of the peptide Phe-Leu-Thr-Pro-Val-Phe 
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Figure A3. MS/MS spectra of the peptide Phe-Val-Leu-Pro-Gln-Phe 
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MS/MS spectra of the most abundant peptides identified in the fraction of gastric + intestinal digest with the highest ACEI 
activity 
 
 
 
Figure A4. MS/MS spectra of the peptide Val-Phe-Leu-Pro-Gln 
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Figure A5. MS/MS spectra of the peptide Thr-Pro-Pro-Ala-Ala-Arg 
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Figure A6. MS/MS spectra of the peptide Trp-Asn-Leu-Asn-Ala 
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Figure A7. MS/MS spectra of the peptide Leu-Leu-Val-His-Val-Val 
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Figure A8. MS/MS spectra of the peptide Asn-Leu-Asp-Thr-Asp-Leu 
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Figure A9. MS/MS spectra of the peptide Gln-Asn-Glu-Gly-Leu-Glu-Trp 
 
 
 
 
 
 
259 
 
 260 
 
 
MS/MS spectra of the most abundant peptides identified in the fraction of FPH (DH: 11. 94 %, molecular mass range: 0.5-1.05 kDa) 
with the highest ACEI activity. 
 
 
Figure A10. MS/MS spectra of the peptide Gly-Leu-Leu-Leu-Pro-Phe 
260 
 
 261 
 
 
 
 Figure A11. MS/MS spectra of the peptide Val-Val-His-Val-Leu-Leu 
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MS/MS spectra of the most abundant peptides identified in the fraction of FPH (DH: 24.63 %, molecular mass range: 0.5-1.05 
kDa) with the highest OH• scavenging activity. 
 
Figure A12. MS/MS spectra of the peptide Asp-Val-Ala-Leu-Leu-Pro-Ala 
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Figure A13. MS/MS spectra of the peptide Phe-Thr-pro-Met-Pro-Glu 
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Figure A14. MS/MS spectra of the peptide Pro-Ser-Asp-Glu-Gln-Phe 
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Figure A15. MS/MS spectra of the peptide Met-Pro-Leu-Asp-Val-Leu-Ser 
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Figure A16. MS/MS spectra of the peptide Trp-Pro-Leu-Asp-Glu 
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